ZA200202148B - Caspase inhibitor. - Google Patents
Caspase inhibitor. Download PDFInfo
- Publication number
- ZA200202148B ZA200202148B ZA200202148A ZA200202148A ZA200202148B ZA 200202148 B ZA200202148 B ZA 200202148B ZA 200202148 A ZA200202148 A ZA 200202148A ZA 200202148 A ZA200202148 A ZA 200202148A ZA 200202148 B ZA200202148 B ZA 200202148B
- Authority
- ZA
- South Africa
- Prior art keywords
- methyl
- carbonylamino
- propyl
- isoxazole
- dihydro
- Prior art date
Links
- 229940123169 Caspase inhibitor Drugs 0.000 title claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 239
- 239000000203 mixture Substances 0.000 claims description 79
- -1 ethanesulfonyl Chemical group 0.000 claims description 75
- 230000006907 apoptotic process Effects 0.000 claims description 65
- 108010076667 Caspases Proteins 0.000 claims description 59
- 102000011727 Caspases Human genes 0.000 claims description 58
- 210000004027 cell Anatomy 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 238000006243 chemical reaction Methods 0.000 claims description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 30
- 150000002547 isoxazolines Chemical class 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 22
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 18
- 239000007924 injection Substances 0.000 claims description 18
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 17
- 208000006454 hepatitis Diseases 0.000 claims description 17
- 231100000283 hepatitis Toxicity 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 15
- 230000004913 activation Effects 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 238000002054 transplantation Methods 0.000 claims description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 150000001923 cyclic compounds Chemical class 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 201000005917 gastric ulcer Diseases 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 230000006735 deficit Effects 0.000 claims description 3
- 125000004185 ester group Chemical group 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 238000007910 systemic administration Methods 0.000 claims description 3
- 229930192474 thiophene Natural products 0.000 claims description 3
- NPYBCRJFMZGCPI-JEVLLQFPSA-N (3s)-3-[[3-[(1s)-1-(benzylsulfonylamino)-2-methylpropyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]-methylamino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(ON=1)(C(=O)N(C)[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)C=1C=CC=CC=1)S(=O)(=O)CC1=CC=CC=C1 NPYBCRJFMZGCPI-JEVLLQFPSA-N 0.000 claims description 2
- SGHANKVVISIETA-NUUXIFOFSA-N (3s)-3-[[5-benzyl-3-[(1s)-1-(1h-indole-2-carbonylamino)-2-methylpropyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2NC3=CC=CC=C3C=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)CC1=CC=CC=C1 SGHANKVVISIETA-NUUXIFOFSA-N 0.000 claims description 2
- PIRHZWPTWBUUOY-HVZFRMHZSA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(3-phenylprop-2-enoylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(CC=2C=CC=CC=2)(ON=1)C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)C(=O)C=CC1=CC=CC=C1 PIRHZWPTWBUUOY-HVZFRMHZSA-N 0.000 claims description 2
- PKVQDEXNZLWPRF-UCWKTWOXSA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(3-phenylprop-2-enoylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-bromo-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(CC=2C=CC=CC=2)(ON=1)C(=O)N[C@@H](CC(O)=O)C(=O)CBr)C(=O)C=CC1=CC=CC=C1 PKVQDEXNZLWPRF-UCWKTWOXSA-N 0.000 claims description 2
- MSLBNHPUNPIBKM-HSFHSNDNSA-N (3s)-3-[methyl-[3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-phenoxypentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)C=1C=CC=CC=1)COC1=CC=CC=C1 MSLBNHPUNPIBKM-HSFHSNDNSA-N 0.000 claims description 2
- FMGZPTNWRRWFMW-YOGAAICWSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[methyl-[3-[(1s)-2-methyl-1-(quinoline-4-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NC(=O)C=1C2=CC=CC=C2N=CC=1)C(C)C)C=1C=CC=CC=1)COC(=O)C1=C(Cl)C=CC=C1Cl FMGZPTNWRRWFMW-YOGAAICWSA-N 0.000 claims description 2
- NCPXZELTLIWUGP-OZIHFDBSSA-N (3s)-5-bromo-3-[[3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(ON=1)C(=O)N[C@@H](CC(O)=O)C(=O)CBr)C(=O)OCC1=CC=CC=C1 NCPXZELTLIWUGP-OZIHFDBSSA-N 0.000 claims description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 2
- 101150065749 Churc1 gene Proteins 0.000 claims description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- 102100038239 Protein Churchill Human genes 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 210000002064 heart cell Anatomy 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- SJKZGWVTHFTCJY-RUFIAJSPSA-N methyl (3s)-3-[[3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoate Chemical compound O1C(C(=O)N[C@@H](CC(=O)OC)C(C)=O)CC([C@@H](NC(=O)OCC=2C=CC=CC=2)C(C)C)=N1 SJKZGWVTHFTCJY-RUFIAJSPSA-N 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 125000004742 propyloxycarbonyl group Chemical group 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims description 2
- 150000003536 tetrazoles Chemical class 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- CAFXLBCDFMSQEF-OZEVUELHSA-N (2s)-2-[[3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carbonyl]amino]butanedioic acid Chemical compound N([C@@H](C(C)C)C=1CC(COC=2C=CC=CC=2)(ON=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C(=O)OCC1=CC=CC=C1 CAFXLBCDFMSQEF-OZEVUELHSA-N 0.000 claims 1
- LYBOETQAQKFHRN-UCWKTWOXSA-N (3S)-3-[[5-benzyl-3-[(1S)-2-methyl-1-(3-phenylprop-2-enoylamino)propyl]-4H-1,2-oxazole-5-carbonyl]amino]-5-diazo-4-oxopentanoic acid Chemical compound CC(C)[C@H](NC(=O)C=Cc1ccccc1)C1=NOC(Cc2ccccc2)(C1)C(=O)N[C@@H](CC(O)=O)C(=O)C=[N+]=[N-] LYBOETQAQKFHRN-UCWKTWOXSA-N 0.000 claims 1
- SHSLHDSOCRANTC-MJLQIQFDSA-N (3S)-5-diazo-3-[[3-[(1S)-1-[[2-(1H-indol-3-yl)acetyl]amino]-2-methylpropyl]-5-phenyl-4H-1,2-oxazole-5-carbonyl]-methylamino]-4-oxopentanoic acid Chemical compound CC([C@H](NC(=O)CC1=CNC2=CC=CC=C12)C1=NOC(C1)(C(=O)N([C@@H](CC(=O)O)C(C=[N+]=[N-])=O)C)C1=CC=CC=C1)C SHSLHDSOCRANTC-MJLQIQFDSA-N 0.000 claims 1
- OIFGAYYNHNLPDN-SFQDAYOWSA-N (3S)-5-diazo-3-[methyl-[3-[(1S)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-5-phenyl-4H-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound CC(C)[C@H](NC(=O)OCc1ccccc1)C1=NOC(C1)(C(=O)N(C)[C@@H](CC(O)=O)C(=O)C=[N+]=[N-])c1ccccc1 OIFGAYYNHNLPDN-SFQDAYOWSA-N 0.000 claims 1
- WIEWPGDCGMZZKI-HGAQVFRKSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-phenoxypentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)C1ON=C(C1)[C@@H](NC(=O)C=1C=C2C=CC=CC2=CC=1)C(C)C)COC1=CC=CC=C1 WIEWPGDCGMZZKI-HGAQVFRKSA-N 0.000 claims 1
- QNIUHMFSURKYFW-ZRHIXDKOSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(ON=1)C(=O)N[C@@H](CC(O)=O)C(C)=O)C(=O)OCC1=CC=CC=C1 QNIUHMFSURKYFW-ZRHIXDKOSA-N 0.000 claims 1
- JKKFMABMEODGRO-TYNJXUSYSA-N (3s)-3-[[5-benzyl-3-[(1s)-1-(1h-indole-3-carbonylamino)-2-methylpropyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C3=CC=CC=C3NC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)CC1=CC=CC=C1 JKKFMABMEODGRO-TYNJXUSYSA-N 0.000 claims 1
- QYZMOSOGHHPYDR-MIQQLYACSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[[5-methyl-3-[(1s)-2-methyl-1-(naphthalene-1-carbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)C1(C)ON=C(C1)[C@@H](NC(=O)C=1C2=CC=CC=C2C=CC=1)C(C)C)COC(=O)C1=C(Cl)C=CC=C1Cl QYZMOSOGHHPYDR-MIQQLYACSA-N 0.000 claims 1
- QZSYZCISKCTEQB-XAUYAMEYSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[methyl-[3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(ON=1)(C(=O)N(C)[C@@H](CC(O)=O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)C=1C=CC=CC=1)C(=O)OCC1=CC=CC=C1 QZSYZCISKCTEQB-XAUYAMEYSA-N 0.000 claims 1
- BIHVRXMWAXQILG-NUOXSBERSA-N (3s)-5-bromo-3-[[3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1([C@@H](NC(=O)C=2N=C3C=CC=CC3=CC=2)C(C)C)=NOC(C(=O)N[C@@H](CC(O)=O)C(=O)CBr)C1 BIHVRXMWAXQILG-NUOXSBERSA-N 0.000 claims 1
- IYHKKWYXBLOLDA-RXKSKBTASA-N (3s)-5-bromo-3-[methyl-[3-[(1s)-2-methyl-1-(naphthalene-1-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C3=CC=CC=C3C=CC=2)C(C)C)=NOC1(C(=O)N(C)[C@@H](CC(O)=O)C(=O)CBr)C1=CC=CC=C1 IYHKKWYXBLOLDA-RXKSKBTASA-N 0.000 claims 1
- FCZSZTADVCWDFD-HXVHBBJOSA-N (3s)-5-bromo-3-[methyl-[3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2N=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N(C)[C@@H](CC(O)=O)C(=O)CBr)C1=CC=CC=C1 FCZSZTADVCWDFD-HXVHBBJOSA-N 0.000 claims 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 135
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 77
- 230000000694 effects Effects 0.000 description 65
- 210000003494 hepatocyte Anatomy 0.000 description 43
- 238000005481 NMR spectroscopy Methods 0.000 description 41
- 239000011734 sodium Substances 0.000 description 41
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 38
- 239000000243 solution Substances 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
- 230000015572 biosynthetic process Effects 0.000 description 34
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 27
- 210000004185 liver Anatomy 0.000 description 26
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 24
- 108010062580 Concanavalin A Proteins 0.000 description 23
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 23
- 229940126639 Compound 33 Drugs 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 239000003112 inhibitor Substances 0.000 description 20
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 20
- 102100040247 Tumor necrosis factor Human genes 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 239000001384 succinic acid Substances 0.000 description 15
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 15
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 12
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 12
- 108090000397 Caspase 3 Proteins 0.000 description 12
- 102100029855 Caspase-3 Human genes 0.000 description 12
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 12
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 11
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 230000001640 apoptogenic effect Effects 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 9
- 102100035904 Caspase-1 Human genes 0.000 description 9
- 108090000426 Caspase-1 Proteins 0.000 description 9
- 108010092160 Dactinomycin Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000003833 cell viability Effects 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229940086542 triethylamine Drugs 0.000 description 8
- 238000010626 work up procedure Methods 0.000 description 8
- 102000004091 Caspase-8 Human genes 0.000 description 7
- 108090000538 Caspase-8 Proteins 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 206010067125 Liver injury Diseases 0.000 description 7
- 230000030833 cell death Effects 0.000 description 7
- 229960000640 dactinomycin Drugs 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 102000004018 Caspase 6 Human genes 0.000 description 6
- 108090000425 Caspase 6 Proteins 0.000 description 6
- 108090000567 Caspase 7 Proteins 0.000 description 6
- 102100038902 Caspase-7 Human genes 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 235000010357 aspartame Nutrition 0.000 description 6
- 231100000234 hepatic damage Toxicity 0.000 description 6
- 230000008818 liver damage Effects 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 150000002923 oximes Chemical class 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- GGXRLUDNGFFUKI-ORGXJRBJSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-(4-nitroanilino)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 GGXRLUDNGFFUKI-ORGXJRBJSA-N 0.000 description 5
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 5
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 5
- UMBVAPCONCILTL-MRHIQRDNSA-N Ac-Asp-Glu-Val-Asp-H Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O UMBVAPCONCILTL-MRHIQRDNSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108010066665 acetyl-aspartyl-glutamyl-valyl-aspartal Proteins 0.000 description 5
- 108010038407 acetyl-aspartyl-glutamyl-valyl-aspartic acid p-nitroanilide Proteins 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000013467 fragmentation Methods 0.000 description 5
- 238000006062 fragmentation reaction Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- FGOJCPKOOGIRPA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CCC1=O FGOJCPKOOGIRPA-UHFFFAOYSA-N 0.000 description 4
- 102000004046 Caspase-2 Human genes 0.000 description 4
- 108090000552 Caspase-2 Proteins 0.000 description 4
- 102100025597 Caspase-4 Human genes 0.000 description 4
- 101710090338 Caspase-4 Proteins 0.000 description 4
- 102000004039 Caspase-9 Human genes 0.000 description 4
- 108090000566 Caspase-9 Proteins 0.000 description 4
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000001952 enzyme assay Methods 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 238000010562 histological examination Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000283891 Kobus Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 238000003235 crystal violet staining Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000028974 hepatocyte apoptotic process Effects 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 230000036732 histological change Effects 0.000 description 3
- 238000007327 hydrogenolysis reaction Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000007056 liver toxicity Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- YDPNOCSPPGFBPX-XNHCRPTKSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-(4-nitroanilino)-4-oxobutanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)NC(C)=O)C1=CC=C(O)C=C1 YDPNOCSPPGFBPX-XNHCRPTKSA-N 0.000 description 2
- LQQKDSXCDXHLLF-UHFFFAOYSA-N 1,3-dibromopropan-2-one Chemical class BrCC(=O)CBr LQQKDSXCDXHLLF-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 2
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 2
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 102100038023 DNA fragmentation factor subunit beta Human genes 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102100039898 Interleukin-18 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 108010008106 acetyl-tyrosyl-valyl-alanyl-aspartic acid p-nitroanilide Proteins 0.000 description 2
- 229930183665 actinomycin Natural products 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940126545 compound 53 Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XXTZHYXQVWRADW-UHFFFAOYSA-N diazomethanone Chemical compound [N]N=C=O XXTZHYXQVWRADW-UHFFFAOYSA-N 0.000 description 2
- ROORDVPLFPIABK-UHFFFAOYSA-N diphenyl carbonate Chemical compound C=1C=CC=CC=1OC(=O)OC1=CC=CC=C1 ROORDVPLFPIABK-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical group C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 2
- MTCMFVTVXAOHNQ-UHFFFAOYSA-N ethyl 2-(bromomethyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)CBr MTCMFVTVXAOHNQ-UHFFFAOYSA-N 0.000 description 2
- OCTNSVPQFFDELX-UHFFFAOYSA-N ethyl 2-(phenoxymethyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)COC1=CC=CC=C1 OCTNSVPQFFDELX-UHFFFAOYSA-N 0.000 description 2
- JFBDHSKKTHAZRP-XADRRFQNSA-N ethyl 3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carboxylate Chemical compound C1C([C@@H](NC(=O)OCC=2C=CC=CC=2)C(C)C)=NOC1(C(=O)OCC)COC1=CC=CC=C1 JFBDHSKKTHAZRP-XADRRFQNSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- YHIUSKMZXDIGNJ-UHFFFAOYSA-N methyl 4,5-dihydro-1,2-oxazole-5-carboxylate Chemical compound COC(=O)C1CC=NO1 YHIUSKMZXDIGNJ-UHFFFAOYSA-N 0.000 description 2
- 125000006357 methylene carbonyl group Chemical group [H]C([H])([*:1])C([*:2])=O 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 150000003901 oxalic acid esters Chemical class 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013037 reversible inhibitor Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- JFGJGQNSFXHKAB-MRVPVSSYSA-N tert-butyl N-[(2S)-1-hydroxyimino-3-methylbutan-2-yl]carbamate Chemical compound CC(C)[C@H](NC(=O)OC(C)(C)C)C=NO JFGJGQNSFXHKAB-MRVPVSSYSA-N 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 238000010977 unit operation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- DVOFEOSDXAVUJD-RXMQYKEDSA-N (2s)-2-amino-3-methylbutanal Chemical compound CC(C)[C@H](N)C=O DVOFEOSDXAVUJD-RXMQYKEDSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- XOQBEABUTUIXHL-RXKSKBTASA-N (3S)-5-bromo-3-[methyl-[3-[(1S)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-phenoxy-4H-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1=C(C=CC2=CC=CC=C12)C(=O)N[C@@H](C(C)C)C1=NOC(C1)(C(=O)N([C@@H](CC(=O)O)C(CBr)=O)C)OC1=CC=CC=C1 XOQBEABUTUIXHL-RXKSKBTASA-N 0.000 description 1
- XXZLTWJRSDEOBQ-RXKSKBTASA-N (3S)-5-diazo-3-[methyl-[3-[(1S)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-phenoxy-4H-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1=C(C=CC2=CC=CC=C12)C(=O)N[C@@H](C(C)C)C1=NOC(C1)(C(=O)N([C@@H](CC(=O)O)C(C=[N+]=[N-])=O)C)OC1=CC=CC=C1 XXZLTWJRSDEOBQ-RXKSKBTASA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- WJYKTKYUYUAMNU-SIPNUGOWSA-N (3s)-3-[[3-[(1s)-1-(1-benzofuran-2-carbonylamino)-2-methylpropyl]-5-methyl-4h-1,2-oxazole-5-carbonyl]amino]-5-(2,6-dichlorobenzoyl)oxy-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)C1(C)ON=C(C1)[C@@H](NC(=O)C=1OC2=CC=CC=C2C=1)C(C)C)COC(=O)C1=C(Cl)C=CC=C1Cl WJYKTKYUYUAMNU-SIPNUGOWSA-N 0.000 description 1
- AMIBKSPSWDLSAW-JERZPMBSSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC(C(=O)N[C@@H](CC(O)=O)C(C)=O)C1 AMIBKSPSWDLSAW-JERZPMBSSA-N 0.000 description 1
- BEYPDRJSGSEUJE-KHLAINANSA-N (3s)-3-[[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-4,5-dihydro-1,2-oxazole-5-carbonyl]amino]-5-naphthalen-2-yloxy-4-oxopentanoic acid Chemical compound C1=CC=CC2=CC(OCC(=O)[C@H](CC(O)=O)NC(=O)C3ON=C(C3)[C@@H](NC(=O)C=3C=C4C=CC=CC4=CC=3)C(C)C)=CC=C21 BEYPDRJSGSEUJE-KHLAINANSA-N 0.000 description 1
- FGUQVUCZQOFWFW-KUVJNVSYSA-N (3s)-3-[[3-[(1s)-3-carboxy-1-(naphthalene-2-carbonylamino)propyl]-5-methyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-phenoxypentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)C1(ON=C(C1)[C@H](CCC(O)=O)NC(=O)C=1C=C2C=CC=CC2=CC=1)C)COC1=CC=CC=C1 FGUQVUCZQOFWFW-KUVJNVSYSA-N 0.000 description 1
- UOMFFTQTZBTJLF-UCWKTWOXSA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(3-phenylpropanoylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-5-bromo-4-oxopentanoic acid Chemical compound N([C@@H](C(C)C)C=1CC(CC=2C=CC=CC=2)(ON=1)C(=O)N[C@@H](CC(O)=O)C(=O)CBr)C(=O)CCC1=CC=CC=C1 UOMFFTQTZBTJLF-UCWKTWOXSA-N 0.000 description 1
- UMGPCOCVBJTMPN-RXKSKBTASA-N (3s)-3-[[5-benzyl-3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N[C@@H](CC(O)=O)C(C)=O)CC1=CC=CC=C1 UMGPCOCVBJTMPN-RXKSKBTASA-N 0.000 description 1
- LXBJVXZEEASILR-HSFHSNDNSA-N (3s)-3-[methyl-[3-[(1s)-2-methyl-1-(naphthalene-1-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxo-5-piperidin-1-ylpentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NC(=O)C=1C2=CC=CC=C2C=CC=1)C(C)C)C=1C=CC=CC=1)CN1CCCCC1 LXBJVXZEEASILR-HSFHSNDNSA-N 0.000 description 1
- NFFMSOKTSYAIPY-OZEXRGSVSA-N (3s)-3-[methyl-[3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-phenoxy-4h-1,2-oxazole-5-carbonyl]amino]-5-naphthalen-2-yloxy-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)N(C)[C@@H](CC(O)=O)C(=O)COC=1C=C2C=CC=CC2=CC=1)OC1=CC=CC=C1 NFFMSOKTSYAIPY-OZEXRGSVSA-N 0.000 description 1
- KVKFNHACKSHMOT-FJCNXOJISA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[[3-[(1s)-1-(isoquinoline-1-carbonylamino)-2-methylpropyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]-methylamino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NC(=O)C=1C2=CC=CC=C2C=CN=1)C(C)C)C=1C=CC=CC=1)COC(=O)C1=C(Cl)C=CC=C1Cl KVKFNHACKSHMOT-FJCNXOJISA-N 0.000 description 1
- JXVRFQHXAYPEBU-LDQYRDBOSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[[3-[(1s)-1-[[2-(1h-indol-3-yl)acetyl]amino]-2-methylpropyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]-methylamino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NC(=O)CC=1C2=CC=CC=C2NC=1)C(C)C)C=1C=CC=CC=1)COC(=O)C1=C(Cl)C=CC=C1Cl JXVRFQHXAYPEBU-LDQYRDBOSA-N 0.000 description 1
- ZVUISQPAUMGPSL-YOGAAICWSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-3-[methyl-[3-[(1s)-2-methyl-1-(quinoline-2-carbonylamino)propyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]amino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)N(C)C(=O)C1(ON=C(C1)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)C=1C=CC=CC=1)COC(=O)C1=C(Cl)C=CC=C1Cl ZVUISQPAUMGPSL-YOGAAICWSA-N 0.000 description 1
- VIEHUFBYHYOQIF-MJLQIQFDSA-N (3s)-5-bromo-3-[[3-[(1s)-1-[[2-(1h-indol-3-yl)acetyl]amino]-2-methylpropyl]-5-phenyl-4h-1,2-oxazole-5-carbonyl]-methylamino]-4-oxopentanoic acid Chemical compound C1C([C@@H](NC(=O)CC=2C3=CC=CC=C3NC=2)C(C)C)=NOC1(C(=O)N(C)[C@@H](CC(O)=O)C(=O)CBr)C1=CC=CC=C1 VIEHUFBYHYOQIF-MJLQIQFDSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- FNRRRFVUTMRVEZ-ANYOKISRSA-N (4s)-2-tert-butyl-4-(9h-fluoren-9-ylmethoxycarbonylamino)pentanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C(C)(C)C)C(O)=O)C(O)=O)C3=CC=CC=C3C2=C1 FNRRRFVUTMRVEZ-ANYOKISRSA-N 0.000 description 1
- ALZSTTDFHZHSCA-RNVDEAKXSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC1=CC(=O)OC2=CC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O)C(C)C)=CC=C21 ALZSTTDFHZHSCA-RNVDEAKXSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- MRUDNSFOFOQZDA-UHFFFAOYSA-N 2,6-dichlorobenzoic acid Chemical compound OC(=O)C1=C(Cl)C=CC=C1Cl MRUDNSFOFOQZDA-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- GFZMFCVDDFHSJK-UHFFFAOYSA-N 2-(methylideneamino)acetonitrile Chemical compound C=NCC#N GFZMFCVDDFHSJK-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- MHAVAHVWZBLHNG-AJZOCDQUSA-N 3-[(1s)-2-methyl-1-(phenylmethoxycarbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carboxylic acid Chemical compound N([C@@H](C(C)C)C=1CC(COC=2C=CC=CC=2)(ON=1)C(O)=O)C(=O)OCC1=CC=CC=C1 MHAVAHVWZBLHNG-AJZOCDQUSA-N 0.000 description 1
- YGLOALWHJIANIH-UHFFFAOYSA-N 3-[2-[[2-[[2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoylamino]-4-[(4-methyl-2-oxochromen-7-yl)amino]-4-oxobutanoic acid Chemical compound C=1C=C2C(C)=CC(=O)OC2=CC=1NC(=O)C(CC(O)=O)NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)C(NC(C)=O)CC1=CC=C(O)C=C1 YGLOALWHJIANIH-UHFFFAOYSA-N 0.000 description 1
- HGFGHLSWVYZKDC-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole-5-carboxylic acid Chemical compound OC(=O)C1CC=NO1 HGFGHLSWVYZKDC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- NHJPTPVROLKOHT-UHFFFAOYSA-N 5-methyl-4h-1,2-oxazole-5-carboxylic acid Chemical compound OC(=O)C1(C)CC=NO1 NHJPTPVROLKOHT-UHFFFAOYSA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108010021160 Ac-aspartyl-glutamyl-valyl-aspartyl-aminomethylcoumarin Proteins 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- GKEMLIWOKAPTEB-XYXHBKGXSA-N C1=CC=CC=2C3=CC=CC=C3C(C12)COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C1=NOC(C1)(C(=O)O)C Chemical compound C1=CC=CC=2C3=CC=CC=C3C(C12)COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C1=NOC(C1)(C(=O)O)C GKEMLIWOKAPTEB-XYXHBKGXSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- WSLTZIVQRZXCHS-MSYZFFFDSA-N CC(C)[C@H](NC(=O)OCc1ccccc1)C1=NOC(COc2ccccc2)(C1)C(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O Chemical compound CC(C)[C@H](NC(=O)OCc1ccccc1)C1=NOC(COc2ccccc2)(C1)C(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O WSLTZIVQRZXCHS-MSYZFFFDSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004068 Caspase-10 Human genes 0.000 description 1
- 108090000572 Caspase-10 Proteins 0.000 description 1
- 102100038916 Caspase-5 Human genes 0.000 description 1
- 101710090333 Caspase-5 Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- TULNGKSILXCZQT-UHFFFAOYSA-N Cysteinyl-Aspartate Chemical compound SCC(N)C(=O)NC(C(O)=O)CC(O)=O TULNGKSILXCZQT-UHFFFAOYSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102100038026 DNA fragmentation factor subunit alpha Human genes 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- GBJVAVGBSGRRKN-JYEBCORGSA-N Z-DEVD-FMK Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)OC)NC(=O)[C@H](CC(=O)OC)NC(=O)OCC1=CC=CC=C1 GBJVAVGBSGRRKN-JYEBCORGSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- MWJMOEDCZMTESZ-CRPGNVGASA-N [(3S)-3-[[5-benzyl-3-[(1S)-2-methyl-1-[[4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoyl]amino]propyl]-4H-1,2-oxazole-5-carbonyl]amino]-5-[(2-methylpropan-2-yl)oxy]-2,5-dioxopentyl] 2,6-dichlorobenzoate Chemical compound C1C([C@@H](NC(=O)CCC(=O)OC(C)(C)C)C(C)C)=NOC1(C(=O)N[C@@H](CC(=O)OC(C)(C)C)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)CC1=CC=CC=C1 MWJMOEDCZMTESZ-CRPGNVGASA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- NMPVEAUIHMEAQP-UHFFFAOYSA-N alpha-bromo-acetaldehyde Natural products BrCC=O NMPVEAUIHMEAQP-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- NQIOYIIIDJVRSG-NSHDSACASA-N benzyl n-[(2s)-1-chloro-1-hydroxyimino-3-methylbutan-2-yl]carbamate Chemical compound ON=C(Cl)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 NQIOYIIIDJVRSG-NSHDSACASA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- AOJDZKCUAATBGE-UHFFFAOYSA-N bromomethane Chemical compound Br[CH2] AOJDZKCUAATBGE-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108010042238 caspase-activated deoxyribonuclease Proteins 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000012592 cell culture supplement Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000017492 cellular component disassembly involved in apoptotic process Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010799 enzyme reaction rate Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- PJMAUGGMECQITE-UHFFFAOYSA-N ethyl 2-(4-bromophenyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)C1=CC=C(Br)C=C1 PJMAUGGMECQITE-UHFFFAOYSA-N 0.000 description 1
- ORRNHFXTIFQQIA-UHFFFAOYSA-N ethyl 2-(acetyloxymethyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)COC(C)=O ORRNHFXTIFQQIA-UHFFFAOYSA-N 0.000 description 1
- SYGAXBISYRORDR-UHFFFAOYSA-N ethyl 2-(hydroxymethyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)CO SYGAXBISYRORDR-UHFFFAOYSA-N 0.000 description 1
- FVLGPYFFONYLRZ-UHFFFAOYSA-N ethyl 2-benzylprop-2-enoate Chemical compound CCOC(=O)C(=C)CC1=CC=CC=C1 FVLGPYFFONYLRZ-UHFFFAOYSA-N 0.000 description 1
- OUGJKAQEYOUGKG-UHFFFAOYSA-N ethyl 2-methylidenebutanoate Chemical compound CCOC(=O)C(=C)CC OUGJKAQEYOUGKG-UHFFFAOYSA-N 0.000 description 1
- ILUCPNVXZDZFIT-UHFFFAOYSA-N ethyl 2-methylidenehexanoate Chemical compound CCCCC(=C)C(=O)OCC ILUCPNVXZDZFIT-UHFFFAOYSA-N 0.000 description 1
- MXUMJFMINXROCH-UHFFFAOYSA-N ethyl 2-methylidenepentanoate Chemical compound CCCC(=C)C(=O)OCC MXUMJFMINXROCH-UHFFFAOYSA-N 0.000 description 1
- BTHRFRGKHNMNIX-UHFFFAOYSA-N ethyl 2-naphthalen-1-ylprop-2-enoate Chemical compound C1=CC=C2C(C(=C)C(=O)OCC)=CC=CC2=C1 BTHRFRGKHNMNIX-UHFFFAOYSA-N 0.000 description 1
- IJBYVNFZITWYRD-UHFFFAOYSA-N ethyl 2-naphthalen-2-ylprop-2-enoate Chemical compound C1=CC=CC2=CC(C(=C)C(=O)OCC)=CC=C21 IJBYVNFZITWYRD-UHFFFAOYSA-N 0.000 description 1
- DYAIDCSUYFVYJB-ALLRNTDFSA-N ethyl 3-[(1s)-2-methyl-1-(naphthalene-1-carbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carboxylate Chemical compound C1C([C@@H](NC(=O)C=2C3=CC=CC=C3C=CC=2)C(C)C)=NOC1(C(=O)OCC)COC1=CC=CC=C1 DYAIDCSUYFVYJB-ALLRNTDFSA-N 0.000 description 1
- BGUDZGCMQVRTFT-ALLRNTDFSA-N ethyl 3-[(1s)-2-methyl-1-(naphthalene-2-carbonylamino)propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carboxylate Chemical compound C1C([C@@H](NC(=O)C=2C=C3C=CC=CC3=CC=2)C(C)C)=NOC1(C(=O)OCC)COC1=CC=CC=C1 BGUDZGCMQVRTFT-ALLRNTDFSA-N 0.000 description 1
- RJIFDLPXARMKIV-HXBUSHRASA-N ethyl 3-[(1s)-2-methyl-1-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-5-(phenoxymethyl)-4h-1,2-oxazole-5-carboxylate Chemical compound C=1C=CC=CC=1OCC1(C(=O)OCC)CC([C@@H](NC(=O)OC(C)(C)C)C(C)C)=NO1 RJIFDLPXARMKIV-HXBUSHRASA-N 0.000 description 1
- MUCWKCBZXAZGTE-BWDMCYIDSA-N ethyl 3-[(1s)-2-methyl-1-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-5-naphthalen-2-yl-4h-1,2-oxazole-5-carboxylate Chemical compound C=1C=C2C=CC=CC2=CC=1C1(C(=O)OCC)CC([C@@H](NC(=O)OC(C)(C)C)C(C)C)=NO1 MUCWKCBZXAZGTE-BWDMCYIDSA-N 0.000 description 1
- LKFKHIQQMSSDSB-UHFFFAOYSA-N ethyl 4,5-dihydro-1,2-oxazole-5-carboxylate Chemical compound CCOC(=O)C1CC=NO1 LKFKHIQQMSSDSB-UHFFFAOYSA-N 0.000 description 1
- HIZJURRUCIDWSM-DBUIHSHHSA-N ethyl 4-methyl-3-[(1S)-2-methyl-1-(2-phenylpropanoylamino)propyl]-5-phenyl-4H-1,2-oxazole-5-carboxylate Chemical compound C1(=CC=CC=C1)C(C)C(=O)N[C@@H](C(C)C)C1=NOC(C1C)(C(=O)OCC)C1=CC=CC=C1 HIZJURRUCIDWSM-DBUIHSHHSA-N 0.000 description 1
- GOWGRPBDVFSWPO-QODXOHEASA-N ethyl 5-benzyl-3-[(1s)-1-[1h-indol-3-yl(propanoyl)amino]-2-methylpropyl]-4h-1,2-oxazole-5-carboxylate Chemical compound C1C([C@H](C(C)C)N(C(=O)CC)C=2C3=CC=CC=C3NC=2)=NOC1(C(=O)OCC)CC1=CC=CC=C1 GOWGRPBDVFSWPO-QODXOHEASA-N 0.000 description 1
- KQQSTOCODYIGEJ-HXBUSHRASA-N ethyl 5-benzyl-3-[(1s)-2-methyl-1-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-4h-1,2-oxazole-5-carboxylate Chemical compound C=1C=CC=CC=1CC1(C(=O)OCC)CC([C@@H](NC(=O)OC(C)(C)C)C(C)C)=NO1 KQQSTOCODYIGEJ-HXBUSHRASA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000005373 execution phase of apoptosis Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 108010035817 human DNA fragmentation factor Proteins 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- KZRAAPTWXAMZHQ-UHFFFAOYSA-N methoxymethanamine Chemical compound COCN KZRAAPTWXAMZHQ-UHFFFAOYSA-N 0.000 description 1
- ZXRPQWHVIZSPFK-LURJTMIESA-N methyl (3s)-4-chloro-4-hydroxyimino-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound COC(=O)C[C@@H](C(Cl)=NO)NC(=O)OC(C)(C)C ZXRPQWHVIZSPFK-LURJTMIESA-N 0.000 description 1
- QBWGSUXSXLLRIP-QASNXKAYSA-N methyl 3-[(1s)-1-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutyl]-5-methyl-4h-1,2-oxazole-5-carboxylate Chemical compound O1C(C(=O)OC)(C)CC([C@H](CCC(=O)OC(C)(C)C)NC(=O)OCC2C3=CC=CC=C3C3=CC=CC=C32)=N1 QBWGSUXSXLLRIP-QASNXKAYSA-N 0.000 description 1
- JFHSPHDCERCVJZ-UBDBMELISA-N methyl 5-methyl-3-[(1s)-4-[(2-methylpropan-2-yl)oxy]-1-(naphthalene-2-carbonylamino)-4-oxobutyl]-4h-1,2-oxazole-5-carboxylate Chemical compound O1C(C(=O)OC)(C)CC([C@H](CCC(=O)OC(C)(C)C)NC(=O)C=2C=C3C=CC=CC3=CC=2)=N1 JFHSPHDCERCVJZ-UBDBMELISA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001577 simple distillation Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- GDEFTSVRKIMSSK-UEWDXFNNSA-N tert-butyl (3s)-3-amino-4-hydroxy-5-phenoxypentanoate Chemical compound CC(C)(C)OC(=O)C[C@H](N)C(O)COC1=CC=CC=C1 GDEFTSVRKIMSSK-UEWDXFNNSA-N 0.000 description 1
- OOQRRYDVICNJGC-MRVPVSSYSA-N tert-butyl n-[(2s)-1-hydroxy-3-methylbutan-2-yl]carbamate Chemical compound CC(C)[C@@H](CO)NC(=O)OC(C)(C)C OOQRRYDVICNJGC-MRVPVSSYSA-N 0.000 description 1
- YMNBXYLOSIKZGL-MRVPVSSYSA-N tert-butyl n-[(2s)-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound CC(C)[C@@H](C=O)NC(=O)OC(C)(C)C YMNBXYLOSIKZGL-MRVPVSSYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
CASPASE INHIBITOR
The present invention relates to a novel isoxazoline derivative, pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof which can serve as an inhibitor for protein caspases (cysteinyl-aspartate proteinases), a process for preparing the same and the use of the derivative as an inhibitor for caspases. The present invention also relates to a pharmaceutical composition for preventing inflammation and apoptosis which comprises the isoxazoline derivative, pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof and the process for preparing the same. The isoxazoline derivative according to : the present invention can effectively be used in treating diseases due to caspases, for example, the disease in which cells are abnormally died, : dementia, cerebral stroke, AIDS, diabetes, gastric ulcer, hepatic injure by hepatitis, sepsis, organ transplantation rejection reaction and anti-inflammation.
All organisms in nature undergo the life cycle consisting of development, differentiation, growth and death. Recently, an extensive research has been made to a mechanism involved in apoptosis which would play a key role in the control of the life cycle and the outbreak of diseases. It has been reported that apoptosis is occurred by a number of factors, but largely due to three kinds of cellular signal transport systems: the first of which is a signal transport system by the protein-protein interaction (See, Muzio M. et al., Cell 85, 817, 1996; Humke E. W. et al., JBC 273, 15702, 1998), the
WO U1/21600 PCT/KR00/01047 second, an incorporation of cytochrome C into cytoplasm via mitochondria (See, Liu X. et al, Cell 86:147, 1996; Li P. et al, Cell 91, 479, 1997), and the third, a cellular signal transport pathway by the
SAPK(Stress-activated protein kinases) activation of mitogen-activation protein kinase(MAPK) enzymes. All the pathways have been known to activate caspases cascade. As such caspases, about 10 kinds of isoenzymes in human and 14 kinds in mouse have been identified (see,
Thomberry N. A. et al, Science 28, 1312 1998; Green D. R. Science 28, 1309, 1998; Ahmad M., et al, Cancer Res. 15, 5201 1998). The enzymes exist within the cells in the form of proenzyme which has no enzymatic activity and converted into an activated form if the cells are damaged or are exposed to a substance which leads to cellular necrosis.
An activated enzyme has a heterodimer structure in which two polypeptides, i.e. larger subunits with the molecular weight of about 17-20 : kDa, and smaller subunits with the molecular weight of about 10 kDa are bound together. .
At present, caspases are classified into three (3) groups in view of the genetic identification analysis results and the biochemical characteristics: the first group is caspase-1, 4 and 5 which are responsible for the processing of cytokine activation, the second is caspase-3, 6 and 7 which carry out apoptosis and the third is caspase-8, 9 and 10 which are responsible for enzymatic activation in the upstream of signal transport system of apoptosis.
Among these caspases, Caspase-3 group and Caspase-8, 9, 10 etc. were recently reported to be related to apoptosis, and diseases (see, Thornberry
N.A. et al, Science, 28, 1312, 1998).
According to the recent research results, caspases are commonly activated as apoptosis is initiated, even though there is a minor difference depending upon the tissues and cells. The activated caspases then activate intracellular
CAD(Caspase-activated DNAse) which finally digests intranuclear DNA to result in cell death (Sakahira H., et al., Nature 1 96, 1998; Enann M et al., Nature 1 43, 1998). In addition, they promote apoptosis by decomposing substrate such as PARP (Poly-ADP ribose polymerase) which is necessary for the survival of cells.
Meantime, according to the recent disease-related researches, it was : reported that the activity of Caspase-3 is increased in the brain of dementia patient which promotes the production of beta-amyloid peptide from beta-amyloid precursor protein that is considered to be a major cause : of dementia, thereby accelerating the apoptosis of brain cells (see, Kuida
K. et al, Nature 28, 368, 1996). Further, it was reported that activation : of caspases can be the direct inducer of various diseases such as sepsis (see, Haendeler J. et al., Shock 6, 405, 1996; Lenhoff R.J. et al, 29, 563, 1999), rheumatoid arthritis (Firestein G.S. et al, J. Clin. Invest 96(3), 1631, 1995), cerebral stroke (see, Hill I.E. et al, Brain Res.10, 398, 1995), ALS disease (see, Alexianu M.E. et al, J Neurochem 63, 2365, 1994), autoimmune isease (see, Rieux-Laucat F, et al, Science 2, 1347, (1995), diabetes mellitusd(see, Juntti-Berggren et al, Science 2, 86, 1993), hepatitis (Haendeler J. et al, Shock 6, 405, 1996), organ transplantation rejection reaction (Koglin J. et al., Transplantation, 27, 904, 1999; Bergese
SD. et al, Ti ransplantation 27, 904, 1999), gastric ulcer (see, Slomiany
B.L. et al, J. Physiol. Pharmacol. 96, 1631, 1995), and the like.
The researches on three dimensional structure of caspase-1 and caspase-3, catalytic mechanism of the enzyme and enzyme-substrate specificity (see,
Wilson, K.P et al, Nature 370, 270, 1994; Walker, N.P.C. et al., Cell 78, 343, 1994; Nature Struc. Biol. 3, 619, 1996) revealed that Caspase-1 group has a hydrolase-substrate specificity for the peptide sequence of (P4)-Val-X-Asp(P1) and Caspase-3 group has a hydrolase-substrate specificity for the sequence of (P4)Asp-X-X-Asp(P1).
Z-VAD-fluoromethyl ketone, and Z-DEVD-fluoromethyl ketone which mimics the above amino acid sequence have already been used in the researches on the inhibitors and were proven to have an inhibitory activity on apoptosis of hepatic cells by an activation of caspases (see, Rodriguez
I. Et al, J. Exp. Med., 184, 2067, 1996; Rouquet N. et al., Curr Biol. 1, 1192, 1996; Kunstle G. et al, Immunol. Lett 55, 5, 1997), and on the apoptosis of brain cells by cerebral ischemias. However, since such peptide derivatives are deficient in drug property for clinical application, . they cannot be used as therapeutics.
Fulminant hepatic failure (FHF) is a clinical syndrome resulting from massive death of liver cells or sudden and severe impairment of liver function (See: Trey, C. et al, 1970, Progress in liver disease, Popper, H. and F. Schaffner, eds. Grune and stratton, New York, pp282-298). The causes of FHF are diverse: hepatitis virus infection, drugs and toxins, alcohol, ischemia, metabolic disorder, massive malignant infiltration, chronic autoimmune hepatitis, etc. However, these mechanisms are not completely clear. Since the prognosis of FHF is very poor while its progress is very rapid, it is not uncommon that a patient falls in lethal condition in 1-2 weeks from the onset of this syndrome (See, Sherlock, S. 1993, Adv.
Intern. Med. 38: 245-267). Consequently, the overall mortality in most series is very high. However, the hepatic lesion is potentially reversible, and survivors usually recover completely.
Different therapeutic options that have been tried in FHF include antibiotics, diuretics, corticosteroids, blood transfusion, charcoal haemoperfusion, and plasmaphresis. However, none of these methods have been shown to be effective in controlled studies. In recent years, liver transplantation is generally accepted as the only therapeutic option to actually improve the prognosis of this syndrome. ‘However, liver transplantation cannot be the perfect treatment for FHF because of immune complication, viral or bacterial infection, and graft availability. Thus, a potent therapeutic agent which can protect hepatic cells from massive death during the acute phase is critically desired.
Apoptosis is a type of cell death characterized by a series of distinct : morphological and biochemical changes accomplished by specialized cellular machinery. Apoptosis is an essential process to remove excess, unwanted and harmful cells and maintain homeostasis, but inappropriate apoptosis is implicated in many human diseases such as neurodegenerative diseases, ischaemic damage, autoimmune disorders, several forms of cancer.
Recently, it became clear that apoptosis of hepatocytes is a critical cause of hepatic injury in viral hepatitis and alcoholic hepatitis and acute hepatic failure in fulminant hepatitis. Many changes which occur in a cell that received apoptotic signal reflect complex biochemical events carried out by a family of cysteine proteases called caspases.
Caspases inactivate proteins that protect living cells from apoptosis, such as I“P/DFF45, an inhibitor of the nuclease responsible for DNA fragmentation, and Bcl-2. At the same time, caspases contribute to apoptosis not only by direct disassembly of cell structures, but also by reorganizing cell structures indirectly by cleaving several proteins involved in cytoskeleton regulation. Since caspase activation is closely related to the initiating, propagating, and terminal event of most forms of apoptosis, this family of enzymes are attractive potential targets for the treatment of disorders resulted from excessive apoptosis or insufficient apoptosis.
Several kinds of caspase inhibitors have been identified. Four distinct classes of viral inhibitors have been described: CmA, p35, a family of
IAP (inhibitors of apoptosis), and the hepatitis B virus-encoded HBx protein (See, Gottlob, K. et al, 1998, J. Biol. Chem. 273: 33347-33353).
However, these molecules are not suitable as the therapeutic agent.
Peptide-based caspase inhibitor such as z-VAD-fmk, z-DEVD-fmk, and
Ac-YVAD-cmk has widely been used for research use and this inhibitor showed apoptosis-blocking activity in cellular level (See: Sane, A. T. et al., 1998, Cancer Res. 58: 3066-3072), in rodent models of liver injury : caused by Fas or by TNFq (See: Kunstle, G. et al, 1997, Immunol. Lett. 55: 5-10) or ischemia after liver transplantation (See: Cursio, R. et al. : 1999, FASEB J. 13: 253-261). Petak and colleagues showed that a bi-functional anticancer agent, BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) had caspase inhibiting activity and inhibited drug-induced apoptosis in vitro (See: Petak, I. et al, 1998, Cancer Res. 58: 614-618). Recently, cyclooxygenase-2 (COX-2) inhibitors are arousing interest as potential therapeutic agents of FHF (See, McCormick, P. A. et al, 1999, Lancet 353: 40-41). However, the efficacy of these materials has not been clinically verified yet.
In the meantime, development of new drugs depends primarily on the availability of suitable animal models relevant to human hepatitis or hepatocytic damage. It is therefore very important to adopt a suitable animal model relevant to human FHF to test efficacy of a candidate for
-7 = therapeutic agent. Two types of experimental hepatitis model were reported. One is hepatic injury induced by bacterial lipopolysaccharide together with D-galactosamine (See: Galanos, C. et al, 1979, Proc. Nall.
Acad. Sci., 76: 5939; Lehman, V. et al., 1987, J Exp. Med. 165-657), and the other is a recently developed experimental model, Con A-induced hepatitis (See: Tiegs, G. et al, 1992, J Clin. Invest. 90: 196-203; .Mizuhara, H. et al., 1994, J Exp. Med. 179: 1529-1537). Con A-induced hepatitis model closely mimics human FHF in many respects, especially in the role of Fas in pathogenesis. Fas is abundantly expressed on the hepatocyte and FasL is expressed on activated T cells and functions as an effector of cytotoxic lymphocytes. Injection of agonistic monoclonal anti-Fas antibody into adult mice caused rapid hepatic failure, indicating that abnormally activated Fas-Fasl. system may play a role in human : fulminant hepatitis which can be caused by the activation of immune system such as cytotoxic T cells. Accumulating data such as the involvement of specific CTLs in the pathogenesis of FHF, the sensitivity of primary hepatocytes to Fas-mediated apoptosis in vitro, and the overexpression of Fas in hepatocytes transformed with human hepatitis virus are consistent with this hypothesis. In recent studies, the activation of
Fas-FasL system has been proved to play an important role in the liver cell injury by Con A-induced hepatitis (See: Tagawa, Y. et al., 1998, Eur.
J. Immunol. 28: 4105-4113). FasL was induced in the liver shortly after the Con A injection was predominantly expressed on intrahepatic T cells.
These results indicate thar Fas-FasL system is a critical element in the development of Con A-induced hepatitis. At the same time, the induction of Con A-hepatitis is associated with the production of various cytokines such as IL-2, TNFq , IL-6, IL-4, and IL-10.
The present inventors have conducted an extensive research for many years in order to develop new therapeutics suitable for caspase inhibitor which has a unique structure over those known in the art. As a result, the inventors have surprisingly discovered a novel isoxazoline derivative of formula (I) which has a different structure over the known inhibitors and has an excellent inhibitory activity against various substrates for caspases, and have completed the present invention.
It is therefore an object of the present invention to provide a novel isoxazoline compound of the formula (I), the pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof which are useful as a caspase inhibitor.
Another object of the present invention is to provide a process for . preparing the compound of formula (I).
Further object of the present invention is to provide a caspase inhibitor which comprises an isoxazoline derivative of the formula (I), the pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof.
Still other object of the present invention is to provide a pharmaceutical composition for inhibiting caspases activity which comprises as the active ingredient a therapeutically effective amount -of the isoxazoline derivative of formula (I) and pharmaceutically acceptable carrier.
Still further object of the present invention is to provide a pharmaceutical composition for preventing inflammation and apoptosis which comprises the isoxazoline derivative, pharmaceutically acceptable salts, esters and
— 0 — stereochemically isomeric forms thereof and the process for preparing the same.
Further objects and advantages of the invention will become apparent through reading the remainder of the specification.
The foregoing has outlined some of the more pertinent objects of the present invention. These objects should be construed to be merely illustrative of some of the more pertinent features of the invention. Many other beneficial results can be obtained by applying the disclosed invention in a different manner or by modifying the invention within the scope of the disclosure. Accordingly, other objects and a more thorough understanding of the invention may be found by referring to the detailed : description of the preferred embodiment in addition to the scope of the invention defined by the claims.
Fig. 1 represents a graph showing inhibition activity of the compound of the invention against recombinant caspase-1, -2, -3, -4, -6, -7, -8 and -9.
Fig. 2 represents a graph showing caspase inhibition activities of the compound of the invention in rat hepatocytes in which apoptosis was derived by TNF, and Actinomycin D treatment.
Fig. 3 represents a graph showing the effect of the compound of the invention on the prevention of apoptosis in rat hepatocytes in which apoptosis were derived by TNF, and Actinomycin D treatment.
Fig. 4 represents a dose-dependent inhibitory activity of the compound of the invention against AST and ALT activities elevated by ConA in vivo, wherein the crossbars show the average of each group and p value was calculated by student's t-test.
Fig. 5 represents a dose-dependent inhibition activity against cytokines elevated by ConA in vivo, wherein the crossbars show the average of each group and p value was calculated by student's t-test.
Fig. 6 represents a photograph showing inhibition activities of the compound of the invention in apoptotic lesions and morphological, histological changes of hepatocytes in ConA-treated mouse liver.
Fig. 7 represents an electrophoresis image showing inhibition activities of } the compound of the invention on PARP cleavage caused by
ConA-induced apoptotic death of hepatocytes. Each lane is representative of 10 mice per group.
Fig. 8 1s a graphical representation showing hepatic protection of the compound of the mvention from IFNy and anti-Fas antibody-induced apoptosis.
Fig. 9 represents hepatic protection of the compound of the invention from anti-Fas antibody-induced apoptosis.
Fig. 10 is a graph showing inhibition activity of the compound of the invention against caspase-3-like activity in anti-Fas antibody-treated liver tissues.
Fig. 11 represents protection of mice by the compound of the invention from anti-Fas antibody-induced lethality.
Fig. 12 is a graphical representation showing the protection of mice liver by the compound of the invention from TNF -induced apoptosis.
Fig. 13 is a graphical representation showing that the compound of the invention inhibits caspase-3-like activity in TNF -treated liver.
Fig. 14 is a graphical representation showing that the compound of the invention protects mice from TNF -induced lethality.
Fig. 15 is a graphical representation showing that the compound of the : invention inhibits TNF, /Actinomycin D-induced caspase activation and apoptosis in primary cultured rat hepatocytes.
Fig. 16 is a graphical representation showing that the compound of the invention prevents hepatocyte apoptosis preinduced by TNF /Actinomycin
D.
Fig. 17 is a graphical representation showing that the compound of the invention prevents TNF /DaIN-mediated mortality.
In advance of illustrating the present invention in datail, some important terms are defined as follows: : a) Simple Alkyl Chain (hereinafter referred to as "SAC") is meant by a wO U1/21600 PCT/KR00/01047 carbohydrate having Cs, and contains a branched isomeric form. b) Simple CycloAlkyl Chain (hereinafter referred to as "SCAC" is meant by a cyclic compound having Cs.o. c) Aryl group (hereinafter referred to as "Ar") represents benzene [1:2,3,4,5,6], naphthalene[1,2:1,2,3,4,5,6,7,8,], pyridine [2,3,4:2,3,4,56], indole[1,2,3,4,5,6,7: 1,2,3,4,5,6,7], quinoline[2,3,4,5,6,7,8: 2,3,4,5,6,7,8], isoquinoline[1,3,4,5,6,7,8: 1,3,4,5,6,7,8], furan [2,3:2,3,4,5], thiophene[2,3:2,3,4,5], pyrole[1,2,3: 1,2,3,4,5], pyrimidine [2,4,5,6: 2,456], mmidazole[1,2,4,5:1,2,4,5], benzofuran[2,3;2,3,4,5,6,7], etc. in which the former digits within the bracket represents a position where the corresponding aryl group is connected to the inhibitor according to the present invention and the latter digits after the colon represents a position : where the substituent Y defined later can be attached. d) Side chain of amino acids represents the side groups which are attached to the chiral carbon of 20 natural amino acids.
Frequently referred terms are abbreviated as follows:
N-chlorosuccinimide : NCS
N-methylmorporline : NMM
N,N-dimethyl formamide : DMF 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide: EDC 1-hydroxybenzotriazole hydrate : HOBt
Trifluoroacetic acid : TFA t-butoxycarbonyl : Boc benzyloxycarbonyl : Cbz methyl : Me ethyl : Et equivalent : Eq or eq
The term "stereochemically isomeric forms" as used in the foregoing and hereinafter defines all the possible isomeric forms which the derivative of formula (1) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes a mixture of all possible stereochemically isomeric forms, said mixture containing all diastereomers of the basic molecular structure. Stereochemically isomeric forms of the derivatives of the formula (1) are intended to be embraced within the scope of this invention.
The pharmaceutically acceptable salts as used in the foregoing and : hereinafter comprises the therapeutically active non-toxic salt forms which can form the derivative of formula (1).
Hereinafter, the invention will be illustrated in more detail.
In one aspect, the present invention provides a novel isoxazoline derivative of the formula (I), the pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof. oT x
Rr _N SN > I
RY “R rR Ir
In the compound of formula (I), the substituents are defined as follows:
R and R' each independently represents hydrogen, simple alkyl chain
(-SAC), simple cycloalkyl (-SCAC), aromatic (-Ar), or simple alkyl chain substituted with aromatic (-SAC-Ar); preferably represents hydrogen.
Throughout the description of the specification, R' has the same meaning as R unless specifically defined.
R' represents -SAC, -SCAC, -Ar, or -SAC-Ar, or represents side chain of amino acids, or -(CH2).COOZ (in which n is 1 or 2, and Z is hydrogen, -SAC, -Ar or -SCAC); preferably represents -CH2COOH. rR’ represents -SAC, -SCAC, -Ar, -SAC-Ar, or side chain of amino acids; preferably represents -CH(CHs),, -CH;COOH, -(CH2).COzH, -CH2C(=O)NHa or -(CH2)2C(=0O)NH.. : In a case where an adjacent position of R' or R® become a stereogenic center, both the stereoisomeric compounds are intended to be embraced within the scope of the present invention. Similarly, a case where two forms of compounds are co-exist (a mixture of diastereomeric compounds) is embraced within the scope of the invention. In addition, the cases where R' or R® are composed of carboxylic acids or bases with side chain residue of amino acids, their protected forms such as simple esters or pharmaceutically acceptable salt forms are also embraced within the scope of the compounds according to the invention.
R? represents -H, -SAC, -SCAC, -Ar, or -SAC-Ar, or represents side chain of amino acids, or represents ~(CH2)u(O)mR’ (in which R®> = -SAC, -SCAC, ‘Ar, -SAC-Ar; n=0, 1 or 2; and m=0 or 1), or -(CH2).OC(=O)R’ (in which R® = -SAC, -SCAC, -Ar, or -SAC-Ar; and n=1 or 2). Preferable R? represents (CH2)a(O)mAr' (in which n=0, 1, or 2; and m = 0 or 1; Ar = substituted phenyl or imidazole), methyl or hydrogen.
In a case where an adjacent position due to R®> become a stereogenic center, both the stereoisomeric compounds are embraced within the context of the compounds of the present invention, Similarly, a case where two forms of compounds are co-exist (a mixture of diastereomeric compounds) is embraced within the category of the compounds according to the invention. In addition, the cases where R® are composed of carboxylic acids or bases with side chain residue of amino acid, their protected forms such as simple esters or pharmaceutically acceptable salt forms are also embraced within the scope of the compounds according to the invention.
R* represents a) amino acid residue in which (O the carboxyl group attached to : the chiral carbon of amino acid is bound to the amine group to form an amide bond, (@ the chiral carbon of amino acid has either R or S configuration, (3 the amino group attached to the chiral carbon of amino acid is protected by formyl, acetyl, propyl, cyclopropylcarbonyl, butyl, methanesulfonyl, ethanesulfonyl, propanesulfonyl, butanesulfonyl, methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, butyloxycarbonyl, methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl, butylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, dipropylcarbamoyl, dibutylcarbamoyl or cyclopropylaminocarbonyl, or the amino group may be replaced with a hydrogen atom, and @ the carboxyl group in the side chain may form an ester group with -SAC or -SCAC, b) -C(=O)R’ (in which R’ = -SAC, -SCAC, -Ar, -SAC-Ar), -COR® (in which R® = hydrogen or R), -C(=O)NR'R®, -SOR’, -SO:R’, or -C(=0)CH=CH-Ar, c) -(C=0)-L-CO;R®, in which L represents a divalent (=capable of > double substitution) linker selected from a group consisting of Cis alkyl,
Css cycloalkyl, furan, thiophene, diazole (1,2 or 1,3), triazole (1,2,3 or 1,3,4), tetrazole, oxazole, isoxazole, thiazole, isothiazole, diazine (1,2 or 1,3 or 1,4), triazine, -Ph(-R’)- (in which R’ = H, F, Cl, Br, I, CHO, OH,
OCHs, CFs, OCFs;, CN, C(=0O)Me), tetrahydrofuran, tetrahydrothiophene, 1 A-dioxane, -CH=CQR'®)- (in which RH, methyl, ethyl), .CH=CHCH®R'%)- , -CH(OR'%)CHz-, -CH>C(=0)CHa-, -C(=O)CH,CH,-
In cases where R' and the adjacent R', and/or R? and the adjacent R are connected to each other to form a cyclic compound, R'.R' or R-R together represents -(CHz)n-, -(CH2)s-O-(CH2)m-, or ~(CH2)o"NR"~(CHy)n- (in which n+m<9, RY™=SAC, -SCAC, -Ar, -SAC-Ar. -C(=0)-SAC. -C(=0)-SCAC, -C(=0)-Ar, or -C(=0)-SAC-Ar),
X represents -CN, -CHO, -C(=0)R' (in which R' = -SAC, -SCAC, -Ar, :
SAC-Ar, or -CHN,), -C(=O)OR" (in which R"” = -SAC, -SCAC, -Ar, or
SAC-Ar), -CONR'R" (in which R'® and R' each represents -H, -SAC, -0-SAC, -SCAC, -Ar, or -SAC-Ar), -C(=0)CH.0(C=0)Ar" (in which Ar" = 2 6-disubstituted phenyl with F, Cl, Br, I, or CHs), -C(=0)CH,0OR"® (in which R'® represents -SAC, -SCAC, -Ar, or -SAC-Ar), or _C(=0)CH,OC(=O)R" (in which R"” = -SAC, -SCAC, -Ar, or -SAC-Ar), or
X represents -COCH.-W, wherein W represents -Nj, -F, -Cl, -Br, -I,
NR®R?" or -SR* (in which wherein R® R* and R* each independently represents -SAC, -SCAC, -Ar, or -SAC-Ar or R* and R*' are connected to form a cyclic compound); or W represents
RY yy RCP, 0 ) ! ° a in which Y represents -OH, OR® (in which R® = -SAC, or -SCAC), -C(=0)R* (in which R* = -H, -SAC, or -SCAC), -F, -Cl, -Br, -I, -CN,
NC, Ns, -CO;H, -CF3, -COR® (in which R® = -SAC, or -SCAC), -C(=0)NHR® (in which R* = -SAC, or -SCAC), and -C(=0)NR*R* (in which R¥, R® = -SAC, or -SCAC) and can be mono- or poly-substituted at its maximum regardless of the order and the kinds.
Among the compound of formula (I), preferred are those in which R* represents -C(=0)(CH2),COOZ (in which p is 1 to 4, and Z is hydrogen, -SAC, -Ar or -SCAC). Also preferred are those in which R! represents -(CH2),.COOZ (in which n is 1 or 2, and Z is hydrogen, -SAC, -Ar or -SCACQC).
Among the compound of formula (I), more preferred are those in which a) R and R' represent hydrogen, b) R' represents -CH:COOH, -CH,COOCH;3, or CH:COOCH:CHs, c) R? represents -(CH2).(O)R’ (in which R’ = -SAC, -SCAC, -Ar, -SAC-Ar; n=0, 1 or 2; and m=0 or 1), SAC, Ar, or Hydrogen, d) R® represents -CH(CHs),, -CH,COOH, -(CH2).CO;H, -CH,C(O)NH:> or -(CH2)2C(O)NHa, e) R' represents -C(=0)(0).R*” (in which n=0, 1; R¥= -Ar or -SAC-Ar), .SO,R* (in which R= -Ar or -SAC-Ar), or -C(=O)NHR®' (in which R® = _Ar, or -SAC-Ar), or f) X represents -C(=O)CHN,, -C(=0)CH2Br, -C(=O)CH:Cl, -C(=0)CH,OPh
~ 18 - or -C(=0)CH0C(=0)Ar" (in which Ar"=26-dichlorophenyl, 2,6-difluoro- phenyl or 2,6-dimethylphenyl).
Most preferred compounds are selected from the group consisting of the following: (38)-3-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-4,5-di- hydro-isoxazole-5-carbonylamino}-4-keto-pentanoic acid, (38)-3-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-S-phenoxy methyl-4,5-dihydro-isoxazole-5-carbonyl-amino }-4-keto-pentanoic acid; (28)-2-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-5-phenoxy methyl-4,5-dihydro-isoxazole-5-carbonyl-amino}-succinic acid 1-(N-methyl-
N-methoxy)-amide; (38)-3-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl}-4,5-dihydro -isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid; : (3S)-3-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-4,5-dihydro -isoxazole-5-carbonylamino }-4-keto-5-bromo-pentanoic acid; (38)-3-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-4,5-dihydro -isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid, (38)-3-{3-[(18)-1-(naphthalene- 1-carbonylamino)-2-methyl-propyl]-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-S-phenoxy-pentanoic acid; (3S)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl}-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-phenoxy-pentanoic acid; (3S)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenoxy- methyl-4, 5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-diazo-pentanoic acid; (3S)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-bromo-pentanoic acid;
~ 19 - (3S)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl- 0Xy)-pentanoic acid, (35)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid(LP and MP); (3S)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-bromo-pentanoic acid(LP and MP); (3S)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid(LP and MP); (3S)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-3-carboxy-propyl]-5-methyl-4, 5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid; (35)-3-{3-[(1S)-1-(quinoline-2-yl-carbonylamino)-2-methyl-propyl]-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-pentanoic acid; (35)-3-{3-[(1S)-1-(naphthalene-2-sulfonylamino)-2-methyl-propyl]-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid; (3S)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2-naphthyloxy)- pentanoic acid; (35)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(1-naphthyloxy)- pentanoic acid; (35)-3-{3-[(1S)-1-(25)-2-acetylamino-succinoylamino)-3-carboxy-propyl]-5- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid; (3S)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-4,5-dihydro-
WO v1/21600 PCT/KR00/01047 ~ 90 - isoxazole-5-carbonylamino }-4-keto-5-(2-naphthyloxy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(2-naphthalenecarbonylamino)-propyl]-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentancic acid (diasteromeric mixture); (35)-3-{3-[2-methyl-(1S)-1-(phenylmethyloxycarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-diazo-pentanoic acid; (35)-3-{3-[2-methyl-(15)-1-(phenylmethyloxycarbonylamino)-propy!]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino} -4-keto-5-bromo-pentanoic acid; (3S)-3-{3-[2-methyl-(15)-1-(phenylmethyloxycarbonylamino)-propy!]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(phenylethylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(phenylethylcarbonylamino)-propyl]-5-phenylmethyl -4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-bromo-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(phenylethylcarbonylamino)-propyl]-5-phenyi- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid; (38)-3-{3-[2-methyl-(1S)-1-(1-naphthalenecarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(1-naphthalenecarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-bromo-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(1-naphthalenecarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoylo
Xy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(1-naphtalenesulfonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-diazo-pentanoic acid
(diastereomeric mixture); (3S)-3-{3-[2-methyl-(1S)-1-(1-naphtalenesulfonylamino)-propyl]-5-phenyl- methyl-4, 5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-bromo-pentanoic acid (diastereomeric mixture); (35)-3-{3-[2-methyl-(1S)-1-(1-naphtalenesulfonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid (diastereomeric mixture); (38)-3-{3-[2-methyl-(1S)-1-((3-indolyl)ethylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-((3-indolyl)ethylcarbonylamino)-propyl]-S-phenyl- - methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-bromo-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-((3-indolyl)ethylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid, (35)-3-{3-[2-methyl-(1S)-1-((3-indolyl)methylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-((3-indolyl)methylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-bromo-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-((3-indolyl)methylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)- 1-(cinnamoylamino)-propyl]-5-phenylmethyi-4,5- dihydro-isoxazole-5-carbonylamino}-4-keto-5-diazo-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(cinnamoylamino)-propyl]-5-phenylmethyl-4,5- dihydro-isoxazole-5-carbonylamino}-4-keto-5-bromo-pentanoic acid; (3S)-3-{3-[2-methyl-(18)- 1-(cinnamoylamino)-propyl]-5-phenylmethyl-4,5- dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)-
pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(phenylmethylsulfonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid; (3S)-3-{3-[2-methyl-(15)-1-(phenylmethylsulfonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-bromo- pentanoic acid, (3S)-3-{3-[2-methyl-(1S)-1-(phenylmethylsulfonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid; (3S)-3-{3-[2~-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-bromo-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-4,5-dihydro- 1soxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino } -4-keto-5-bromo-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino } -4-keto-5-phenoxy-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-5-(1-
imidazolyl-methyl)-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-phenoxy- pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(2-naphthalenecarbonylamino)-propyl]-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-pentanoic acid; (38)-3-{3-[(1S)-1-(succinoylamino)-3-carboxy-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid, (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(1-naphthalenylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(1-piperidinyl)- pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(isoquinoline-1-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid, (35)-3-{3-[2-methyl-(1S)- 1-(isoquinoline-3-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino } -4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(quinoline-4-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid, (3S)-3-{3-[2-methyl-(1S)-1-(benzofuran-2-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoylo xy)-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(naphthalene-1-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-difluorobenzoylo
Xy)-pentanoic acid, (38)-3-{3-[2-methyl-(1S)-1-(quinoline-3-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoylo xy)- pentanoic acid;
(3S)-3-{3-[2-methyl-(1S)-1-(naphthalene-1-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino } -4-keto-5-(2,6-dimethylbenzoylo xy)-pentanoic acid[diastereomeric mixture]; (35)-3-{3-[2-methyl-(18)-1-(quinoline-8-carbonylamino)-propyl]-5-phenylmethy 1-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)- pentanoic acid [diastereomeric mixture]; (3S)-3-{3-[2-methyl-(1S)-1-(indole-2-carbonylamino)-propyl]-5-phenylmethyl-4, 5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)- pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(indole-3-carbonylamino)-propyl]-5-phenylmethyl-4,
S-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2 6-dichlorobenzovloxy)- pentanoic acid, (35)-3-{3-[2-methyl-(1S5)-1-(naphthalene- 1-carbonylamino)-propyl]-5-methyl-4, 5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)- pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(benzofuran-2-carbonylamino)-propyl]-5-methyl- 4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pen tanoic acid; (38)-3-{3-[3-carboxy-(1S)-1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-propyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(N-piperidine)-pentanoic acid[diastereomeric mixture]; (3S)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(N-pyrrolidine)-pentanoic acid
[diastereomeric mixture]; (3S)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-butyl-4,5-dihydro- isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino}-4-keto-5-(2-naphthyloxy)-pentanoic acid, (3S)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-propyl-4,5-dihydro- isoxazole-5-carbonylamino}-4-keto-5-phenoxy-pentanoic acid [diastereomeric mixture]; (3S)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-hydroxymethyl-4,5-dihy dro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid [diastereomeric mixture]; (3S)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-phenylmethyl-4,5- dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentano ic acid; (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-S-methoxymethyl-4,5-di- hydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic ‘acid [diastereomeric mixture]; (3S)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-n-pentyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-ethyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(glutaroylamino)-propyl]-5-methyl-4,5-dihydro- iso-xazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid, and (3S)-3-{3-[2-methyl-(1S)-1-(phenylmethyloxycarbonylamino)-propyl]-4,5- dihydro-isoxazole-5-carbonylamino}-4-keto-pentanoic acid methyl ester.
In another aspect, the present invention provides a process for preparing a compound of formula (I).
Hereinafter, a process for preparing the isoxazoline derivatives of formula (I) according to the present invention will be explained with respect to
Reaction Schemes 1 and 2. It should be understood that the reaction schemes generally illustrate the specific process used in the present invention, but any modification of the unit operations may be made without departure of the spirit of the invention. Therefore, the present invention should not be limited to the following preferred embodiments.
In the first step, amino protected amino acid (II) (commerically available from Novabiochem) is reduced to give N-protected amino alcohol (TIT) which is then oxidized to give N-protected amino aldehyde (IV).
N-protected amino aldehyde (IV) is reacted with hydroxylamine- hydrochloride and sodium carbonate in a mixed solution of an alcohol and water to give an oxime (V) (syn- and anti-oxime). The resulting oxime derivative (V) is treated with NCS (N-chlorosuccinimide) in an aqueous solution of dimethylformamide to give hydroxamoyl chloride (VI). As the representative substituents used in the synthesis of hydroxamoyl chloride, the following groups may be exemplified: P; represents Cbz, t-Boc, Fmoc,
Teoc(trimethylsilyl-ethyloxycarbonyl), etc.; R represents H and R’ represents -CH,CH,CO2Bu(t), -CH.CO:Me, -CH.CO2Bu(t), -isopropyl, phenylmethyl, and the like.
Reaction Scheme 1
Chg 0 Tg
R RS R ® NE in 1 Iv
H NOH H oH
PN Ha nE— pA
R R Rg Rr
Vi \'%
In the above Reaction Scheme 1, the following combinations of a) to g) for the commercially available compounds (II) to (VI) may be synthesized. a) P; = Cbz, R = H, R’ = i-Pr b) P; = t-Boc, R =H, R’ = i-Pr ¢) P; = Fmoc, R = H, R’ = CH,CH,CO2Bu(t) d) P, = t-Boc, R = H, R’ = CH,CO;Me e) P, = Cbz, R = H, R> = CH>CO:Bu(t) f) P; = Fmoc, R = H, R® = CH:CO:Bu(t) - g) Pi = Boc or Cbz, R = H, R® = CH:Ph
Reaction Scheme 2
WU 01/21600 PCT/KR00/01047 — H — ana —_— vi * cor, Py” SANAor, RY SOAeor, vil RB yy RB x i
NX
PY
X
Py x
N N X
R RB Oo RR 1
In the second step, the hydroxamoyl chioride (VI) thus obtained is then reacted with acrylate derivative (VII) to give isoxazoline derivative (VIII).
If necessary, isoxazoline derivative (VIII) may be synthesized directly from the oxime derivative (V).
If a compound having the protecting group P; can be used as the inhibitor © (for example, P; is a Cbz group), the isoxazoline derivative (VIII) 1s directly reacted with the compound (X) to give a compound of formula (I), and there is need to convert the protecting group P; into other substituent, P; is removed and R* is introduced thereinto.
In the above Reacion Scheme 2, the following combination of substituents may be synthesized.
In the compound (VIII), a) P, = Cbz, R =H, R’> = iPr, R” = H, P, = Et b) P, =Cbz, R =H, R' =iPr, R* =H, P, = H ¢) Pi = Cbz, R = H, R’ = i-Pr, R*> = CH,OPh, P, = Et d) P, = Cbz, R = H, R® = i-Pr, R® = CH,0Ph, P, = H e) P; = Fmoc, R = H, R’ = CH,CH,CO,Bu(t), R* = CHs, P, = CHs(or
Et) f) P, = Teoc, R = H, R> = i-Pr, R> = CH;, P, = H g) P, = t-Boc, R = H, R’ = i-Pr, R’>= PhCH,, P=Et h) P, = t-Boc, R = H, R’ = i-Pr, R> = PhOCH;, P, = Et i) Py, = t-Boc, R = H, R’ = i-Pr, R* = 1-naphthyl, P, = Et i) Pi = t-Boc, R = H, R’ = i-Pr, R> = 2-naphthyl, P; = Et k) P; = +-Boc, R = H, R’ = i-Pr, R® = phenyl, P, = Et
I) P; = t-Boc, R = H, R® = 1-Pr, R? = 4-bromophenyl, P» = Et m) P) = t-Boc, R = H, R® = i-Pr, R? = AcOCH;, P; = Et
In the compound (IX), a) R* = Cbz, R = H, R® = i-Pr, R> = H, P; = Et : b)R'=Cbz, R=H R*=iP, R®=H, P, =H ¢) R* = Cbz, R = H, R? = i-Pr, R> = CH;0OPh, P; = Et d) R* = Cbz, R = H, R® = i-Pr, R? = CH,0OPh, P. = H e) R* = l-naphthoyl, R = H, R® = i-Pr, R®> = CH,OPh, P, = Et f) R* = 1-naphthoyl, R = H, R’ = i-Pr, R®> = CH,OPh, P, = H g) R* = 2-naphthoyl, R = H, R® = i-Pr, R*> = CH,OPh, P, = Et h) R* = 2-naphthoyl, R = H, R® = i-Pr, R> = CH.0Ph, P, = H i) R* = 2-naphthoyl, R = H, R® = CH,CH,COBu(t), R> = CH, P, = CHs j) R* = 2-naphthoyl, R = H, R® = CH,CH,CO;Bu(t), R’> = CHs, P, = H k) R* = 2-naphthoyl, R = H, R® = i-Pr, R> = PhCH, P, = Et 1) R* = 2-naphthoyl, R = H, R’ = i-Pr, R®> = PhCH,, P, = H m) R* = 2-naphthalenesulfonyl, R = H, R’> = i-Pr, R®> = PhOCH,, P, = Et n) R* = 2-naphthalenesulfonyl, R = H, R® = 1-Pr, R? = PhOCH,, P; = H 0) RY = 2-quinolinecarbonyl, R = H, R® = i-Pr, R? = PhOCH;, P> = Et p) R* = 2-quinolinecarbonyl, R = H, R® = i-Pr, R?> = PhOCH,, P, = H q) R* = 2-naphthoyl, R = H, R® = i-Pr, R> = H, P, = Et
~ 30 - 1) R® = 2-naphthoyl, R = H, R> = i-Pr, R® =H, P, =H s) R* = hydrocinnamoyl, R = H, R® = i-Pr, R* = PhCH,, P, = Et t) R* = hydrocinnamoyl, R = H, R’ = i-Pr, R*> = PhCH,, P» = H u) R* = 1-paphthoyl, R = H, R® = i-Pr, R* = PhCH,, P; = Et v) R* = I-naphthoyl, R = H, R® = i-Pr, R> = PhCHa, P, = H
Ww) R* = 1-naphthalenesulfonyl, R = H, R= 1-Pr, R?* = PhCH,, P, = Et x) R* = l-naphthalenesulfonyl, R = H, R> = i-Pr, R> = PhCH, P; = H y) R* = 3-indoleacetyl, R = H, R® = i-Pr, R* = PhCH,, P, = Et z) R* = 3-indoleacetyl, R = H, R® = i-Pr, R> = PhCH,, P, = H aa) R* = 3-indolepropionyl, R = H, R’ = i-Pr, R*> = PhCH, P, = Et ah) R* = 3-indolepropionyl, R = H, R® = i-Pr, R> = PhCH,, P, = H ac) R* = trans-cinnamoyl, R = H, R® = i-Pr, R* = PhCH,, P; = Et ad) R* = trans-cinnamoyl, R = H, R® = i-Pr, R> = PhCH, P, = H ae) R* = phenylmethylsulfonyl, R = H, R®> = i-Pr, R*> = PhCH,, P, = Et : af) R* = phenylmethylsulfonyl, R = H, R® = i-Pr, R* = PhCH,, P, = H ag) R' = 2-quinolinecarbonyl, R = H, R’ = i-Pr, R’ = H, P; = Et ah) R* = 2-quinolinecarbonyl, R = H, R’ = i-Pr, R® = H, P, = H ai) RY = 2-quinolinecarbonyl, R = H, R= i-Pr, R* = PhCH,, P, = Et aj) R* = 2-quinolinecarbonyl, R = H, R’> = i-Pr, R®> = PhCHa, P, = H ak) R* = 2-quinolinecarbonyl, R = H, R® = 1-Pr, R? = I-imidazolyl, P> =
Et al) R* = 1-quinolinecarbonyl, R = H, R’> = i-Pr, R?> = l-imidazolyl, P; =
H am) R* = COCH,CH>CO:Bu(t), R = H, R? = CH,CH.CO,Bu(t), R* = CH,
P, = CH; an) R* = COCH,CH,CO:Bu(t), R = H, R’ = CH,CH,CO:Bu(t), R* = CH,
P, =H ao) R* = COCH,CH,CO:Bu(t), R = H, R® = i-Pr, R* = CHs, P, = CHs ap) R* = COCH,CH,CO;Bu(t), R = H, R®> = i-Pr, R> = CH3, P, = H
In the compound (X), a) P3 = Cbz, R = H, R'=CH,CO;Bu(t), X =CO:Me b) P; = HCI+H, R = H, R'=CH,CO:Bu(t), X =CO,Me ¢) Ps = Cbz, R = H, R'=CH,CO:Bu(t), X =COCH:N; d) Ps = Cbz, R = H, R'=CH,CO;Bu(t), X =COCH,Br e) Ps = Cbz, R = H, R'=CH,CO,Bu(t), X =COCH,OPh f) Ps = Cbz, R = H, R'=CH,COBu(t), X =CH(OH)CH,OPh g) Ps = H, R = H, R'=CH,CO,Bu(t), X =CH(OH)CH,OPh h) Ps = Cbz, R = H, R'=CH,CO;Bu(t),
X = CH(OH)CH>OC(O)Ph(2,6-dichloro) i) Ps = H, R = H, R'=CH>CO;Bu(t),
X =CH(OH)CH,OC(O)Ph(2,6-dichloro) j) Ps = Cbz, R = H, R'=CH2CO.Bu(t), X =CONMe(OMe) k) Ps = H, R = H, R'=CH,CO;Bu(t), X =CONMe(OMe) 1) Ps = Cbz, R = H, R'=CH>CO;Bu(t), X =CH(OH)CH,O- (1-naphthyl) m) Ps = H, R = H, R'=CH,CO,Bu(t), X =CH(OH)CH;O- (1-naphthyl)
In the compound (I), a) R* = 2-naphthoyl, R = H, R’ = i-Pr, R®> = PhOCH;, R' =
CH,CO:Bu(t), X = COH b) R* = 2maphthoyl, R = H, R’ = iPr, R® = PhOCH; R' =
CH,CO:Bu(t), X = C(=0)CHaN; ¢) R* = 2-naphthoyl, R = H, R® = iPr, R*> = PhOCH, R' =
CH2CO2Bu(t), X = C(=0)CH2Br d) R* = 2-naphthoyl, R = H, R’ = iPr, R°> = PhOCH;, R' =
CH,CO,Bu(t), X = C(=0)CH,0Ph ¢) R' = 2-naphthoyl, R = H, R’ = iPr, R> = PhOCH,, R' =
CH,CO;Bu(t), X = C(=0)CH20C(=0)Ph (2,6-dichloro)
f) R® = 2-naphthoyl, R = H, R® = iPr, R® = PhOCH; R' =
CH,CO;Bu(t), X = 2-naphthyloxymethylcarbonyl g) R* = 2-naphthoyl, R = H, R} = 1-Pr, R> = PhOCH,, R' =
CH>CO:Bu(t), X = l-naphthyloxymethylcarbonyl h) R* = 2-naphthoyl, R = H, R’ = iPr, R*> = PhOCH, R' =
CH,CO:Bu(t), X = CH(OH)CH;OPh i) R* = 1lnaphthoyl, R = H, R® = iPr, R®> = PhOCH, R! =
CH,COzBu(t), X = C(=0)CH,OPh 1) R* = 2-naphthalenesulfonyl, R = H, R? = 1-Pr, R? = PhOCH,, R! =
CH,CO,Bu(t), X = CH(OH)CH:OPh k) R* = 2-naphthalenesulfonyl, R = H, R’ = i-Pr, R*> = PhOCH». R' =
CH,CO:Bu(t), X = C(=0)CH,OPh
I) R* = 2-quinolinecarbonyl, R = H, R’ = i-Pr, R* = PhOCH,, R' =
CH,CO,Bu(t), X = CH(OH)CH,OPh m) R* = 2-quinolinecarbonyl, R = H, R’ = i-Pr, R® = PhOCH,, R' =
CH,COzBu(t), X = CH(OH)CH,OPh n) R® = 2-naphthoyl, R = H, R?® = i-Pr, R> = PhCH,, R' — CH2CO:Bu(t),
X = C(=0)CH:N; 0) R* = 2-naphthoyl, R = H, R’ = i-Pr, R® = PhCH, R' = CH,COBu(t),
X = C(=0)CHzBr p) R* = 2-naphthoyl, R = H, R’ = i-Pr, R> = PhCH, R' = CH,CO:Bu(t),
X = C(=0)CH;OPh q R* = 2-naphthoyl, R = H, R’ = i-Pr, R> = PhCH,, R' = CH,CO:Bu(t),
X = C(=0)CH,0C(=0)-Ph-(2,6-dichloro) r) R® = N-acetyl-g -t-butyl aspartyl, R = H, R® = CH,CH.CO:Bu(t), R* =
CHs, R' = CH2CO:Bu(t), X = CH(OH)CH,OPh s) RY = N-acetyl-g -t-butyl aspartyl, R = H, R® = CH,CH.CO:Bu(t), R? =
CHs, R' = CH,COzBu(t), X = C (=0)CH,0Ph t) R* = Cbz, R = H, R’ = i-Pr, R> = H, R' = CH.COBu(t), X =
C(=0)NMe(OMe) u) R* = Cbz, R = H, R® = iPr, RZ = H, R' = CH,COBu(t), X =
C(=0)CHj v) R* = Cbz, R = H, R® = i-Pr, R? = PhOCH,, R' = CH,CO:Bu(t), X =
CO,CH3 w) R* = Cbz, R = H, R® = i-Pr, R?> = PhOCH;, R' = CH,CO:Bu(t), X =
COH
10x) R* = Cbz, R = H, R® = i-Pr, R®> = PhOCH,, R' = CH,CO:Bu(t), X = C(=0)CH2N:z © y) R* = Cbz, R = H, R® = i-Pr, R* = PhOCH;, R' = CH.COBu(t), X =
C(=0)CH:Br z) R* = Cbz, R = H, R® = i-Pr, R> = PhOCH,, R' = CH.CO:Bu(t), X =
C(=0)CH;0C(=0)-Ph-2,6-dichloro aa) R* = Cbz, R = H, R® = i-Pr, R* = PhOCH,, R' = CH2CO.Bu(t), X =
C(=0)NMe(OMe) ab) R* = Cbz, R = H, R® = i-Pr, R* = PhOCHa, R' = CH,CO:Bu(t), X =
C(=0)CH; ac) R* = Cbz, R = H, R’ = iPr, R®> = H, R' = CH,CO:Bu(t), X =
CO,CH; ad) R®* = Cbz, R = H, R® = iPr, R* = H, R' = CH:CO:Bu(t), X =
C(=0)CH20C(=0)Ph(2,6-dichloro) ae) R* = 2-naphthoyl, R = H, R® = i-Pr, R®> = H, R' = CH,CO;Bu(t), X = C(=0)CH,OPh af) R* = hydrocinnamoyl, R = H, R’ = i-Pr, R®> = PhCH,, R' =
CH.CO,Bu(t), X = C(=0)CH,0C(=0)Ph(2,6-dichloro) ag) R* = l-naphthoyl, R = H, R® = i-Pr, R*> = PhCH, R' = CH,CO;Bu(t),
X = C(=0)CH20C(=0)Ph(2,6-dichloro) ah) R* = l-naphthalenesulphonyl, R = H, R® = i-Pr, R® = PhCH,, R' =
CH,CO;Bu(t), X = C(=0)CH;0C(=0)Ph(2,6-dichloro)
ai) R* = 3-indoleacetyl, R = H, R’ = iPr, R> = PhCH, R! =
CH;CO2Bu(t), X = C(=0)CH20C(=0)Ph(2,6-dichloro) aj) R* = 3-indolepropionyl, R = H, R’ = iPr, R? = PhCH,, R' =
CH,COzBu(t), X = C(=0)CH20C(=0)Ph(2,6-dichloro) ak) R* = trans-cinnamoyl, R = H, R® = i-Pr, R* = PhCH,, R! =
CH>COzBu(t), X = C(=0)CH20C(=0)Ph(2,6-dichloro) al) R* = phenylmethylsulfonyl, R = H, R’ = i-Pr, R*> = PhCH,, R! =
CH,COzBu(t), X = C(=0)CH20C(=0)Ph(2,6-dichloro) am) R' = 2-quinolinecarbonyl, R = H, R’ = i-Pr, R® = H, R' =
CH2CO2Bu(t), X = C(=0)CH20C(=0)Ph(2,6-dichloro) an) R* = 2-quinolinecarbonyl, R = H, R* = iPr. R® = H. R' =
CH>COBu(t), X = C(=0)CH,0OPh ao) R* = 2-quinolinecarbonyl, R = H, R’ = i-Pr, R> = PhCH,, R' =
CH2COzBu(t), X = C(=0)CH.0C(=0)Ph(2,6-dichloro) : ap) R* = 2-quinolinecarbonyl, R = H, R® = i-Pr, R? = PhCH,, R' =
CH,CO,Bu(t), X = C(=0)CH.OPh : aq) R* = 2-quinolinecarbonyl, R = H, R’> = i-Pr, R®> = l-mmidazolyl, R' =
CH2COzBu(t), X = C(=0)CH,0CPh ar) R* = 2-naphthoyl, R = H, R® = i-Pr, R® = H, R' = CH,CO,Bu(t), X = C(=0)CH3 as) R* = COCH,CH.CO;Bu(t), R = H, R® = (CH,CH,CO.Bu(t), R*> = CHs,
R' = CH,CO,Bu(t), X = C(=0)CH,OPh at) R* = COCH.CH:COBu(t), R = H, R’ = i-Pr, R®> = CH; R' =
CH2CO:Bu(t), X = C(=0)CH,OPh au) R* = 1-naphthoyl, R = H, R’ = i-Pr, R> = PhCH), R' = CH.CO;Bu(t),
X = C(=0)CHuN(CHy)s
In Reaction Scheme 2, the functional group X of compound (X) may be introduced by several unit operations after the reactions involved in the synthesis of the compound (VIII) or (IX), or the compound (VIII) or (IX) already having desired substituent X may be proceed with the subsequent reactions.
The acrylate derivative (VII) may be synthesized by any one of two processes as depicted in Reaction Scheme 3 below.
Reaction Scheme 3
R’__ COP: R? z rR’ COP: _, I — PR -— x 07 >CcoaEt COz2P2 CO2P2 x Xi vii XIN
Ester derivative (XI) is reacted with diethyl oxalate to give oxalate derivative (XII) which is then reacted in the presence of a base to give desired acrylate derivative (VII). Alternatively, it may be synthesized by various processes starting from the known compound (XII). That is, the known compound (XIIIa) is easily converted into compounds (XIIIb), (VIIe), (VII), (VIlg), etc.
In the compounds (XI) and (XII), the substituents are examplified as follows: a) P, = Et, R> = Ph b) P» = Et, R? = 4-bromophenyl c) Po, = Et, R® = 1-naphthyl d) P, = Et, R? = 2-naphthyl
In the compounds (VII) and (XIII), the following combination of the substituents can be synthesized by the above process.
In the compound of (VII), a) R> = Ph, P, = Et b) R? = 4-bromophenyl, P; = Et ¢) R® = 1-naphthyl, P; = Et d) R? = 2-naphthyl, P, = Et e) R> = CH;0Ac, P; = Et f) R? = CHyPh, P; = Et g) R®> = CH,OPh, P, = Et
In the compound (XIII), a) R*> = Et, Z = OH b) R® = Et, Z = Br
Hereinafter, the representative compounds synthesized by the process of the invention will be listed according to their structural formulae. The representative compounds according to the invention are numbered by the inventors for convenience’ sake in which MP represents more polar fractions from HPLC at the previous step of deprotection while LP represents less polar fractions from HPLC. However, they are presented for the purpose of illustration of the synthesis of the compounds of the invention and for substantiating the fact that the compounds of the invention can be synthesized by the above mentioned process, but the present invention should not be limited to the listed compounds in any manner.
Cl ; IP { 1 0] N N . (3) Y AA PN Diastereomer
I SOE EN
CO.H
OPh i N—0 i 0 (10) 0 N N PN Diastercomer
T i i { (less polar)
Pa Neo
OPh oo ! P ; J (11) 4] N n IL Diastereomer
Di ; (more pola) 0} A [0] S
AN Nco,n
Ph : Cl i NO i 0 oO Diastereomer (12) hd I NO (less poler) °C AN “NcoMe
Ph
Cl i J ] i
O N N i . '& eons RIES
Oo Fy 3
ZN NCo Me cl
H N—O H (14) Qa JIA Ia I Diastercome ; 0 i 1
AN NCo,H
OPh
CLI an (2 3 ; : OPh Diastereomer 0 _A o ~~ Sco.H
OPh i N—0 H 0 (18) NO NP Sterecisomer © AN © cou i N—0 Me i 0
AAA i
Y Y Diastereomer (19) oO N 0 Neo . . , :
CO,H
HOC
H N I1 lo] hi I Me Lo, (20) Aen Y” ri Yo AG Diastereomer ~ coi
COyH
OPh = H N —-0 H Q
LA J Ao Diastereomer (22) N I ! o AN © Nco,H
Ph
SOUS» JS (23) N NA om Stercoisomer 0 _AL 6) co,H
OPh
H N H 0
N no 0 PW 0 i C Diastereomer (24) CO.H
OPh
A N——O0 H 0 Diastereamer
N nM _o 0} - 0 2
ZN cou
OPh
DOCK
(26) > N : Nn AL or Diastercomer 0 o 3 i <N co.H
OPh al
SUN eI 0 NS N PN Stereoisomner i i
[6] Pas cou [eo] 1
Ph cl 0H —~
Stereo (28) NS x Ao tereo; 0 A 0 0 1
ON NcoH
C1) H N HH 0 Diastereomer
H H
ZN SCo,H
COUT
Q a0 AK : TO ° AN % Scop cl
H N—O] H O ~" No 0 _A IE 0 « (31) NN ScoH
H N—©O H O ct
N NAL o i : z (32) CAN % Seon °F
H N—O H O cl
Oi ls 33) @ 0 AL 9 gop © © 4
N cl ® H N—O H 0
Cr oY i : al 0_AL 0 poy © © : 7 Cl — H N—-2©O H ©
HN ~ N No (35) [0] A [o] COM lo} Cl
H N—O H O c
Oy {3 / : : ~ (36) oH FES COH
HO H N—o] H o © {Eo (37) RN NcoH 0 !
H N—OJ H © cl
N NAL o (38) © AN © Sco
H N—oO] H © cl
A Le ) OL: : : (39) aS Nco,H x H N—-O H lo} cl
NZ AAA
: : (40) NN co ™ H N—oOy HO
NZ YY
(41) 7A cox
XN H N—O] H 0 cl
NP N _ No (42) N° com
WO v1/21600 PCT/KR00/01047
RS H N—O H O
NZ N , Ne (43) CAN 0% “cos J
N
(>
H N—-2O H 0 (44) ° © Neon
OC JCI
MAA AA
0 _A 0 (45) NN CO,H
HO N—OpMfT ©
HOC. _~ IAA Jo. 1® : : © N ° co Z (46) CoH
Teel 1 oe AAA 0 47) © PAN o “co,H \®
HO N—O0 J) H ©
PPP
(48) @ o i o
ZN CoH
Ph cl
N N—o0 0
OI: NP 17 49) N_ NG 0 6 A o oO cl
ZN ~Sco,H
Ph cl
N N—O 0
OI: PY ve o o i oO cl ~~ “Sco.H
Ph cl
Oi pg NTO], © (51) NS NA _o Lp 0 0 0 cl _ Sco.H . Ph cl
Ol H N———0 - 0 (52) NS N Ao Mp o 0 0 cl
ZN Sco,H
Ph Cl
N N—O 0
Ol PY - 53) N. N. 0 0 o 0 cl
ZN Sco,H
Ph cl
TO Hq N—O0 q 0
MP
I. No N Ao o i 0 0 cl ~~ Sco,H
Ph a yu Yo), © (55) D N No LP 0 od i
Oo i o o «a _ ScosH © Ph cl \ L No]. 0 (56) © . No MP 0 0 HH fe} z 0) Cl
ZN co.H
Ph F p Ji I O 57) A N : No AN LP 0 _A 0 oO F @) Pa co,
Ph F
N—O 0)
H H
(58) AY M oO A o i 0 F
Pas cou
Ph cl
N—O 0
Ol JVs (59) N N N Ao LP oO o i o da a co,H
Ph cl
N—O 0
Os JT . Da L200 y o o i 0 «Cl
ZN ScoH
O Ph CH;
O uw Yo J, © 0 o i O CH
ZN co,H 3
Ph ci
N—oO o) 62) No Ne 0 o) 0 _A 0 i 0 a
FE Sco,H
Ph cl a N91, 9
N PY
(63) OLA N lo) LP
H § o 0 «cl
ZN Sco,H
Ph cl go 0 goo
N 7 !
H : : 0] Pa 0) cou oO Cl
Ph cl . No]. 9 (65) HN / 7 ; 0 A 0 3 o «cl ra ~Sco,H
Ph cl
J 0 (66) I~" No MP o o 0 cl
ZN Sco,H cl @ N—O0 lo] : I 67) O FAS 0 LP 0 i 0 0 Cl a ~Sco,H cl
N—O 0 i J i @ No Ne 0 MP 0 A o i 0 cl
FE Sco,H cl \ yw NTO 0°
LP
(69) QAI 0 | : il : il 0 = 0] z 0 Cl
TN co,H cl \ g gy 0 (70) OIA MP 0 : | i 0) A lo} 2 0 Cl
Pa ~Sco,H cl vw NTO. 9
LP
(71) oe IAA A , o i lo! : 0 Cl ™ Sco,H
Co,H cl
Hoo uo
MP
(72) ose AAA Ao 0 i 0 0 «a ™ co,H
CO.H
Cl
N—O 0 c N vn Mo Lp my TO dh , o o 0 cl
ZN “Sco.H
Cl yg N—O ©
MP
(74) HO,C ~~" ANA Ao 0 _A 0 E o Cl
ZN Sco.H cl
N—O fo)
N FR Mo Lp (75) HOES : : fo) i lo) H oO «al
A Nco,H cl
N—O lo)
N PR Ao MP (76) HOES ‘ v o i o i oO Cl
SN “Sco,H
N—O lo) an Re v : ~~ 0 _A 0 i
Pa Nco,H
N—O fo)
N ge N Mi (78) HOES - y ~~ lo) H Io) H
ZN Nco,H
N—O0 0 “
H nBu (79) HOA N 0 LP 0 : 0] : 0 «cl
Pas “~co,H
N— 0 “
H nBuy] (80) HOA N 0 MP 0 : 0] : o «cl
Pa co,H
N—20 0 (81) HOES N ON LP le) 2 0 FS
A co,u
N—0 0
H H
82) oie AAA A MP
SORRGROE
Pas “Sco,u
N—O 0
HO a Mix (83) 2 - : 0 AL <
CO,H
N OH o ct
H H , 4) wen AAT Is JO Mix 0 : 0 o cl
IN ~Sco,H
Ph Cl
H il H 9 (85) BENS = #_ Jo LP [o] ; (e} : 0 Cl
ZN co,H
Ph Ci
H N H f 5, BENS N Ao MP 0 i o i 0 cl
ZN co H
OMe ct
N—O o
H H
@7n HOC ~~" Ak Jo JO Mix i oi Oo Cl
EAN co,H
Cl - N——O ol ¢} (89) OST AKA LP o _A o i o «a
ZN Sco,H
Cl
Hq N——O pent 0 (90) ose A MAAN Ao Mp (0) : 0 : (0) Cl
ZN “~co,H
Ct gy YOR, 0° on roe AAAs LP 0 _AL 0 iL 0 cl
CoH
Cl y Nom. © 0 _AL 0 co, co cl
N—O ¢H 0 I~
H H ek) HO PAS NS WP) 0 Lp 0 AL 0 iL : I 5
CO,H
N—O 0 ct q
H hz! (94) ern AIT JO Mp 0 _AL 0 com o cl
The isoxazoline derivative of formula (I) and the pharmaceutically acceptable salts, esters, and isomers thereof have useful pharmacological properties. For example, they have an inhibitory activity for caspases.
Due to their pharmacological activity such as effects on anti-inflammation or inhibition of apoptosis, they can effectively be used as the therapeutics for a number of diseases, for example, the disease in which cells are abnormally died, dementia, cerebral stroke, brain impairment due to AIDS, diabetes, gastric ulcer, cerebral injure by hepatitis, fulminant hepatic failure (FHF), sepsis, organ transplantation rejection reaction, rheumatic arthritis, cardiac cell apoptosis due to ischaemic cardiac diseases and anti-inflammation.
In particular, the composition according to the invention can preferably be used as the therapeutics for fulminant hepatic failure.
As described in detail hereinafter, the present inventors examined, using the compound of formula (I), in vitro and in vivo caspase inhibitory activities, the viability ratio of hepatocytes in case where hepatic diseases were induced by ConA or TNF, /Actinomycin D, therapeutic effect against hepatitis, reduction of hepatocytic apoptosis, and inhibition of PARP cleavage.
The present inventors have .also conducted experiments on the effect of the compound of formula (I) according to the invention on cellular viability in case where apoptosis was induced by IFNy and anti-Fas antibody, and compared the results thereof with the existing caspase inhibitors,
Ac-DEVD-CHO and/or 2-DEVD-cmk. Briefly, we examined the efficacy of the new caspase inhibitor of formula (I) to inhibit Con A-induced acute hepatic failure in mice. As a result, this small-molecule, non-peptide-based inhibitor showed inhibition of not only caspase activities but also apoptotic death of hepatocytes in vitro and in vivo. These results suggest that the compound of formula (I) according to the present invention could be a candidate of therapeutic agent for human FHF caused by massive apoptotic death of hepatocytes.
The compound of the invention is a small-molecule, non-peptide-based caspase inhibitor which has a broad-spectrum activity (see Figures 1 & 2).
The compound of formula (I) is different from BCNU or COX-2 inhibitor in the fact that it was originally designed as a specific inhibitor of caspase family enzymes. It is noteworthy that apoptotic process is very complicated and caspases are critically involved in several steps of this process. Moreover, relatively little is known about caspase regulation largely because many of the known substrates have been found serendipitously. Thus, to block short-term, massive apoptosis of hepatocytes during acute phase of FHF, a broad-spectrum caspase inhibitor might exert more potent effect than a specific-spectrum caspase inhibitor.
In this regard, the compound of formula (I) could be an ideal candidate.
The present inventors used ConA-induced hepatitis model to test the apoptosis-blocking effect of caspase inhibitor, the compound of formula (I).
Several cytokines are involved in Com A-induced hepatitis: IL-2, IFNy ,
TNFq , IL-6, IL-4, and IL-10. The present inventors assessed the effect of the compound of formula (I) to serum IL-1g, IL-2 IL-4, and IFNy : concentrations elevated by Con A. As a result, the compound of formula (I) according to the present invention significantly suppressed IL-13 level in a dose-dependent manner (see Figure 5A) due to its caspase-l-inhibiting activity shown in Figures 1 and 2. However, the compound of formula (I) did not significantly affect IL-2, IL-4, and IFNy levels (Figure 5B, C, D).
These results could be attributed to the fact that the major cell population to which the compound of formula (I) exerted its activity as a caspase inhibitor is Fas-expressing hepatocytes. The compound of formula (I) rescued hepatocytes from caspase-involved apoptosis, but did not directly suppress activated T cells. One of the biosubstrates for caspase-3-like protease in cells is PARP (116 kDa) which is cleaved into 85- and 31-kDa fragments in cells undergoing apoptosis. Therefore, the appearance of an 85 kDa-cleavage product of PARP has been proposed as an early marker of apoptosis (See, Lazebnik, Y. A. et al, 1994, Nature 371: 346-347; Kaufmann, S. H. et al, 1993, Cancer Res. 53: 3976-3985).
The compound of formula (I) inhibited PARP cleavage caused by Con
A-induced apoptotic death of hepatic cells in a dose-dependent manner (see
Figure 7). On Western blot analysis, the amount of 85 kDa-cleavage product gradually reduced as dose of compound 33 is increased, but intact 116 kDa PARP appeared relatively constant. It is considered the hepatocytes which virtually underwent apoptosis comprise only a small portion compared with the whole liver mass. This result is consistent with histological examination. As shown in Figure 6, Con A induced severe - morphological and histological changes to hepatocytes and the apoptotic lesions were clearly detectable. However, a large proportion of hepatocytes : still remained alive and apoptotic cells comprise a part. This phenomenon explains the appearance of intact 116 kDa PARP even in the liver of
ConA/vehicle mice.
Meantime, the present inventors induced an artificial apoptosis by treating
Fas responsive cell with IFNy and anti-Fas antibody, and conducted experiments in order to evaluate the inhibitory activity of the compound of formula (I) on the cells against apoptosis. As a result, the inventors discovered that the compound of formula (I) revealed 2-fold or more superior inhibitory effect over the known Ac-DEVD-CHO or z-DEVD-cmk (At the same concentration, the cell viability was 35.1%(Ac-DEVD-CHO) , 47.3%z-DEVD-cmk, and 100%(Compound 33), see Table 1 and Fig. 8).
From the above experiment results, it is noted that the non-peptidic compound of formula (I) has a wide variety of caspase inhibitory activities and thus, anti-inflammation and apoptosis prevention effects, especially can effectively be used as therapeutics for preventing massive apoptosis of hepatocytes in human FHF.
The compound of formula (I) is a new, non-peptide based caspase inhibitor. Its broad-spectrum activity could be a beneficial property as a therapeutic agent blocking the massive apoptosis of hepatocytes in human
FHF.
The compounds of the present invention, therefore, may be used as medicines against above-mentioned diseases. Said use as a medicine or method of treatment comprises local or systemic administration to patients of an effective amount of the compounds according to the invention for : treating the diseases.
The subject compounds may be formulated into various pharmaceutical forms for administration purposes. Said pharmaceutical forms or : compositions are deemed to novel and consequently constitute a further aspect of the present invention. Also the preparation of said composition constitutes a further aspect of the present invention. To prepare the pharmaceutical composition of this invention, an effective amount of the compound, in base or salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier which may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, percutaneously, or by parenteral injection. It is especially advantageous to formulate the above pharmaceutical composition in unit dosage form for ease of administration and uniformity of dosage. For example, in preparing the composition in oral dosage form, any of the usual pharmaceutical media may be employed for example, water, glycols, oils, alcohols and the like in the case of oral liqud preparations such as suspensions, syrups, elixirs and solutions: or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agent and the like in the case of powders, pills, capsules and tablets. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. It is preferable that tablets and fills are enteric-coated.
For parenteral compositions, the carrier will usually include sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example sterilized aqueous injection suspension or oil suspension, may be prepared with suitable dispersing agents, wetting agents or suspending agents. Solvents which can be used for this purpose include water, Linger's solution, isotonic
NaCl solution, etc. Sterilized fixed oils can also be used as a solvent or a suspending medium. Any non-excitatory fixed oils including mono-, diglycerides can be used for this purpose and fatty acids such as oleic acid can be used in the injectable preparation.
In the preparation suitable for percutaneous administration, the carrier optionally includes a penetration enhancing agents and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, wherein the additives do not give a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may assist preparation of the desired compositions. These compositions may be administered in various routes, €.g., as a transdermal patch, as a spot-on or as an ointment.
Dosage unit as used in the specification and claims herein refers to physically discrete units suitable as unitary dosage, each unit containing a
~ 56 ~ predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets, capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
In view of the usefulness of the subject compounds in the treatment of the disease in which cells are abnormally died, dementia, cerebral stroke,
AIDS, diabetes, gastric ulcer, hepatic injure by hepatitis, sepsis, organ transplantation rejection reaction and anti-inflaimmation, it is evident that the present invention provides a method of treating patients suffering from the diseases, which comprises the local or systemic administration of a pharmaceutically effective amount of the compound of formula (I) or the pharmaceutically acceptable salt, ester or stereochemically isomeric form thereof in admixture with a pharmaceutical carrier.
Those skilled in the treatment of the diseases associated could easily determine the effective amount of the caspase inhibitor, especially the compound of formula (I) to be administered into a subject. In general, it is contemplated that an effective amount would range from 0.01 mg/kg to 100 mg/kg body weight a day in a unit dosage or divided dosage.
However, it is evident to those skilled in the art that such amount ranges are guidelines only and are not intended to limit the scope or use of the invention in any manner. The specific dosage level for a specific subject would depend upon the particular compound to be employed, weight of a subject, health conditions, regimen, administration period of the drug, administration route, excretion rate, combination of drug, the severity of diseases, etc.
The present invention will be described in greater detail through the following examples. The examples are presented for illustrating purposes only and should not be construed as limiting the invention which is properly delineated in the claims.
(A) Hydroxamoyl chloride synthesis (Examples 1 to 4)
Example 1: Synthesis of N-t-butoxycarbonyl-(S)-valinal and
N-t-butoxy-carbonyl-(S)-valinal oxime
To a solution of dimethyl sulfoxide (11.7 mL, 3.0 eq) in dry CHCl; : (~200 mL) under N> at -60 °C was added slowly oxalyl chloride (5.78 mL, 1.2 eq). After 10 min.,, a solution of N-t-butoxycarbonyl-(S)-valinol (11.23g, 55.2 mmol) in CH,Cl2 (30 mL) was added slowly, and the flask was rinsed with 20 mL of CH)Cl;. The resulting white suspension was stirred for 1h at ~ -50 °C. The reaction solution was treated with diisopropylethylamine (28.8 mL, 3.0 eq) and stirred for about 20 min. at -23 °C then diluted with hexanes (400 mL). The mixture was washed with water(150 mL), IN-KHSOs solution (x 3, total 1 L), dried with anhydrous
NaySQ,, filtered and concentrated. The yellowish liquid obtained was used directly in next step without further purification.
The crude valinal in ethanol (60 mL)-water (30 mL) at water bath temperature was treated with hydroxylamine hydrochloride (5.76g, 1.5 eq) and Na;COs; (4.39g, 0.75 eq.). The reaction generated a lot of solid in 1 min., thus diluted with ethanol-water (1:1, 60 mL) and stirred for lh. The reaction solution was poured into saturated NaCl (100 mL), and then
~ 58 - extracted with ethyl acetate twice (300 mL). Organic extracts were washed with satd NaHCO; (100mL x 2), dred (anh. NasSO,), filtered and concentrated to yield white powder (11.34g, syn, anti mixture of oximes).
Example 2: Synthesis of (25)-2-(t-butoxycarbonyl)amino-1-chloro-3-methyl- butane-1-one oxime
N-t-butoxy-carbonyl-(S)-valinal oxime (11.34g) in DMF (100 mL) was treated with NCS (7.75g) and stirred in warm water bath (~40 °C) for 1h. After removal of DMF, the residue was extracted with ethyl acetate-hexanes (1:1, 150 mL), washed with water (100 mL x 3), dried (anh. NaySO4), filtered and concentrated to give 13.69g of the title compound.
Example 3: Synthesis of 4-(9-fluorenylmethoxycarbonyl)amino-(4S)-5- hydroxy-pentanoic acid t-butyl ester
To a solution of N-(9-fluorenylmethoxycarbonyl)-y -t-butyl glutamic acid (8.51g, 20.0 mmol) and NMM (2.42mL, 1.1 eq) in dry THF (110 mL) under N; at 0 °C was added isobutyl chloroformate (2.72mL, 1.05eq).
After 20 min., the reaction mixture was filter-added to a solution of
NaBH; (1.5g) in THF (120mL)-MeOH (30 mL) at -78 °C under N, and rinsed with dry THF (20mL). After stirring for 2.5h at -78 °C, the reaction was quenched with acetic acid (13mL). After concentrating to ~ 50mL, the residue was dissolved in ethyl acetate-hexanes (200 mL, 1:1), washed with water (150 mL x 2). Aqueous layer was re-extracted with ethyl acetate-hexanes (150 mL,1:1). Combined extract was washed with satd NaHCOs (150 mL x 2), dried (anhydrous NazSOs), filtered and concentrated to give 8.30g of the title compound as glasslike solid. The crude alcohol was used directly. "H-NMR (500 MHz, CDCl) § 7.77 (2H, d, J=7.3Hz), 7.66 (2H, d, J = 7.8 Hz), 741 (2H, t, J = 7.3 Hz), 731 (2H, pseudo t, J = 7.8, 7.3 Hz), 5.18 (NH, d), 441 (2H, m), 422 (1H, m), 3.72-3.57 (3H, m), 233 (2H, m), 1.93-1.77 (2H, m), 1.45(9H, s).
Example 4: Synthesis of 4-(9-fluorenylmethyloxycarbonyl)amino-(4S)-5- chloro-5- hydroxyimino-pentanoic acid t-butyl ester
To a solution of DMSO (3.0 mL) in dry CH>Cl; (100 mL) at -65°C under
N; was added oxalyl chloride (2.10 mL, 1.2eq) slowly. After 15 min, a solution of 4-(9-fluorenylmethyloxycarbonyl)amino-(4S)-5-hydroxypentanoic acid t-butyl ester (8.30 g, 20 mmol) in CHCl (50 mL) was added and rinsed with dry CH2Cl, (20 mL). The resulting solution was stirred for 2h at -40 ~ -50 °C. EtN(i-Pr); (10.45 mL, 3.0eq) was added thereto and the reaction solution was slowly warmed up to -10 °C with TLC checking (conversion to aldehyde is relatively slow, ~1h). The reaction mixture was diluted with hexanes (300 mL), washed with water(150 mL), with
IN-KHSOs (x 3, total 500 mL), dried with anh. Na;SOa., filtered and concentrated to give the corresponding aldehyde.
The crude aldehyde in ethanol(60 mL)-CH>Cl; (30 mL)-water(10 mL) at 0°C was treated with HoNOH « HCl (2.08 g, 1.5eq) and Na,COs (1.60g, 0.75 eq). The reaction was stirred at room temperature for 30 min., then water (10 mL) was added and stirred for additional 1h. The reaction was stirred further(lh) with additional HoNOH « HCl (400 mg) and Na,COs; (320 mg). Most of the volatiles were removed in vacuo, and the residue was taken up with ethyl acetate (200 mL), washed with water(100 mL), sad NaHCO; (100 mL), dried (anh. Na,SQs), filtered and concentrated to give the desired oxime (8.30g, syn + anti) as white powder.
The crude oxime in DMF (35 mL) was treated with NCS (2.67g, 20.0 mmol). The reaction was stirred in warm (40°C) bath for 1h. After removal of the DMF in high vacuum rotary evaporator, the residue was taken up with hexane-ethyl acetate (1:1, 150 mL), washed with water (100 mL x 3), dried (anh. Na»SOs), filtered and concentrated to give the title compound (9.25g, syn + anti). 'H-NMR (500 MHz, CDCl) § 8.88(1H, s), 7.75QH, d, J = 7.3Hz), 7.57(2H, m), 7.39(2H, t, J = 7.32Hz), 7.30 (2h, pseudo t, J = 7.8,7.3Hz), 546(1H, d), J = 93 Hz). 4.63(1H. m), 4.43-438(2H, m), 4.19(1H, m), 2.3(2H, m), 2.03(2H, m), 1.43(9H, s). (NMR data reported for major isomer.)
The Following compounds were prepared in the same manner as the above examples. .1-chloro-3-methyl-(25)-2-phenylmethyloxycarbonylamino-butane-1-one oxime, . 3-(t-butoxycarbonylamino)-(3S)-4- chloro-4-hydroxyimino-butanoic acid methyl ester, . 3-(phenylmethyloxycarbonylamino)-(3S)-4-chloro-4-hydroxyimino-butanoic acid t-butyl ester, and . 3-(9-fluorenylmethyloxycarbonylamino)-(3S)-4-chloro-4-hydroxyimino- butanoic acid t-butyl ester. (B) Synthesis of acrylate derivatives (Examples 5 to 8)
Example 5: Synthesis of ethyl 2-acetoxymethylacrylate
A solution of ethyl 2-hydroxymethyl acrylate (17.3g, 133 mmol, purity ~ 70%, ref: Villieras, J. and Rambaud, M. Synthesis, 1982, 9/4) in dry
CH,Cl, (200 mL) under N; at 0 °C was treated with acetic anhydride (18.8 mL, 1.5 eq) and triethyl amine (37 mL, 2.0 eq). After overnight stirring at room temperature, the reaction was diluted with hexanes (400 mL), washed with satd NaHCOs; (300 mL x 2), dried (anh NaxSOa), filtered and concentrated. Simple distillation gave 4.6g of the title compound as clear liquid. NMR analysis showed ~ 70 % purity. "H-NMR (500 MHz, CDCl) § 6.36 (1H, s), 5.84 (1H, s), 4.81(2H, s), 425 (2H, q, J = 7.3 Hz), 2.11 (3H, s), 1.31 (3H, t, J = 7.3 Hz)
Example 6: Synthesis of ethyl 2-phenoxymethylacrylate
A solution of ethyl 2-bromomethylacrylate (2.00g, 10.4 mmol, ref:
Villieras, J. and Rambaud, M. Synthesis, 1982, 9/4) and phenol(975 mg, 1.0eq) in dry THF (20 mL) under N; at O °C was treated with anhydrous
K2COs (1.43g, 1.0 mol eq). No reaction was observed for 1h. Anhydrous
DMF (20 mL) was added and stirred for 2h at 0 °C and for lh at room temperature. After evaporation of DMF, water(100 mL) was added, and the reaction was extracted with ethyl acetate (100 mL x 2). The organic extract was washed with brine (100 mL), dried (anh. Na;SO,), filtered and concentrated. Flash chromatography (40% CH:Cly/hexanes) gave 1.712g (80%) of the title compound.
H-NMR (500 MHz, CDCl) § 7.30 (2H, yt, J = 7.3 Hz), 6.99-6.96 (3H, m), 6.41 (1H, s), 6.01 (1H, s), 4.78 (2H, s), 427 (2H, q, J = 7.33 Hz)
Example 7: Synthesis of ethyl 2-benzylacrylate
To a solution of bromobenzene (7.15g, 45.5 mmol) in THF (30mL) was added n-BuLi (16.6mL, 2.5M in Hexane, 41.4mmol) under N; at -78 °C.
WO U1/21600 PCT/KR00/01047 ~ 62 ~
It was stirred for 10min. To a suspension of CuCN (3.71g, 41.4mmol) in
THF (30mL) was added lithiated benzene solution via cannula under N; at . -78 °C. The reaction mixture was stirred for another 10 min. at -78 °C and ethyl 2-bromomethyl acrylate (4.00g, 20.7 mmol) in THF was added.
The reaction mixture was warmed up to room temperature slowly and quenched with 2N HCl. All precipitates were filtered off and the filtrate was diluted with hexanes (400 mL), washed with sat'd NaHCO; (300 mL x 2), dried (anh Na,SO,), filtered and concentrated. Flash chromatography (2% ethyl acetate-hexanes) gave 3.04g(77%) of the title compounds . "H-NMR (500 MHz, CDCls) § 7.34-7.22 (5H, m), 6.26 (1H, s), 5.48(1H, s). 4.22(2H, gq. J = 6.3Hz). 3.66 (2H. s). 1.29 (3H, q, J = 6.3 Hz).
Example 8: Synthesis of ethyl 2-(4-bromophenyl)acrylate
The title compound was prepared according to the known procedure (Helvetica Chimica Acta 1986, 69 2048). "H-NMR (500 MHz, CDCls) § 7.46 (2H, d), 7.29 (2H, d), 6.37 (1H, s), 5.90 (1H, s), 4.29 (2H, q), 1.33 (3H, t)
The following compounds were similarly prepared. . Ethyl 2-(1-naphthyl)acrylate 'H-NMR (500 MHz, CDCls) § 7.86 (2H, t, J = 7.3 Hz), 7.44 (1H, d, J = 8.8 Hz), 7.48-743 (3H, m), 7.37 (1H, d, J = 6.8 Hz), 6.70 (1H, d, J = 2.0 Hz), 5.89 (1H, d, J = 2.0 Hz), 422 (2H, q, J = 73 Hz), 1.21 (3H, t,
J = 73 Hz), . Ethyl 2-(2-naphthyl)acrylate "H-NMR (500 MHz, CDCl) § 7.95 (1H, s), 7.90-7.86 (3H, m), 7.59-7.52 (3H, m), 6.47 (1H, d, J = 1.0Hz), 6.06 (1H, d, J = 1.0 Hz), 438 (2H, gq,
J = 6.8 Hz), 1.40 (3H, t, J] = 6.8Hz).
Ethyl 2-butyl acrylate 'H.NMR (500 MHz, CDCl) § 6.11 (s, 1H), 549 (d, J = 1.4 Hz, 1H), 4.19 (q, J = 6.9 Hz, 2H), 2.29 (m, 2H), 1.45-1.28 (m, 7H), 0.90 (t, J] = 7.3 Hz, 3H).
Ethyl 2-propyl acrylate "H-NMR (500 MHz, CDCl5) § 6.12 (d, J] = 0.9 Hz, 1H), 549 (4, J = 1.4 Hz, 1H), 4.20 (q, J = 6.9 Hz, 2H), 2.27 (m, 2H), 1.49 (m, 2H), 1.29 tJ = 7.3 Hz, 3H), 0.92 (t, J] = 7.3 Hz, 3H).
Ethyl 2-ethyl acrylate "H-NMR (500 MHz, CDCl3) § 6.11 (d, J = 0.9 Hz, 1H), 5.50 (s, 1H), 420 (q, J = 6.9 Hz, 2H), 2.32 (m, 2H), 1.29 (t, J = 6.9 Hz, 3H), 1.07 (1,
J = 7.4 Hz, 3H). :
Ethyl 2-pentyl acrylate "H-NMR (300 MHz, CDCl) § 6.12 (s, 1H), 5.50 (s, 1H), 4.21 (q, J = 7.1
Hz, 2H), 2.29 (m, 2H), 1.51-1.13 (m, 9H), 0.89 (t, J] = 6.8 Hz, 3H). (C) General procedure for isoxazoline synthesis (Examples 9 and 10)
Example 9: Synthesis of 3-((1S)-1-phenylmethyloxycarbonylamino-2-methyl- propyl)-5-phenoxymethyl-4,5-dihydro-isoxazole-5-carboxylic acid ethyl ester
A solution of (2S)-2-phenylmethyloxycarbonylamino-1-chloro-3-methyl- butane-1-one oxime (640 mg, 2.25mmol) and ethyl 2-phenoxymethylacrylate (464mg) in dry ether(10 mL) under N; at -78°C was treated with triethylamine (627 ul, 2.0 eq). The reaction was stirred overnight, allowing to warm up to room temperature slowly. Water(100 mL) was added, and the reaction was extracted with ethyl acetate (100 mL x 2), washed with water(100mL), dried (anh. Na;SOs), filterd and concentrated. Flash chromatography (15% ethyl acetate-hexanes) gave 851mg(83%) of the title compounds as 1:1 mixture of diastereomers. 'H.NMR (500 MHz, CDCl) § 7.34(7H, m), 6.98 (1H, t, J = 7.3Hz), 6.89 (2H, d, J = 7.7Hz), 5.61 (1H, d, J = 93 Hz), 5.15-5.08 (2H, m), 450 (1H, br s), 4.33-422 (4H, m), 3.60-3.54(1H, m), 3.32-3.27(1H, m), 2.10 (1H, m), 1.29 (3H, m), 1.02-0.94 (6H, m).
The following compounds were prepared similarly: . Ethyl 3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-5-phenyl- : methyl-4,5-dihydro-isoxazole-5-carboxylate (diastereomeric) : : ‘H-NMR (500 MHz, CDCl) § 7.45-7.15 (m, 10H), 5.07 (m, 2.5H), 4.90 (d, 0.5H), 430-4.18 (m, 3H), 3.36-2.88 (m, 4H), 1.95-1.80 (m, 1H), 1.27 (m, 3H), 0.86-0.55 (m, 6H). . 3-[(1S)-1-t-butoxycarbonylamino-2-methyl-propyl]-5-(2-naphthyl)-4,5-di- hydro-isoxazole-5-carboxylic acid ethyl ester 'H-NMR (500 MHz, CDCL) § 7.97(1H, s), 7.86-7.82 (3H, m), 7.52-7.48 (3H, m), 4.93 (1H, br), 4.37 (1H, m), 4.25 -4.18 (2H, m), 4.10-4.05 (1H, two doublets, J=17.1, 17.6 Hz), 3.28-322 (1H, two doublets, J = 17.1, 17.1 Hz), 2.05 (1H, m), 1.43 ((H, s), 1.24-120 (3H, m), 0.98-0.91 (6H, m). . 3-[(1S)-1-t-butoxycarbonylamino-2-methyl-propyl]-5-phenylmethyl-4,5-dihyd ro-isoxazole-5-carboxylic acid ethyl ester (~1:1 diastereomers)
"H-NMR (500 MHz, CDCls) § 7.25 (5H, m), 4.82 and 4.60 (1H, two m),
4.25-4.15 (3H, m), 3.38-3.29 (2H, m), 3.10 (1H, m), 2.90 (1H, m), 1.43 and 1.42 (9H, two s), 1.27 (3H, m), 0.90-0.80 (6H, m).
. 5-acetoxymethyl-3-[(1S)-1-t-butoxy-carbonylamino-2-methyl-propyl}-4,5-di-
hydro-isoxazole-5-carboxylic acid ethyl ester
'H-NMR (500 MHz, CDCl) § 4.93 (1H, br), 4.44-426 (SH, m), 3.50
(1H, m), 3.10 (1H, m), 2.08 (4H, s + br 1H), 1.46 (9H, s), 1.32-1.30
(3H, m), 1.02-0.96 (6H, m).
. Ethyl 3-[2-methyl-(1S)-1-(tert-butyloxycarbonylamino)-propyl]-5-butyl-4,5-
dihydro-isoxazole-5-carboxylate (diastereomeric mixture)
'H-.NMR (500 MHz, CDCl3) § 4.96 & 4.87 (two br s, 1H), 4.34-4.18 (m, 3H), 3.42-3.36 (m, 1H), 2.90-2.83 (m, 1H), 2.02 (m, 1H), 1.91 (m, 2H),
1.43 (s, 9H), 1.37-1.26 (m, 7H), 0.98-0.87 (m, 9H).
. Ethyl 3-[2-methyl-(1S)-1-(tert-butyloxycarbonylamino)-propyl]-5-propyl-4,5-
dihydro-isoxazole-5-carboxylate (diastereomeric mixture)
'H.NMR (500 MHz, CDCl3) § 4.96-4.86 (m, 1H), 4.33-4.18 (m, 3H),
3.42-3.36 (m, 1H), 2.90-2.83 (m, 1H), 2.02 (m, 1H), 1.89 (m, 2H), 1.43
(s, 9H), 1.29 (m, SH), 0.98-0.87 (m, 9H).
. Methyl 3-[2-methyl-(1S)-1-(tert-butyloxycarbonylamino)-propyl]-5-methoxy-
methyl-4,5-dihydro-isoxazole-5-carboxylate (diastereomeric mixture)
'H-.NMR (500 MHz, CDClz) § 4.92 (m, 1H), 4.35 (m, 1H), 3.80 & 3.79
(two s, 3H), 3.40 (s, 3H), 3.88-3.13 (m, 4H), 2.04 (m, 1H), 1.44 (s, 9H),
0.99-0.91 (m, 6H).
~ 66 ~ - Ethyl ~~ 3-[2-methyl-(1S)-1-(tert-butyloxycarbonylamino)-propyl]-5-n-pentyl- 4,5-dihydro-isoxazole-5-carboxylate (diastereomeric mixture) 'H-NMR (500 MHz, CDCl) § 4.95& 4.88 (two br s, 1H), 4.30-4.17 (m, 3H), 3.42-3.36 (m, 1H), 2.89-2.83 (m, 1H), 2.02 (m, 1H), 1.90 (m, 2H), 1.43 (s, 9H), 1.28 (m, 9H), 0.98-0.85 (m, 9H). - Ethyl 3-[2-methyl-(1S)-1-(tert-butyloxycarbonylamino)-propyl]-5-ethyl-4,5- dihydro-isoxazole-5-carboxylate (diastereomeric mixture)
IH-NMR (500 MHz, CDCl) § 4.96& 4.88 (two br s, 1H), 4.31-4.18 (m, 3H), 3.42-336 (m, 1H), 2.89-2.80 (m, 1H), 2.03 (m, 1H), 1.94 (m, 2H), 1.43 (s, 9H), 1.29 (m, 3H), 0.97-0.86 (m, 9H).
Example 10: Synthesis of 3-[(1S)-1-(9-fluorenylmethyloxycarbonylamino)-3- t-butoxycarbonyl-propyl]-5-methyl-4,5-dihydro-isoxazole-5-carboxylic acid methyl ester
A solution of 4-(9-fluorenylmethoxycarbonyl)amino-(4S)-5-chloro-5-hydroxy- imino-pentanoic acid t-butyl ester (3.44g, 7.50 mmol) and methyl methacrylate (2.40mL, 3.0 eq) in dry ether under N; at -78 °C was treated with EtN@-Pr); (1.96mL, 1.5eq). Similar treatment as described previously followed by flash chromatography with 25-30% ethyl acetate/hexanes gave 3.46g (89% overall) of the title compound as diastereomeric mixture, 'H-NMR (500 MHz, CDCL) § 7.77 (2H, d, J=7.3Hz), 7.59 (2H, d, J =73Hz), 7.40 (2H, t, J = 7.3Hz), 7.31 (2H, t, J =7.3 Hz), 5.34 (1H, m), 458-438 (3H, m), 4.21 (1H, m), 3.78 (3H, s), 3.48 (1H, m), 2.90-2.81 (1H, m), 2.42-227 (2H, m), 2.18 (1H, m), 1.93 (1H, m), 1.63 (3H, s),
1.45 (9H, s) (D) Transformations of isoxazolines (Deprotection, Introduction of Pas group, Hydrolysis of ester group) (Examples 11 and 12)
Example 11: Synthesis of 3-{2-methyl-(1S)-1-(naphthalene-2-carbonyl- amino)-propyl }-5-phenoxymethyl-4,5-dihydro-isoxazole-5-carboxylic acid ethyl ester
A solution of 3-{(1S)-1-(t-butoxycarbonylamino)-2-methyl-propyl}-5- phenoxy-methyl-4,5-dihydro-isoxazole-5-carboxylic acid ethyl ester (2.00g, 4.76 mmol) in dry CH.Cl, (10 mL) at 0°C under N: was treated with
TFA (6 mL) and stirred for 1.5h. After removal of volatiles, the residue was taken up with ethyl acetate (200 mL), washed with satd NaHCO; (100 mL x 2), dried (anh Na;SQOs), filtered and concentrated. To a solution of the crude product, EDC (1.09g, 1.2 eq), 2-naphthoic acid (983 mg, 1.2 eq) and HOBt (771 mg, 1.2 eq) in DMF (20 mL) at 0°C was added triethylamine (663 uL, 1.0 eq). The reaction was stirred overnight at room temperature. After removal of volatiles in vacuo, the residue was taken up with ethyl acetate (250 mL), washed with water(100 mL), sat'd NaHCO; (100 mL x 2), dried (anh Na;SQO.), filtered and concentrated. Flash chromatography with 25-33% ethyl acetate/hexanes gave 2.04g (90%) of the title compound. 'H-NMR (500 MHz, CDCls) § 8.30 (1H,s), 7.93-7.84 (4H, m), 7.58-7.52 (2H, m), 7.29-7.22 (2H, m), 7.00-6.81 (4H, m), 5.06-5.01 (1H, m), 436-424 (4H, m), 3.68-3.61 (1H, m), 3.43-3.39 (1H, m), 2.28 (1H, m), 1.31-1.26 (3H, m), 1.12-1.05 (6H, m).
Hydrolysis of isoxazoline 5-carboxylic acid ester: The above compound
(2.04g) in distilled THF (40 mL) (not completely soluble) was treated with
IN-NaOH(5.2 mL, 12 eq). After 4h (~50% completion), additional
IN-N2aOH (1.0 mL) was added. After stirring overnight, the reaction was neutralized with concentrated 1N-HCl. The residue was taken up with
CH,Cl; (>700 mL), washed with water, dried (anh NaxSO.), filtered and concentrated to give 1.948g (103%) of the free carboxylic acid, which was used directly in next step.
The following compounds were prepared similarly: ; . 3-{2-methyl-(1S)-1-(naphthalene-1-carbonylamino)-propyl } -5-phenoxymethyl -4,5-dihydro-isoxazole-5-carboxylic acid ethyl ester 'H-NMR (500 MHz, CDCl) § 8.23 (IH, d, J = 8.3 Hz), 7.93-7.86 (2H, m), 7.66 (1H, m), 7.54-7.42 (3H, m), 7.29-7.25 (2H, m), 7.00-6.90 (3H, m), 6.49 (1H, m), 5.13-5.09 (1H, m), 4.40-426 (4H, m), 3.69-3.64 (1H, m), 3.44-3.41 (1H, m), 2.28 (1H, m), 1.32-1.01 (9H, m). . 3-{2-methyl-(18)-1-(naphthalene-2-carbonylamino)-propyl}-4,5-dihydro-isoxa zole-5-carboxylic acid ethyl ester "H-NMR (500 MHz, CDCl) § 8.30 (1H, s), 7.94-7.83 (4H, m), 7.59-7.53 (2H, m), 6.80-6.70 (NH, two d), 5.07-5.03 (2H, m), 4.28-4.21 (2H, m), 337-333 (2H, m), 2.28 (1H, m), 1.34-1.25 (3H, m), 1.12-1.02 (6H, m). . 3-[(18)-1-(1-naphthalenecarbonylamino)-2-methyl-propyl}-5-phenylmethyl-4, 5- dihydro-isoxazole-5-carboxylic acid ethyl ester (diastereomeric) 'H.NMR (500 MHz, CDCl) § 8.28 (d, J = 7.8 Hz, 1H), 7.94-7.86 (m, 2H), 7.61-7.11 (m, 9H), 6.36 (d, J = 9.3 Hz, 0.5H), 6.09 9d, J = 9.3 Hz, 0.5H), 4.94-485 (m, 1H), 4.27-4.21 (m, 2H), 3.49-2.98 (m, 4H), 2.15 &
1.97 (two m, 1H), 1.30-1.26 (m, 3H), 1.03-0.59 (m, 6H). . Ethyl 3-[(1S)-1-phenethylcarbonylamino-2-methyl-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carboxylate (diastereomeric) 'H-.NMR (500 MHz, CDCl) § 7.28-7.17 (m, 10H), 5.74 & 5.50 (two d,
J = 93 Hz, NH), 458-452 (m, 1H), 4.24-4.20 (m, 2H), 3.34-3.25 (m, 2H), 3.11-2.82 (m, 4H), 252-245 (m, 2H), 193 &1.75 (two m, 1H), 1.29-1.25 (m, 3H), 0.79-0.41 (m, 6H). . 3-[(18)-1-(1-naphthalenesulfonylamino)-2-methyl-propyl]-5-phenylmethyl-4,5 -dihydro-isoxazole-5-carboxylic acid ethyl ester (diastereomeric) 'H-NMR (500 MHz, CDCl) § 8.68-8.64 (m, 1H), 8.29-8.25 (m, 1H), 8.07 (m, 1H), 7.93 (m, 1H), 7.71-7.52 (m, 3H), 7.23-6.98 (m, 5H), 5.27 & 5.19 (two m, 1H), 4.12-4.07 (m, 2H), 3.75 & 3.66 (two m, 1H), 3.16-2.43 (m, 4H), 1.77-1.62 (m, 1H), 1.25-1.16 (m, 3H), 0.86-0.57 (m, 6H). . 3-[(1S)-1-(indole-3-yl-ethylcarbonylamino)-2-methyl-propyl]-5-phenylmethyl- 4,5 -dihydro-isoxazole-5-carboxylic acid ethyl ester (diastereomeric) 'H-.NMR (500 MHz, CDCL) § 8.16-8.12 (m, 1H), 7.62-7.56 (m, 1H), 736-694 (m, 9H), 5.71 (d, J = 9.3 Hz, 05H), 542 (d, J] = 88 Hz 0.5H), 4.56-4.50 (m, 1H), 4.25-4.17 (m, 2H), 3.30-2.51 (m, 8H), 1.89-1.70 (m, 1H), 1.28-1.24 (m, 3H), 0.73-0.41 (m, 6H). . 3-[(1S)-1-(indole-3-yl-methylcarbonylamino)-2-methyl-propyl]-5-phenylmeth yl-4,5 -dihydro-isoxazole-5-carboxylic acid ethyl ester (diastereomeric) "H-NMR (500 MHz, CDCl) § 8.56 & 8.52 (two br s, 1H), 7.55-7.05 (m, 10H), 5.98-5.91 (m, 1H), 4.57 (m, 1H), 4.22-4.15 (m, 2H), 3.73 (m, 2H), 3.28-2.79 (m, 4H), 1.87-1.68 (m, 1H), 1.27-120 (m, 3H), 0.75-0.34
(m, 6H).
- 3-[(1S)-1-(cinnamoylamino)-2-methyl-propyl]-5-phenylmethyl-4,5-dihydro-is oxazole-5-carboxylic acid ethyl ester (diastereomeric)
'H-NMR (500 MHz, CDCl) § 7.61-7.23 (m, 11H), 6.40-6.34 (m, 1H),
6.06 (d, J] = 88 Hz, 05H), 581 (d, J] = 9.3 Hz, 05H), 4.76-4.69 (m,
1H), 4.26-4.19 (m, 2H), 3.42-2.94 (m, 4H), 2.06 & 1.88 (two m, 1H),
1.28-1.24 (m, 3H), 0.93-0.57 (m, 6H).
- 3-[(18S)-1-(phenylmethylsufonylamino)-2-methyl-propyl]-5-phenylmethyl-4, 5-
dihvdro-icoxazole-5-carhoxvlic acid ethyl ester (diastereomeric)
"H-NMR (500 MHz, CDCl) § 7.35-7.16 (m, 10H), 4.66-4.61 (m, 1H),
4.25 (m, 2H), 4.11-3.84 (m, 3H), 3.71-2.82 (m, 4H), 1.80 & 1.70 (two m,
1H), 1.28 (m, 3H), 0.85-0.58 (m, 6H).
- Methyl 3-[2-methyl-(1S)-1-(4-tert-butyloxycarbonylbutanoylamino)-propyl]-
5-methyl-4,5-dihydro-isoxazole-5-carboxylate (diastereomeric mixture)
'H-NMR (500 MHz, CDCL) § 6.05-5.99 (two d, 1H), 4.71 (m, 1H), 3.77
(s, 3H), 3.49-3.44 (m, 1H), 2.87-2.80 (m, 1H), 2.27 (m, 4H), 2.07 (m,
1H), 1.92 (m, 2H), ~1.6 (s, 3H), 1.43 (s, 9H), 1.29 (m, 3H), 0.99-0.86
(m, 6H).
. Ethyl 3-[2-methyl-(1S)-1-(3-tert-butyloxycarbonylproanoylamino)-propyl]-5-
ethyl-4,5-dihydro-isoxazole-5-carboxylate (diastereomeric mixture)
'H-NMR (500 MHz, CDCL) § 6.20-6.15 (two d, 1H), 4.68 (m, 1H), 4.21
(m, 2H), 3.40-3.36 (m, 1H), 2.90-2.82 (m, 1H), 2.57 (m, 2H), 2.46 (m,
2H), 2.07 (m, 1H), 1.94 (m, 2H), 1.43 (s, 9H), 1.29 (m, 3H), 0.96-0.88
(m, 9H).
. Ethyl 3-[2-methyl-(1S)-1-(3-tert-butyloxycarbonylproanoylamino)-propyl]-5- n-pentyl-4,5-dihydro-isoxazole-5-carboxylate (diastereomeric mixture) 'H-NMR (500 MHz, CDCl) § 6.18-6.13 (two d, 1H), 4.68 (m, 1H), 4.23 (m, 2H), 3.41-336 (m, 1H), 2.90-2.82 (m, 1H), 2.57 (m, 2H), 2.46 (m, 2H), 2.08 (m, 1H), 1.88 (m, 2H), 1.43 (s, 9H), 1.28 (m, 9H), 0.96-0.85 (m, SH). . Methyl 3-[2-methyl-(1S)-1-(3-tert-butyloxycarbonylproanoylamino)-propyl]- 5-methoxymethyl-4,5-dihydro-isoxazole-5-carboxylate (diastereomeric mixture) 'H-NMR (500 MHz, CDCl3) § 6.17 (m, 1H), 4.71 (m, 1H), 3.78 (s, 3H), 3.72-3,65 (m, 2H), 3.39 (two s, 3H), 3.39-3.34 (m, 1H), 3.17-3.12 (m, 1H), 2.57 (m, 2H), 2.46 (m, 2H), 2.08 (m, 1H), 1.43 (s, 9H), 0.97-0.88 (m, 6H). . 3-[2-methyl-(1S)-1-amino-propyl]-5-(2-naphthyl)-4,5-dihydro-isoxazole-5-car : boxylic acid ethyl ester (~1.3:1 diastereomers) "H-NMR (500 MHz, CDCl5) § 7.99 (1H, s), 7.86-7.82 (3H, m), 7.53-7.49 (3H, m), 4.25-4.02 (3H, m), 3.55-3.48 (1H, two d, J = 7.3, 6.8Hz), 3.35 (0.45H, d, J=17.1 Hz), 3.19 (0.55H, d, ] = 17.1Hz), 1.78 (1H, m), 1.22 (3H, t, J = 7.3 Hz), 0.96-0.82 (6H, m)
Example 12: Synthesis of 3-{(1S)-1- (2-naphthoylamino)-3-t-butoxycarbonyl- propyl }-5-methyl-4,5-dihydro-isoxazole-5-carboxylic acid methyl ester
A solution of 3-[(1S)-1-(9-fluorenylmethyloxycarbonylamino)-3-t-butoxy- carbonyl-propyl]-5-methyl-4,5-dihydro-isoxazole-5-carboxylic ~~ acid methyl ester (440mg, 0.842 mmol) in DMF (8.0 mL) at room temperature was treated with piperidine (2.5 mL) for 5 min. After concentration, the residue was dissolved in DMF (10 mL), and treated with 2-naphthoic acid (174 mg, 12 eq), EDC (210 mg, 13 eq), HOBt (148 mg, 13 eq) and triethylamine (0.35 mL, 3.0 eq), then stired overnight (0°C toroom temperature). Usual workup followed by chromatography gave 133 mg of the title compound and 260 mg (~50% purity) mixture. "H-NMR (500 MHz, CDCl) § 8.33 (1H, s), 7.92-7.83 (4H, m), 7.58-7.48 (2H, m), 7.34 (1H, d, J=7.8Hz), 5.04 (1H, m), 3.78 and 3.74 (3H, two s), 3.62-3.53 (1H, two d, J=17.1, 17.6Hz), 3.00-2.96 (1H, two d, J =17.1, 17.6 Hz), 2.56-2.08 (4H, m), 1.63 and 1,59 (3H, two s), 1.41 and 1.40 (9H, two s) (E) Synthesis of aspartic acid derivatives (Examples 13 to 18)
Example 13: Synthesis of N-phenylmethyloxycarbonyl-g -t-butyl aspartic acid (N-methoxy) methyl amide
A solution of N-benzyloxycarbonyl-g -t-butyl aspartic acid (2.0g, 6.2 mmol), N,O-dimethylhydroxylamine hydrochloride (724 mg, 1.2 eq) and
HOBt (1.00g, 1.2 eq) in DMF (20 mL) at 0°C was treated with EDC (142g, 12 eq) and triethylamine (129 mL, 1.5 eq). After stirring overnight (0°C toroom temperature), the reaction was diluted with water(100mL), extracted with ethyl acetate-hexanes (1:1, 100 mL x 2), washed with water(100 mL), dried (anh Na;SOa), filtered and concentrated.
Flash chromatography with ethyl acetate-hexanes (3:7) gave 2.039g (90%) of the title compound. 'H.NMR (500 MHz, CDCl) § 736-731 (SH, m), 5.70 (1H, bn), 5.16-5.08 (3H, m), 3.80 (3H, s), 3.23 (3H, s), 2.74-2.71(1H, m), 2.59 -2.57 (1H, m), 1.43 (9H, s).
Example 14: Synthesis of pg -t-butyl aspartic acid N,O-dimethylhydroxyl- amine amide
Conventional hydrogenolysis of N-phenylmethyloxycarbonyl-g -t-butyl aspartic acid (N-methoxy)methyl amide (Hz balloon, 10% Pd/C, EtOH) gave the title compound (100%). 'H-NMR (500 MHz, CDCl) § 4.13 (1H, m), 3.77 (3H, s), 3.22 (3H, s), 2.71-2.67 (1H, m), 2.42-2.38 (1H, m), 1.46 (9H, s)
Example 15: Synthesis of N-phenylmethyloxycarbonyl-g -t-butyl aspartic acid methyl ester
Treatment of N-benzyloxycarbonyl-g -t-butyl aspartic acid with diazomethane/ ether gave the desired methyl ester (100%). 'H-NMR (500 MHz, CDCl) § 7.35-7.27 (5H, m), 5.75 (1H, d), 5.13 (2H, s), 4.60 (1H, m), 3.75 (3H, m), 2.90 (1H, m), 2.76 (1H, m), 1.42 (9H, s). :
Example 16: Synthesis of g -t-butyl aspartic acid methyl ester hydrochloride
Conventional hydrogenolysis of N-phenylmethyloxycarbonyl-g -t-butyl aspartic acid methyl ester (Hz balloon, 10% Pd/C, EtOH-HCI) gave the desired product as hydrochloride salt.
Example 17: Synthesis of (35)-3-phenylmethyloxycarbonylamino-4- hydroxy-5-phenoxy-pentanoic acid t-butyl ester
A solution of N-phenylmethyloxycarbonyl-g -t-butyl-aspartic acid (5.03g,
15.6 mmol), NMM (1.90 mL, 17.1 mmol) in dry THF (60 mL) under Nj at -15°C was treated with isobutyl chloroformate (2.12 mL, 16.3 mmol) and the resulting suspension was stirred for 20 min. To the mixture at 0°C was added dry diazomethane/ether (synthesized from 2.0 eq of 1-methyl-3-nitro-1- nitroso-guanidine, 60 mL) and stirred for 30 min.
When the diazo ketone synthesis was completed (TLC analysis), 30%
HBr/AcOH (6.42 mL, 2.0 eq) was introduced thereto (stirred for 30-60 min.) at 0°C. The reaction was extracted with ethyl acetate, washed with satd NaHCO; (x 2), brine, dried (anh. NazSOs), filtered and concentrated to give bromomethyl ketone derivative (6.4g). " The bromomethyl ketone(4.36g) and phenol (113g, 1.1 eq) in DMF (18 ml) at room temperature were treated with freshly dried KF (1.58g, 2.5 © eq) and stirred for 2 h. Usual extractive workup gave crude phenoxy ketone. The crude phenoxy ketone in methanol (20 mL) at -78 °C was treated with NaBH; (412 mg) in MeOH (40 mL) (78 °C to room temperature, 2h). The reaction was quenched with acetic acid. Usual extractive workup followed by flash chromatography (ethyl acetate-hexanes = 1:5) gave 2.58g (57%) of the title compound as diastereomeric mixture. 'H-NMR (500 MHz, CDClh) § 7.36-7.26 (7H, m), 6.98-6.87 (3H, m), 5.71-5.53 (NH, two d), 5.10 (2H, s), 4.24-3.92 (4H, m), 2.70-2.63 (2H, m), 1.44 and 1.43 (9H, two s).
The following compound was prepared similarly: . (3S)-3-phenylmethyloxycarbonylamino-4-hydroxy-5-(1-naphthyl)oxy- pentanoic acid t-butyl ester 'H-NMR (500 MHz, CDCl) § 821 (1H, m), 7.80 (1H, m), 7.50-7.33 (9H, m), 6.80 (1H, m), 5.73 and 5.55 (1H, two d, J = 8.3 Hz), 5.10 (2H,
s), 4.30-4.15 (4H, m), 2.76-2.69 (2H, m), 1.44 (9H, s).
Example 18: Synthesis of (3S)-3-amino-4-hydroxy-5-phenoxy-pentanoic acid t-butyl ester
Conventional hydrogenolysis of (3S)-3-phenylmethyloxycarbonylamino- 4-hydroxy-5-phenoxy-pentanoic acid t-butyl ester (Hz balloon, Pd/C, EtOH) gave the desired product (100%). "H-NMR (500 MHz, CDCl) § 7.29-7.26 (2H, m), 6.97-6.90 (3H, m), 4.08-3.82 (3H, m), 3.43 (1H, m), 2.63-2.37 (2H+NH,+OH, m), 1.46 and 1.45 (9H, two s).
The following compound was prepared similarly: : . (3S)-3-amino-4-hydroxy-5-(1-naphthyl)oxy-pentanoic acid t-butyl ester 'H-NMR (500 MHz, CDCl) § 8.22 (1H, m), 7.80 (1H, m), 7.50-7.34 (4H, m), 6.84 (1H, m), 4.26-4.20 (2H, m), 4.03-3.94 (1H, m), 3.51 (1H, m), 2.70-2.40 (2H, m), 1.47 and 1.46 (9H,. two s). (F) Coupling of isoxazoline derivatives and aspartic acid derivatives and further transformations thereof (Examples 19 to 24).
Example 19: Synthesis of (2S)-2-{3-[(1S)-1-phenylmethyloxycarbonyl- amino-2-methyl-propyl]-5-phenoxymethyl-4,5-dihydro-isoxazole-5-carbonyl-ami ‘no}-succinic acid 4-t-butyl ester 1-(N-methyl-N-methoxy) amide
A solution of 3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-5- phenoxymethyl-4,5-dihydro-isoxazole-5-carboxylic acid ethyl ester (502mg, 1.10 mmol) in THF (6.6 mL) was treated with IN-NaOH (1.33mL). After stirring for 2.5h at room temperature, the reaction solution was quenched
~ 76 - with IN-HCI (1.33 mL), then concentrated in vacuo. The residue together with satd NaCl(50 mL+ 2-3 mL] IN-HCI) was extracted with ethyl acetate (100 mL x 2), dried (anh NaSOy), filtered and concentrated to give 476mg (101 %) of 3-[(1S)-1-phenylmethyl-oxycarbonylamino-2-methyl- propyl]-5-phenoxymethyl-4,5-dihydro-isoxazole-5-carboxylic acid.
The crude acid (320 mg, 0.75 mmol) and p -t-butyl aspartic acid
N-methyl- (N-methoxy) amide (209 mg, 1.2 eq) in DMF (5mL) at 0°C were treated with HOBt (122mg, 1.2 eq), EDC (172mg, 1.2 eq) and triethylamine (0.31 mL, 3.0 eq), and then stirred for 3h (0°C to room temperature). Concentration, conventional workup followed hy flash chromatography gave less polar isomer (160mg) and more polar isomer (213mg, 33%).
More polar isomer: 'H-NMR (500 MHz, CDCl) § 7.64 (1H, d), : 735-724 (7H, m), 6.95 (1H, t, J = 7.3 Hz), 6.88 (2H, d, J] = 7.8 Hz), 555 (1H, d), 5.18-5.08 (3H, m), 4.44 (1H, m), 432-425 (2H, m), 3.75 (3H, s), 3.32-3.25 (2H, m), 3.12 (3H, s), 2.77-2.71(1H, m), 2.62-2.56 (1H, m), 2.12 (1H, m), 1.44 (9H, s), 1.03-0.91 (6H, m).
Less polar isomer: 'H-NMR (500 MHz, CDCls) § 7.65 (1H, d, J = 8.3
Hz), 7.36-7.23 (7H, m), 6.95 (1H, t, J = 7.3 Hz), 6.88 (2H, d, J = 83
Hz), 5.19-5.11 (4H, m), 4.46 (1H, m), 4.33-4.22 (2H, ABq, J =10.3 Hz), 3.75 (3H, s), 3.33 (2H, s), 3.23 (3H, s), 2.73 (1H, m), 2.57 (1H, m), 2.07 (1H, m), 1.43 (9H, s), 1.03-0.92 (6H, m).
Example 20: Synthesis of (3S)-3-{3-[(1S)-1-phenylmethyloxycarbonyl- amino-2-methyl-propyl]-5-phenoxymethyl-4, 5-dihydro-isoxazole-5-carbonyl-ami no}-4-keto-pentanoic acid t-butyl ester
The title compound was obtained from treatment of excess MeMgBr (3.0M in ether, > 3.0 eq) to a solution of less polar isomer of (25)-2-{3-[(1S)-1- phenylmethyloxycarbonylamino-2-methyl-propyl]-5-phenoxymethyl-4,5-dihydro -isoxa-zole-5-carbonyl-amino}-succinic acid 4-t-butyl ester 1-(N-methyl-
N-methoxy) amide (110 mg, 0.17 mmol) in THF (5 mL) + LiCl satuated
THF (2 mL) at 0°C - room temperature (44mg, 43%).
From less polar isomer: 'H-NMR (500 MHz, CDCl) § 8.00 (1H, d, J = 9.3 Hz), 7.36-7.24 (7H, m), 6.96 (1H, t, J = 7.2 Hz), 6.87 2H, d, ] = 8.3 Hz), 526 (1H, d, J = 8.8 Hz), 5.12-5.09 (2H, m), 4.66 (1H, m), 4.43 (1H, d, J= 9.8 Hz), 4.21 (1H, d, J = 9.8 Hz0, 3.37-3.19 (2H, ABq, J = 18.0 Hz), 2.88 (1H, m), 2.58 (1H, m), 2.25 (3H, s), 2.03 (1H, m), 1.42 (9H, s), 0.99-0.89 (6H, m).
Similar treatment of more polar isomer of (2S)-2-{3-[(1S)-1-phenylmethyl- oxy-carbonylamino-2-methyl-propyl]-5-phenoxymethyl-4,5-dihydro-isoxazole-5- carbonyl-amino }-succinic acid 4-t-butyl ester 1-(N-methyl-N-methoxy) amide (135 mg) gave 52mg (41%) of the corresponding methyl ketone.
Example 21: Synthesis of (25)-2-{3-[2-methyl-(1S)-1-(naphthalene-2- carbonyl-amino)-propyl]-5-phenylmethyl-4,5-dihydro-isoxazole-5-carbonyl-amin o}-succinic acid 4-t-butyl ester 1-methyl ester
A solution of 3-[2-methyl-(1S)-1-(naphthalene-2-carbonylamino)-propyl}-5- phenyl- methyl-4,5-dihydro-isoxazole-5-carboxylic acid (2.14g, 5.07 mmol), aspartic acid p -t-butyl ester methyl ester hydrochloride (1.46g, 1.2 eq),
EDC (1.17g, 1.2 eq) and HOBt (822 mg, 1.2 eq) in DMF (19 mL) was treated with triethylamine (2.12 mL, 3.0 eq), and stirred overnight.
Conventional workup followed by flash chromatography (40-50% ethyl acetate-hexanes) gave the title compound (2.94g, 94%) as a white foam.
'H-NMR (500 MHz, CDCl3) § 8.30 and 825 (1H, two s), 7.96-7.79 (4H, m), 7.65-7.54 (3H, m), 7.31-7.18 (5H, m), 6.76 (0.5H, d, J = 9.3 Hz), 6.43 (0.5H, d, J = 8.8 Hz), 4.96-4.70 (2H, m), 3.71 and 3.60 (3H, two s), 3.45-3.14 (4H, m), 3.08-2.34 (2H, m), 2.15 (1H, m), 1.47 and 1.44 (SH, two s), 1.04-0.88 (6H, m).
The above compound was hydrolyzed according to the above described method (IN-NaOH in THF) to obtain the coresponding carboxylic acid (100%).
The following esters and free carboxylic acids were prepared similarly. . (28)-2-{3-[2-methyl-(1S)-1-(naphthalene-2-carbonylamino)-propyl]-5-phen- oxy-methyl-4,5-dihydro-isoxazole-5-carbonyl-amino}-succinic acid 4-t-butyl ester 1-methyl ester 'H-NMR (500 MHz, CDCl) § 8.33 and 8.30 (1H, two s), 7.95-7.74 (5H, m), 7.59-7.53 (2H, m), 7.28-7.22 (2H, m), 6.99-6.89 (3.5H, m), 6.71 (0.5H, d, J] = 88 Hz), 5.08-5.01 (1H, m), 4.83-4.79 (1H, m), 4.39-4.29 (2H, m), 3.76 and 3.64 (3H, two s), 3.44 (2H, s), 2.97-2.93 (IH, m), 2.74269 (1H, m), 234-223 (1H, m), 145 and 142 (9H, two s), 1.15-1.01 (6H, m).
Hydrolysis of the above compound gave free carboxylic acid. - (28)-2-{3-[(1S)-1-(phenylmethyloxycarbonyl)-amino-2-methyl-propyl]-4,5-di hydro-isoxazole-5-carbonyl-amino}-succinic acid 4-t-butyl ester 1-methyl ester 'H-NMR (500 MHz, CDCL) § 7.59-7.49 (1H, m), 7.38-7.32 (5H, m), 525-495 (4H, m), 4.86 (1H, m), 4.48 (1H, m), 3.76 and 3.67 (3H, two s), 3.29 (2H, m), 2.92 (1H, m), 2.71-2.62 (1H, m), 2.04 (1H, m), 1.48
(9H, s), 1.01-0.85 (6H, m)
- (28)-2-{3-[(1S)-1-phenethylcarbonylamino-2-methyl-propyl]-5-phenylmethyl-
4,5-dihydro-isoxazole-5-carbonylamino}-succinic acid 4-t-butyl ester-1-methyl ester (diastereomeric)
"H-NMR (500 MHz, CDCl) § 7.56 (d, J] = 8.3 Hz, 0.5H), 747 (d, J =
93 Hz, 0.5 H), 7.28-7.18 (m, 10H), 5.83 & 5.44 (two d, J] = 8.8 Hz,
1H), 4.70-4.52 (m, 2H), 3.68 & 3.65 (two s, 3H), 3.33-2.28 (m, 10H),
1.89 (m, 1H), 143 & 1.42 (two s, 9H), 0.79-0.63 (m, 6H).
. (25)-2-{3-[(1S)-1-(1-naphthalenecarbonylamino)-2-methyl-propyl]-5-phenylm ethyl-4,5-dihydro-isoxazole-S-carbonylamino}-succinic acid 4-t-butyl ester-
1-methyl ester (diastereomeric)
"H-NMR (500 MHz, CDCL) § 827 (m, 1H), 7.92-7.85 (m, 2H),
7.61-7.15 (m, 10H), 6.45 & 6.05 (two d, NH), 4.99-485 (m, 1H), 4.70
(m, 1H), 3.69 & 3.52 (two s, 3H), 3.50-2.32 (m, 6H), 2.12 (m, 1H), 1.40
& 1.39 (two s, 9H), 1.05-0.80 (m, 6H).
. (25)-2-{3-[(1S)-1-(1-naphthalenesulfonylamino-2-methyl-propyl]-5-phenylmet hyl-4,5-dihydro-isoxazole-5-carbonylamino }-succinic acid 4-t-butyl ester-1-
methyl ester (diastereomeric)
"H-NMR (500 MHz, CDCl) § 8.69-8.62 (m, 1H), 8.33-7.94 (m, 3H),
7.70-7.47 (m, 3H), 7.20-7.05 (m, 5H), 532 & 5.15 (two m, 1H), 4.68 &
4.54 (two m, 1H), 3.85 & 3.59 (two m, 1H), 3.82 & 3.62 (two s, 3H),
3.23-1.75 (m, 7H), 1.40 & 1.34 (two s, 9H), 0.85-0.48 (m, 6H).
. (25)-2-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino}-succinic acid 4-t-butyl ester-
1-methy] ester (diastereomeric) "H-NMR (500 MHz, CDCL) § 7.53-749 (two d, 1H), 7.35-7.25 (m, 10H), 5.09-5.07 (m, 2.5 H), 4.88 (d, 0.5 H), 4.69 (m, 1H), 4.34 & 4.23 (two m, 1H), 3.68 &3.63 (two s, 3H), 3.36-2.23 (m, 6H), 1.89 & 1.70 (two m, 1H), 1.42 & 1.40 (two s, 9H), 0.88-0.73 (m, 6H). - (28)-2-{3-[(1S)-1-(indole-3-yl-ethylcarbonylamino)-2-methyl-propyl}-5-pheny
Imethyl-4,5-dthydro-isoxazole-5-carbonylamino}-succinic acid 4-t-butyl ester- 1-methyl ester (diastereomeric) 'H-NMR (500 MHz, CDCl) § 8.54 & 8.38 (two br s, 1H), 7.62-6.97 (m, TH), 583 (d, IT = 88 Hz, 05H), 520 (d, T = 93 Hz, 05H) 4.73-4.69 (m, 1H), 4.61 & 4.48 (two m, 1H), 3.71 & 3.59 (two s, 3H), 3.28-2.26 (m, 10H), 1.87-1.75 (m, 1H), 1.43 &1.42 (two s, 9H), 0.78-0.50 (m, 6H). . (28)-2-{3-[(1S)-1-(indole-3-yl-methylcarbonylamino)-2-methyl-propyl}-5-phe nylmethyl-4,5-dihydro-isoxazole-5-carbonylamino }-succinic acid 4-t-butyl- ester-1-methy!l ester (diastereomeric) 'H-NMR (500 MHz, CDCl) § 837 & 8.26 (two br s, 1H), 7.54-7.12 (m, 11H), 5.95 (d, ] = 8.8 Hz, 05H), 576 (d, J = 1.5 Hz, 0.5H), 4.68-4.51 (m, 2H), 3.78-3.68 (m, 2H), 3.66 & 3.62 (two s, 3H), 3.28-2.21 (m, 6H), 1.80 (m, 1H), 1.41 & 1.37 (two s, 9H), 0.75-0.46 (m, 6H). . (25)-2-{3-[(18)-1-(cinnamoylamino)-2-methyl-propyl]-5-phenylmethyl-4,5-di hydro-isoxazole-5-carbonylamino}-succinic acid 4-t-butyl ester-1-methyl ester (diastereomeric) 'H-NMR (500 MHz, CDCl) § 7.63-7.25 (m, 12H), 6.43-6.32 (two d, J = 15.6 Hz, 1H), 6.09 & 5.68 (two d, J = 9.3 Hz, 1H), 4.78-4.70 (m, 1H), 3.69 & 3.68 (two s, 3H), 3.35-2.31 (m, 6H), 2.03 (m, 1H), 1.43 & 1.40
(two s, 9H), 0.92-0.76 (m, 6H). . (28)-2-{3-[(1S)-1-(phenylmethylsulfonylamino)-2-methyl-propyl]-5-phenylme thyl-4,5-dihydro-isoxazole-5-carbonylamino}-succinic acid 4-t-butyl ester- 1-methyl ester (diastereomeric) 'H-NMR (500 MHz, CDCl3) § 7.67 & 7.60 (two d, J = 8.8 Hz, 1H), 7.40-7.17 (m, 10H), 3.71 & 3.55 (two s, 3H), 3.37-2.23 (m, 6H), 1.70 (m, 1H), 1.42 & 1.47 (two s, 9H), 0.91-0.65 (m, 6H).
Example 22: Synthesis of (3S)-3-{3-[2-methyl-(1S)-1-(naphthalene-2- carbonyl-amino)-propyl]-5-phenylmethyl-4,5-dihydro-isoxazole-5-carbonyl-amin o0}-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid-t-butyl ester
A solution of (28)-2-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl- propyl]-4,5-dihydro-5-phenylmethyl-isoxazole-5-carbonyl-amino}-succinic acid 4-t-butyl ester (2.86g, 4.75 mmol) and NMM (0.57 mL, 1.1 eq) in dry
THF (x mL) under N; at 0°C was treated with isobutyl chloroformate (0.65 mL, 1.05eq), and stirred for 20 min. To the solution at 0°C was added diazomethane, and stirred for 30 min. (TLC analysis). Additional diazomethane was needed to complete the reaction(lh). After completion of the diazoketone formation, 30% HBr/AcOH (4.0 mL, 4.0 eq) was added at 0 °C and the reaction was stirred for 1h. The reaction was extracted with ethyl acetate (x2) and the organic layer was washed with water, sat'd
NaHCO; and brine, dried (anh Na,SO,), filtered and concentrated to give 3.36g of a yellow solid. Half of the solid (~2.375 mmol) was reacted with anhydrous KF (345 mg, 2.5 eq) and 2,6-dichlorobenzoic acid (545 mg, 1.2 eq) in DMF (10 mL) under N; at room temperature. Usual workup followed by flash chromatography gave the title compound as diastereomeric mixture (1.53g). Preparative HPLC (38% EtOAc/Hexane)
- 82 ~ gave less polar diastereomer (585 mg) and more polar diastereomer (358mg).
Less polar diastereomer: "H-NMR (500 MHz, CDCL) § 8.28 (1H, s), 7.84-7.80 (4H, m), 7.55-7.46 93H, m), 7.29-7.24 98H, m), 6.87 (1H, d, J = 8.8 Hz), 5.05-4.93 (3H, m), 4.73 (1H, m), 3.54 (1H, d, J = 18.1 Hz), 334 (1H, d, J = 13.7 Hz), 3.19 (1H, d, J] = 14.2 Hz), 3.11 (1H, 4, J = 17.6 Hz), 2.74-2.70 (1H, m), 229-224 (2H, m), 1.39 (9H, s), 1.02 (3H, d, J] = 64 Hz), 0.92 (3H, d, J = 6.8 Hz).
More polar diastereomer: 'H-NMR (500 MHz, CDCl) § 8.28 (1H, s), 7.97-7.75 (5H, m), 7.62-7.57 (2H, m), 7.37-7.22 (8H, m), 6.56 (1H, d, J] = 83 Hz), 4.94 (1H, m), 478 (1H, m), 451-442 (2H, m). 3.51-3.43 (2H, m), 3.24-3.15 (2H, m), 2.99-2.95 (1H, m), 2.56-2.52 (1H, m), 2.18 (1H, m), 1.45 (9H, s), 1.02 GH, d, J = 6.8 Hz), 0.97 3H, d, J = 6.4 Hz).
The following compounds were prepared similarly. . (38)-3-{3-[2-methyl-(1S)-1-(naphthalene-2-carbonylamino)-propyl]-5-phenox ymethyl-4,5-dihydro-isoxazole-5-carbonyl-amino }-4-keto-5-(2,6-dichlorobenzoy loxy)-pentanoic acid-t-butyl ester
Less polar diastereomer : H-NMR (500 MHz, CDChL) § 8.29 (1H, s), 7.85-7.81 (SH, m), 7.54-7.46 (2H, m), 7.31-7.23 (SH, m), 6.98-6.87 (4H, m), 5.13-5.03 (3H, m), 4.90 (1H, m), 439-427 (2H, ABq, J = 93 Hz), 3.51 (1H, d, J = 17.6 Hz), 3.41 (1H, d, J = 17.6 Hz), 2.94-2.78 (2H, m), 2.38 (1H, m), 1.41 99H, s), 1.12-1.08 (6H, two d, J = 6.4 Hz).
More polar diastereomer : 'H-NMR (500 MHz, CDCl) § 8.30 (1H, s), 8.11 (1H, d, J = 8.8 Hz), 7.93-7.83 (4H, m), 7.59-7.53 (2H, m), 7.33-7.22 (5H, m), 697-691 (3H, m), 6.77 (1H, d, J = 88 Hz), 537 (IH, d, J = 17.1 Hz), 5.16 (1H, d, J = 17.1 Hz), 501-495 (2H, m), 453 (1H, d, J = 9.8 Hz), 4.25 (1H, d, J = 9.8 Hz), 3.50 (1H, d, J] = 7.6 Hz), 3.32 (1H, d,
J = 7.6 Hz), 3.04-3.00 (1H, dd, J = 17.1, 49 Hz), 2.73-7.68 (1H, dd, 17.1, 5.4 Hz), 2.24 (1H, m), 1.47 (9H, s), 1.10-1.03 (6H, two d, J = 6.4
Hz). - (38)-3-{3-[2-methyl-(15)-1-(phenylmethyloxycarbonylamino)-propyl]-4,5-di- hydro-isoxazole-5-carbonyl-amino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoi ¢ acid-t-butyl ester (diastereomeric mixture) 'H.NMR (500 MHz, CDChL) § 7.72-7.60 (1H, m), 7.37-7.30 (8H, m), 5.40 (0.5H, d), 5.23-4.85 (6.5H, m), 440 (1H, m), 3.30 (2H, m), 2.92-2.65 (2H, m), 2.10-1.98 (1H, m), 1.44 (9H, s), 1.00-0.87 (6H, m).
Following compounds were similarly prepared: . (3S)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-5-phenox ymethyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl oxy)-pentanoic acid t-butyl ester :
More polar isomer: 'H-NMR (500 MHz, CDCL) § 8.59 (d, J = 8.7 Hz, 1H), 8.31 (d, J = 8.3 Hz, 1H), 826 (d, J = 8.7 Hz, 1H), 813 (d, J = 8.7 Hz, 1H), 7.98 (d, J = 8.7 Hz, 1H), 7.88 9d, J = 7.8 Hz, 1H), 7.78 (m, 1H), 7.63 (m, 1H), 7.22-7.15 (m, 4H), 6.96-6.81 (m, 6H), 4.99-4.81 (m, 4H), 4.40 (d, J = 10.1 Hz, 1H), 4.21 (d, J = 10.0 Hz, 1H), 3.44 (d,
J = 17.9 Hz, 1H), 3.24 (d, J = 17.9 Hz, 1H), 3.03 (dd, J = 17.0, 4.6 Hz, 1H), 2.76 (dd, J = 17.0, 5.5 Hz, 1H), 2.30(m, 1H), 1.45 (s, 9H), 1.10 (m, 6H)
Less polar isomer: 'H-NMR (500 MHz, CDCL) § 8.68 (d, J = 8.7 Hz, 1H), 8.32-8.26 (m, 2H), 8.17 (d, J = 8.7 Hz, 1H), 7.91 (m, 2H), 7.80 (m, 1H), 7.66 (m, 1H), 7.28 (m, 4H), 7.02-6.87 (m, 6H), 5.01-4.77 (m, 4H), 438-430 (m, 2H), 3.50-3.38 (ABq, J = 17.9 Hz, 2H), 3.06-3.02 (m, 1H), 2.84-2.80 (m, 1H), 2.34 (m, 1H), 1.44 (s, 9H), 1.14 (m, 6H)
. (35)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-5-phen- oxymethy-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzo yloxy)-pentanoic acid.
From more polar isomer: 'H-NMR (500 MHz, DMSO-ds) § 9.01 (d, J = 92 Hz, 1H), 887 (d, J = 83 Hz, 1H), 855 (d, J = 83 Hz, 1H), 8.18-8.07 (m, 3H), 7.87 (m, 1H), 7.73 (m, 1H), 7.28-7.14 (m, 4H), 6.96-6.75 (m, 6H), 5.00-4.75 (m, 4H), 4.42 (d, J = 10.6 Hz, 1H), 4.22 (d,
J = 10.6 Hz, 1H), 3.47-3.35 (ABq, J = 17.9 Hz, 2H), 2.82 (dd, J = 17.0, 6.4 Hz, 2.56 (m, 1H), 2.33 (m, 1H), 0.98 (m, 6H).
From less polar isomer: "H-NMR (500 MHz, DMSO-de) § 906 (d, T = 92 Hz, 1H), 888 (d, J = 7.8 Hz, 1H), 857 (d, J = 8.7 Hz, IH), 8.22-8.07 (m, 3H), 7.87 (m, 1H), 7.73 (m, 1H), 7.17 (m, 4H), 6.91-6.78 (m, 6H), 498-490 (ABq, J = 17.9 Hz, 2H), 4.77 (m, 2H), 435 d, J = 10.6 Hz, 1H), 420 (d, J = 10.6 Hz, 1H), 3.47-3.35 (ABq, J = 183 Hz, 2H), 2.89 (dd, J = 17.0, 6.4 Hz, 2.61 (dd, J =17.0, 6.4, 1H), 2.31 (m, 1H), 0.98 (d, J = 6.9 Hz, 3H), 0.90 (d, J = 6.9 Hz, 3H). . (38)-3-{3-[2-methyl-(1S)-1-(1-naphthalenecarbonylamino)-propyl]-5-phenylm ethyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy )-pentanoic acid t-butyl ester
More polar isomer: 'H-NMR (500 MHz, CDCL) § 8.29 (d, J = 8.3 Hz), 7.94 (d, J = 8.3 Hz), 7.88 (d, ] = 7.4 Hz, 1H), 7.74 (d, J = 9.7 Hz, 1H), 7.61-7.44 (m, 4H), 7.35-7.18 (m, 8H), 6.23 (d, J = 8.7 Hz, 1H), 4.95 (m, 1H), 4.76 (m, 1H), 4.49-4.41 (ABq, J = 17.5 Hz, 2H), 3.49-3.41 (m, 2H), 322-312 (m, 2H), 2.92 (dd, J = 17.0, 42 Hz, 1H), 2.52 (dd, J = 17.0, 5.1 Hz, 1H), 2.13 (m, 1H), 1.37 (s, 9H), 1.04 (d, J = 6.9 Hz, 3H), 0.91 (d, J = 6.9 Hz, 3H).
Less polar isomer: "H-NMR (500 MHz, CDCl) § 8.24 (d, J = 8.3 Hz
~ 85 - 1H), 7.83 (m, 2H), 7.57-7.47 (m, 4H), 7.38-7.22 (m, SH), 6.64 (d, J = 9.2
Hz, 1H), 5.00-4.87 (m, 3H), 4.72 (m, 1H), 3.60 (d, J = 17.9 Hz, 1H), 336 (d, J = 14.2 Hz, 1H), 3.20 (d, J = 14.2 Hz, 1H), 3.12 (d, J = 17.9
Hz, 1H), 2.69 (dd, J = 17.0, 4.6 Hz, 1H), 2.28-2.18 (m, 2H), 1.38 (s, 9H), 1.06 (d, J] = 6.4 Hz, 3H), 0.88 (d, J] = 6.9 Hz, 3H). . (3S)-3-{3-[2-methyl-(1S)- 1-(cinnamoylamino)-propyl]-5-phenylmethyl-4,5-di hydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid t-butyl ester (more polar isomer) 'H-NMR (500 MHz, CDCl) § 7.72 (d, 1H), 7.62 (d, ] = 15.6 Hz, 1H), 7.50 (m, 1H), 7.38-7.21 (m, 12H), 6.39 (d, J = 15.6 Hz, 1H), 590 (d, J = 92 Hz, 1H), 4.76 (m. 2H), 449-441 (ABq, J = 174 Hz, 2H), 3.42-3.38 (m, 2H), 3.17 (d, J = 14.2 Hz, 1H), 3.09 (d, J = 17.9 Hz, 1H), 291 (dd, J = 174, 46 Hz, 1H), 2.52 (dd, J = 17.4, 5.0 Hz, 1H), 2.04 (m, 1H), 1.41 (s, 9H), 0.90 (m, 6H).
Less polar isomer: "H-NMR (500 MHz, CDCl) § 7.61 (d, 1H), 7.52 (4, 1H), 7.41 (d, 1H), 7.28 (m, 12H), 6.64-6.41 (m, 2H), 5.09-4.99 (ABq, J = 17.4 Hz, 2H), 4.81 (m, 1H), 4.69 (m, 1H), 3.50 (d, J = 179 Hz, 1H), 3.34 (d, J] = 14.2 Hz, 1H), 3.17 (d, J = 14.2 Hz, 1H), 3.04 (d, J = 17.9
Hz, 1H), 2.74 (dd, J = 17.0, 42 Hz, 1H), 2.22 (m, 2H), 1.39 (s, 9H), 0.97-0.88 (m, 6H). . (3S)-3-{3-[2-methyl-(1S)-1-(phenylmethylsulfonylamino)-propyl]-5-phenylme thyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy) -pentanoic acid t-butyl ester
More polar isomer: 'H-NMR (500 MHz, CDCl) § 7.77 (d, J = 9.3 Hg, 1H), 7.38-7.23 (m, 13H), 4.80-4.63 (m, 2H), 4.56-4.46 (ABq, J = 17.1 Hz, 2H), 4.21-4.10 (m, 2H), 3.83 (m, 2H), 3.41-3.37 (m, 1H), 3.19 (d, J = 142 Hz, 1H), 2.90-2.83 (m, 2H), 2.53 (m, 1H), 1.76 (m, 1H), 1.41 (s,
9H), 0.83 (d, J = 6.8 Hz, 3H), 0.77 (d, J = 6.8 Hz, 3H).
Less polar isomer: "H-NMR (500 MHz, CDCl) § 7.64 (d, J = 9.2 Hz, 1H), 7.36-7.26 (m, 13H), 5.05-4.95 (m, 3H), 4.74 (m, 1H), 4.17 (m, 2H), 3.96 (m, 1H), 3.41-2.99 (m, 4H), 2.70 (m, 1H), 2.19 (m, 1H), 1.79 (m, 1H), 1.39 (s, 9H), 0.86 (d, J] = 6.4 Hz, 3H), 0.77 (d, J = 6.8 Hz, 3H). + (35)-3-{3-[2-methyl~(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-4,5-dihyd ro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid t-butyl ester
More polar isomer: "H-NMR (500 MHz, CDCl) § 8.59 (d, J = 8.7 hz,
TH), R31 (d, J = 87 Hz, 1H), 826 (d, 1 = 87 Hz, 1H), 812 (dT = 8.3 Hz, 1H), 7.88 (d, J = 8.3 Hz, 1H), 7.78-7.72 (m, 2H), 7.62 (m, 1H), 733-727 (m, 3H), 5.20-5.05 (m, 3H), 4.92-4.80 (m, 2H), 3.47-3.34 (m, 2H), 2.95 (dd, J = 17.0, 4.6 Hz, 1H), 2.73 (dd, J = 17.0, 5.1 Hz, 1H), 2.28 (m, 1H), 1.45 (s, 9H), 1.07 (m, 6H).
Less polar isomer: "H-NMR (500 MHz, CDCk) § 8.58 (d, J = 9.2 Hz, : 1H), 8.28-8.24 (m, 2H), 8.12 (d, J = 8.7 Hz, 1H), 7.85 (d, J = 7.8 Hz 1H), 7.75-7.59 (m, 3H), 7.31-7.25 (m, 3H), 5.12-4.89 (m, SH), 3.46-3.41 (m, 2H), 2.92 (dd, J = 17.0, 5.1 Hz, 1H), 2.78 (dd, J = 17.0, 5.5 Hz, 1H), 2.30 (m, 1H), 1.44 (s, 9H), 1.10 (m, 6H) - (3 $)-3- {3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoylo
Xy)-pentanoic acid t-butyl ester
More polar isomer: 'H-NMR (500 MHz, CDCl) § 8.52 (d, J = 9.2 Hz, 1H), 8.32 94, J = 8.3 Hz, 1H), 826 (d, J = 83 Hz, 1H), 8.12 (d, J = 8.7 Hz, 1H), 7.88 (d, J = 8.3 Hz, 1H), 7.80-7.63 (m, 3H), 7.36-7.18 (m, 8H), 4.82 (m, 1H), 4.72 (m, 1H), 4.47-4.37 (ABq, J = 17.0 Hz, 2H), 3.47 (d, J = 17.9 Hz, 1H), 3.41 (d, J = 13.8 Hz, 1H), 3.19 (d, J = 14.2 Hz
1H), 3.14 (d, J = 17.9 Hz, 1H), 2.94 (dd, J = 174, 4.1 Hz, 1H), 2.53 (dd, J = 17.0, 5.0 Hz, 1H), 2.18 (m, 1H), 1.45 (s, 9H), 0.98 (m, 6H).
Less polar isomer: "H-NMR (500 MHz, CDCl) § 8.52 (d, J = 9.2 Hz, 1H), 8.28-8.23 (m, 2H), 8.12 (d, J] = 8.7 Hz, 1H), 7.85 (d, J = 8.3 Hz, 1H), 7.73 (m, 1H), 7.62-7.55 (m, 2H), 7.31-7.17 (m, 8H), 5.06-4.98 (ABq,
J = 17.0 Hz, 2H), 4.84 (m, 1H), 4.69 (m, 1H), 554 (d, J] = 17.9 Hz, 1H), 3.29 (d, J = 14.2 H, 1H), 3.16 (d, J = 142 Hz, 1H), 3.10 (d, J = 17.9 Hz, 1H), 2.70 (dd, J = 17.0, 4.1 Hz, 1H), 2.21 (m, 1H), 2.11 (dd, J = 17.0, 5.1 Hz, 1H), 1.38 (s, 9H), 0.98 (m, 6H). . (3S)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid t-butyl ester
More polar isomer: "H-NMR (500 MHz, CDCls) § 8.47 (d, J = 9.2 Hz, 1H), 832 (d, J = 8.7 Hz, 1H), 825 (d, J = 83 Hz, 1H), 8.13 (4, J = 8.7 Hz, 1H), 7.89 (d, J = 7.8 Hz, 1H), 7.78 (m, 1H), 7.69 (d, J = 8.8
Hz, 1H), 7.64 (t, J = 7.3 Hz, 1H), 7.29-7.17 (m, 4H), 7.06 (t, J = 7.4
Hz, 1H), 6.96 (t, J] = 7.4 Hz, 1H), 6.78 (d, J = 8.3 Hz, 2H), 4.81-4.72 (m, 2H), 4.47-4.28 (ABq, J = 17.9 Hz, 2H), 342 (d, J = 17.9 Hz, 1H), 334 (d, J = 14.2 Hz, 1H), 3.15 (d, J = 13.7 Hz, 1H), 3.10 (d, J = 17.9
Hz, 1H), 2.94 (dd, J = 17.4, 41 Hz, 1H), 2.64 (dd, J = 174, 55 Hz, 1H), 2.15 (m, 1H), 1.43 (s, 9H), 0.95 (m, 6H).
Less polar isomer: "H-NMR (500 MHz, CDCl) § 8.50 (d, J] = 9.2 Hz, 1H), 8.24 (d, J = 8.3 Hz, 1H), 8.18 (d, J = 8.3 Hz, 1H), 8.10 (d, J = 82 Hz, 1H), 7.85 (d, J = 7.7 Hz, 1H), 7.74 (m, 1H), 7.62-7.56 (m, 2H), 7.29-7.16 (m, SH), 6.88 (t, J = 7.4 Hz, 1H), 6.78 (d, J = 7.8 Hz, 2H), 4.81-4.66 (m, 4H), 3.46 (d, J = 17.9 Hz, 1H), 3.29 (d, J = 13.8 Hz, 1H), 3.15 (d, J = 13.8 Hz, 1H), 3.07 (d, J = 17.9 Hz, 1H), 2.76 (dd, J = 17.0, 4.1 Hz, 1H), 2.21-2.09 (m, 2H), 1.37 (s, 9H), 0.93 (m, 6H).
- 88 ~ + (35)-3-{3-[2-methyl-(1S)-1-(2-naphthalenecarbonylamino)-propyl]-4,5-dihydr o-isoxazole-5-carbonylamino}-4-keto-pentanoic acid t-butyl ester
Diastereomeric mixture: ‘H-NMR (500 MHz, CDCl) § 8.29 (m, 1H), 7.96-7.50 (m, 7H), 6.85-6.73 (m, 1H), 5.10-4.97 (m, 2H), 4.66 (m, 1H), 340 (m, 2H), 2.94-2.60 (m, 2H), 2.32-2.14 (m, 1H), 2.22 & 2.10 (two s, 3H), 1.43 & 1.42 (two s, 9H), 1.10-0.95 (m, 6H).
Example 23: Synthesis of (3S)-3-{3-[2-methyl-(1S)-1-(naphthalene-2-car- bonyl-amino)-propyl]-S-phenoxymethyl-4,5-dihydro-isoxazole-5-carbonyl-amino }-4-keto-5-phenoxy-pentanoic acid t-butyl ester
The title compound was prepared with conventional EDC coupling of 3-[2-methyl-(1S)-1-(naphthalene-2-car-bonylamino)-propyl]-5-phenoxymethyl-4, 5-dihydro-isoxazole-S-carboxylic acid (1.00g, 2.24 mmol) and (35)-3-amino- 4-hydroxy-5- phenoxy-pentanoic acid t-butyl ester (630 mg, 1.0 eq), EDC (558 mg, 1.3 eq), HOBt(394 mg, 1.3 eq) and triethylamine (094 mL, 3.0 eq) im DMF (5 mL). Usual workup followed by flash chromatography gave 1.44g of coupled product. The coupled product and
Dess-Martin reagent (2.15g, 2.5 mol eq) in dry CH.Cl: (25mL) under N, at room temperature was stirred for 1h, then quenched with isopropyl alcohol(3 mL). Usual extractive workup followed by flash chromatography (36% ethyl acetate-hexane) gave 1.27g of the title compound as diastereomeric mixture. Preparative HPLC (36% ethyl acetate-hexanes, 10 mL/min, 278 nm UV detection) afforded less polar (352 mg) and more polar (536 mg) diastereomers.
Less polar diastercomer: 'H-NMR (500 MHz, CDCl) § 8.29 (1H, s), 7.93-7.81 (5H, m), 7.58-7.51 (2H, m), 7.28-7.21 94H, m), 6.99-6.76 (7H, m), 5.00-4.98 (2H, m), 4.79-4.66 (2H, ABq, J = 16.6 Hz), 4.35-429 (2H,
ABq, J = 10.3 Hz), 3.40 (2H, s), 3.02-2.98 (1H, dd, J = 16.6, 4.9 Hz), 2.84-279 (1H, dd, J = 16.6, 47 Hz), 2.30 (1H, m), 1.41 (9H, s), 1.12-1.07 (6H, two d, J = 6.8 Hz).
More polar diastereomer: "H-NMR (500 MHz, CDCls) § 8.29 (1H, 5s), 7.99-7.82 (5H, m), 7.59-7.53 (2H, m), 7.26-7.18 (4H, m), 6.97-6.83 (6H, m ), 6.68 (1H, d, J = 8.3 Hz), 5.01-4.95 3H, m), 483 (1H, d, J = 17.1
Hz), 442 (1H, d, J] = 9.8 Hz), 423 (1H, d, J = 9.8 Hz), 3.49-3.32 (2H,
ABq, J = 18.1 Hz), 3.06-3.02 (1H, dd, J = 17.1, 4.4 Hz), 2.76-2.72 (1H, dd, J = 17.1, 5.4 Hz), 224 (1H, m), 1.45 (9H, s), 1.10-1.02 (6H, two d,
J = 6.8 Hz).
The following compounds were prepared similarly: . (38)-3-{3-[2-methyl-(1S)-1-(naphthalene-2-carbonylamino)-propyl]}-5-phenox ymethyl-4,5-dihydro-isoxazole-5-carbonyl-amino } -4-keto-5-(2-naphthyloxy)-pen tanoic acid-t-butyl ester
Less polar diastereomer: "H-NMR (500 MHz, CDCl) § 8.27(1H, s), 7.89 (8H, m), 7.56-7.26 (6H, m), 7.23-6.87 (5H, m), 6.74 (1H, d, J] = 9.3 Hz), 5.04-495 (2H, m), 4.92-4.80 (2H, ABq, J = 16.6 Hz), 437-430 (2H,
ABq, J = 234, 103 Hz), 343-338 (2H, ABq, J] = 225, 17.8 Haz), 3.05-3.00 (1H, dd, J = 16.6, 49 Hz), 286-282 (1H, dd, J = 16.6, 4.9
Hz), 2.25 (1H, m), 1.42 (9H, s), 1.09-1.05 (6H, two d, J = 6.8, 6.7 Hz).
More polar diastereomer: 'H-.NMR (500 MHz, CDCls) § 8.30 (1H, s), 8.02-7.55 (10H, m), 7.41-7.05 (6H, m), 6.89-6.66 (4H, m), 5.10-4.94 (4H, m), 4.41 (1H, d, J = 9.8 Hz), 423 91H, d, J = 10.3 Hz), 3.50-3.34 (2H,
ABq, J = 17.6 Hz), 3.09-3.05 (1H, dd, J = 17.1, 44 Hz), 2.79-2.74 (1H, dd, J] = 17.1, 54 Hz), 2.25 (1H, m), 1.45 (9H, s), 1.10-1.02 (6H, two d,
J = 6.8 Hz).
- (35)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-4,5-dihyd ro-isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid t-butyl ester
More polar isomer: "H-NMR (500 MHz, CDCl) § 8.60 (d, J = 9.2 Hz, 1H), 8.32-8.25 (m, 2H), 8.13 (d, J] = 8.8 Hz, 1H), 7.88 (d, ] = 7.8 Hz, 1H), 7.79-7.62 (m, 3H), 7.27 (m, 2H), 6.97 (m, 1H), 6.88 (m, 2H), 5.04-4.72 (m, 5H), 3.48-3.34 (m, 2H), 3.00 (dd, J = 17.0, 4.6 Hz, 1H), 277 (dd, J = 17.0, 5.5 Hz, 1H), 2.27 (m, 1H), 1.45 (s, 9H), 1.06 (m, 6H).
Less polar isomer: "H-NMR (500 MHz, CDCl3) § 8.58 (d, J = 9.2 Hz, 1H); 827 (d, J] = 8.2 Hz, 1H), 821 (d, J = 83 Hz, 1H), 813 (d, J = 83 Hz, 1H), 786 (d, J = 83 Hz 1H), 778-759 (m 3H) 772 (m, 2H), 6.92 (m, 1H), 6.82 (m, 2H), 5.04-4.88 (m, 3H), 4.82-4.69 (ABq, J = 17.0
Hz, 2H), 3.45-3.33 (m,2H), 2.99 (dd, J = 16.5, 4.6 Hz, 1H), 2.78 (dd, J = . 16.5, 5.1 Hz, 1H), 2.26 (m, 1H), 1.42 (s, 9H), 1.06 (m, 6H) . t-Butyl ~~ (35)-3-{3-[2-methyl-(1S)-1-(3-t-butyloxycarbonylpropanoylamino)- propyl]-5-n-pentyl-4,5-dihydro-isoxazole-5-carbonylamino} -4-keto-5-(2,6-dichlo robenzoyloxy)-pentanoate; less polar isomer (Compound 89LP precursor) 'H-NMR (500 MHz, CDCl) § 7.67 (d, J = 8.7 Hz, 1H), 7.32 (m, 3H), 6.42 (m, 1H), 5.20-5.05 (ABq, J = 17.0 Hz, 2H), 4.90 (m, 1H) 4.67 (m, 1H), 3.38 (d, J = 17.9 Hz, 1H), 2.92 (m, 2H), 2.78 (m, 1H), 2.53 (m, 2H), 2.40 (m, 2H), 2.18 (m, 1H), 2.03 (m, 1H), 1.79 (m, 1H), 1.44 (s, 9H), 1.41 (s, 9H), 1.26 (m, 6H), 0.94 (m, 6H), 0.86 (t, J = 6.9 Hz, 3H). . t-Butyl ~~ (3S)-3-{3-[2-methyl-(1S)-1-(3-t-butyloxycarbonylpropanoylamino)- propyl]-5-n-pentyl-4,5-dihydro-isoxazole-5-carbonylamino } -4-keto-5-(2,6-dichlo robenzoyloxy)-pentanoate; more polar isomer (Compound 90MP precursor) "H-NMR (500 MHz, CDCl) § 7.76 (d, J = 8.7 Hz, 1H), 7.31 (m, 3H), 6.17 (d, J = 8.7 Hz, 1H), 5.17-5.07 (ABq, J = 17.0 Hz, 2H), 4.87 (m,
1H) 4.65 (m, 1H), 3.30 (d, J = 17.9 Hz, 1H), 2.96-2.90 (m, 2H), 2.69 (m, 1H), 2.56 (m, 2H), 2.45 (m, 2H), 2.03 (m, 2H), 1.81 (m, 1H), 1.43 (s, 9H), 1.41 (s, 9H), 1.26 (m, 6H), 0.94-0.86 (m, SH). . t-Butyl (3S)-3-{3-[2-methyl-(1S)-1-(3-t-butyloxycarbonylpropanoylamino)- propyl]-5-phenylmethyl-4,5-dihydro-isoxazole-5-carbonylamino } -4-keto-5-(2,6- dichlorobenzoyloxy)-pentanoate; less polar isomer (Compound 85LP precursor)
H-NMR (500 MHz, CDCl) § 751 (4, J = 92 Hz, 1H), 734-722 (m, 8H), 6.37 (d, J = 9.2 Hz, 1H), 5.10-4.98 (ABq, J = 174 Hz, 2H), 4.70 (m, 1H) 4.61 (m, 1H), 346 (d, J = 17.9 Hz, 1H), 3.31 (d, J = 14.2 Hz 1H), 3.14 (d, J = 14.2 Hz, 1H), 2.99 (d, J = 17.9 Hz, 1H), 2.73 (m, 1H), 2.53 (m, 2H), 2.40 (m, 2H), 2.18 (m, 1H), 2.09 (m, 1H), 1.42 (s, SH), 1.39 (s, 9H), 0.90 (d, J = 6.9 Hz, 3H), 0.84 (d, J = 6.4 Hz, 3H). . t-Butyl (3S)-3-{3-[2-methyl-(1S)-1-(3-t-butyloxycarbonylpropanoylamino)- propyl]-5-ethyl-4,5-dihydro-isoxazole-5-carbonylamino } -4-keto-5-(2,6-dichlorob enzoyloxy)-pentanoate; less polar isomer (Compound 91LP precursor) 'H-NMR (500 MHz, CDCl;) § 7.68 (d, J = 8.7 Hz, 1H), 7.32 (m, 3H), 642 (d, J = 9.2, 1H), 521-505 (ABq, J] = 17.0 Hz, 2H), 491 (m, 1H) 4.67 (m, 1H), 337 (d, J = 179 Hz, 1H), 2.94 (m, 2H), 2.79 (m, 1H), 2.53 (m, 2H), 2.40 (m, 2H), 2.18 (m, 1H), 2.07 (m, 1H), 1.86 (m, 1H), 1.43 (s, 9H), 1.41 (s, 9H), 0.94 (m, SH). . t-Butyl (3S)-3-{3-[2-methyl-(1S)-1-(3-t-butyloxycarbonylpropanoylamino)- propyl}-5-methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlor obenzoyloxy)-pentanoate; less polar isomer (Compound 73LP precursor) "H-NMR (500 MHz, CDCl3) § 7.66 (d, J = 8.7 Hz, 1H), 7.32 (m, 3H),
6.44 (d, J = 9.2, 1H), 5.20-5.04 (ABq, J = 17.0 Hz, 2H), 4.88 (m, 1H) 4.67 (m, 1H), 3.46 (d, J = 17.9 Hz, 1H), 2.94-2.76 (m, 3H), 2.53 (m, 2H), 240 (m, 2H), 2.19 (m, 1H), 1.62 (s, 3H), 1.43 (s, SH), 1.41 (s, 9H), 0.95 (m, 6H). t-Butyl (3S)-3-{3-[2-methyl-(1S)-1-(3-t-butyloxycarbonylpropanoylamino)- propyl]-5-methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlor obenzoyloxy)-pentanoate; more polar isomer (compound 74MP precursor) "H-NMR (500 MHz, CDCl;) § 7.74 (d, J = 8.7 Hz, 1H), 7.33 (m, 3H), . 6.18 (d, J = 8.7 Hz, 1H), 5.18-5.05 (ABq, J] = 16.5 Hz, 2H), 4.87 (m, 1H) 465 (m, 1H), 338 (d, JT = 179 Hz, 1H), 2.93-2.89 (m, 2H), 271 (m, 1H), 2.57 (m, 2H), 2.46 (m, 2H), 2.02 (m, 1H), 1.66 (s, 3H), 1.58 (5, : 9H), 1.46 (s, 9H), 0.95-0.86 (m, 6H). t-Butyl (3S)-3-{3-[2-methyl-(1S)-1-(3-t-butyloxycarbonylpropanoylamino)- propyl}-5-phenylmethyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6- dichlorobenzoyloxy)-pentanoate; more polar isomer (Compound 86MP precursor) 'H-NMR (500 MHz, CDCL) § 7.68 (d, J = 9.2 Hz, 1H), 7.30 (m, 8H), 6.07 (d, J = 8.7 Hz, 1H), 4.72 (m, 1H), 4.60 (m, 1H), 4.45-4.36 (ABgq, J = 17.0 Hz, 2H), 3.40-3.32 (m, 2H), 3.17 (d, J = 14.2 Hz, 1H), 3.06 (d, J = 17.9 Hz, 1H), 2.93 (m, 1H), 2.60-2.38 (m, 5H), 1.98 (m, 1H), 1.44 (s, 9H), 1.41 (s, 9H), 0.88-0.82 (m, 6H).
Example 24: Synthesis of (3S)-3-{3-[(1S)-1-benzyloxycarbonylamino-2- methyl-propyl]-5-phenoxymethyl-4,5-dihydro-isoxazole-5-carbonyl-amino } -4-ke to-pentanoic acid
A solution of (3S)-3-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-
propyl]-5-phenoxymethyl-4,5-dihydro-isoxazole-5-carbonyl-amino }-4-keto-pent anoic acid t-butyl ester (less polar diastereomer) (44mg) in CHCl (2 mL) at 0°C was treated with TFA (1 mL). The reaction mixture was stirred for 2h while slowly warming to room temperature. Concentration gave the title compound (compound 10, quantitative) 'H NMR (500 MHz, CD;OD) § 7.35-6.90 (10H, m), 5.11 (2H, s), 4.53 (1H, m), 4.47 (1H, m), 4.23 (2H, dd), 2.86 (1H, dd), 2.54 (1H, dd), 2.24 . (BH, s), 2.00 (1H, m), 1.00 and 0.97 (6H, two d); MS [M+Na] 562
The following compound was prepared similarly from the less polar isomer: . (3S)-3-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-S-phenox ymethyl-4,5-dihydro-isoxazole-5-carbonyl-amino }-4-keto-pentanoic acid (compound 11). 'H NMR (500 MHz, ) § 8.76 (1H,d, J = 7.8 Hz), 7.76 (1H, d, J = 8.38
Hz), 7.36-6.87 (10H, m), 5.06 (2H, m), 4.50 (1H, m), 4.32 (1H, m), 4.16 (2H, m), 3.21 (2H, app s), 2.79 (1H, m), 2.06 (3H, s), 1.89 (1H, m), 0.91 (3H, d, J = 6.3 Hz), 0.80 (3H, d, J] = 6.3 Hz).
The following final compounds were obtained by a similar TFA deprotection of the corresponding t-butyl ester. . (3S)-3-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-4,5-dihy dro-isoxazole-5-carbonylamino }-4-keto-pentanoic acid (compound 3, diastereomeric mixture) 'H NMR (500 MHz, DMSO-ds) § 8. 49 (1H, m), 7.72 (1H, m), 7.35 (5H, m), 5.03 (3H, m), 440 (1H, m), 4.15 (1H, m), 3.24 (2H, m), 2.54 (2H, m), 2.04 and 1.95 (3H, wo s), 1.88 (1H, m), 0.90-0.81 (6H, m): MS [M+Na]" 456
~ 94 - - (35)-3-{3-[(15)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-4,5-dihy dro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid (compound 14, diastereomeric mixture) 'H NMR (500 MHz, DMSO-d¢) § 8.58 (1H, br s), 7.75 (1H, m), 7.61-7.30 (8H, m), 5.30-5.00 (5H, m), 4.70 (1H, m), 4.16 (1H, m), 2.66 (2H, m), 1.90 (1H, m), 0.95-0.79 (6H, m): MS [M+Na]" 644 . (3S)-3-{3-[(1S)-1-(naphthalene-1-carbonylamino)-2-methyl-propyl]-5-phenox ymethyl-4,5-dihydro-isoxazole-5-carbonylaminoe }-4-keto-5-phenoxy-pentanoic acid (compound 17, diastereomeric mixture) 'H NMR (500 MHz, DMSO-d¢) § 8.92-8.55 (2H, m), 8.15-7.98 (3H, m), 7.63-7.55 (4H, m), 7.25-7.15 (4H, m), 6.95-6.74 (6H, m), 5.20-4.15 (6H, m), 2.80-2.55 (2H, m), 2.05 (1H, m), 1.05-0.89 (6H, m): MS [M+Na]" : 674. - (35)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl}-5-phenox ymethyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid (compound 18)
From less polar t-butyl ester: 'H NMR (500 MHz, DMSO-ds) § 8.93 (1H, d, J] = 7.8 Hz), 8.79 (1H, d, J = 8.3 Hz), 8.48 (1H, s), 8.05-7.94 (4H, m), 7.64-7.58 (2H, m), 7.30-7.17 (4H, m), 6.94-6.83 (6H, m), 4.96 (2H, app s), 4.78 (1H, m), 4.73 (1H, m), 436 (1H, d, J = 10.2 Hz), 4.22 (1H, d, J = 10.2 Hz), 3.37 (2H, app s), 2.91 (IH, dd, J] = 16.6, 6.4 Hz), 2.62 (1H, dd, J = 16.6, 5.9 Hz), 2.12 (1H, m), 1.00 3H, d, J] = 6.3 Hz), 0.87 93H, d, J = 6.3 Hz): MS [M+Na]' 674
From more polar t-butyl ester: 'H NMR (500 MHz, DMSO-ds) 5 8.88 (1H, d, J] = 83 Hz), 8.79 (1H, d, J = 8.8 Hz), 8.43 (1H, s), 8.00-7.80 (4H, m), 7.61 (2H, m), 7.23-7.17 94H, m), 6.93-6.77 (6H, m), 4.99 (1H,
d, J = 17.6 Hz), 486 (1H, d, J = 18.1 Hz), 4.79 (1H, m), 4.72 (1H, mo, 443 (1H, d, J = 10.7 Hz), 420 (1H, d, J = 102 Hz), 2.81 (1H, dd), 2.56 (1H, dd), 2.17 (1H, m), 1.01 (3H, d, J = 6.3 Hz), 099 3H, d, J = 6.3 Hz): MS [M+Na]® 674 . (3S)-3-{3-[(1S)-1-(naphthalene- 1-carbonylamino)-2-methyl-propyl]-5-phenox ymethyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl oxy)-pentanoic acid (compound 27)
From less polar t-butyl ester: 'H NMR (500 MHz, DMSO-ds) § 9.08 (1H, d, J = 7.8 Hz), 8.87 (1H, d, J = 8.8 Hz), 855 (1H, s), 8.10-8.01 (4H, m), 7.68 7.58 (SH, m), 7.26 (2H, t, J = 7.8 Hz), 6.98-6.92 (3H, m), 527 (2H, ABg, J = 16.6 Hz0, 4.82-4.78 (2H, m), 4.43 (1H, d, J = 10.7
Hz), 4.29 (1H, d, J = 10. 3 Hz), 3.44 (2H, ABq, J = 18.1 Hz), 3.01 (1H, dd, J = 17.1, 6.4 Hz), 2.67 (1H, dd, J = 17.1, 6.3 Hz), 2.21 (1H, m), 1.07 3H, d, J = 6.2 Hz), 0.97 (3H, d, J = 6.2 Hz): MS [M+Na]" 770
From more polar t-butyl ester: 'H NMR (500 MHz, DMSO-ds) § 8.97 (1H, d, J] = 7.8 Hz), 8.85 (1H, d, J = 8.3 hz), 8.50 (1H, s), 8.09-7.96 (4H, m), 7.67-7.60 (SH, m), 7.32 (2H, t, J = 6.3 Hz), 7.00 (3H, m), 5.38 (1H, d, J = 17.1 Hz), 5.13 (1H, d, J = 17.1 Hz), 492 (1H, d, J = 6.3
Hz), 479 (1H, t, J = 7.8 Hz), 455 (1H, d, J = 9.7 Hz), 428 (1H, d, J = 8.7 Hz), 3.48 (1H, d, J = 18.1 Hz), 3.38 (1H, d, J = 18.1 Hz), 2.87 (1H, dd, J = 17.1, 49 Hz), 2.60 (1H, dd, J = 17.1, 49 Hz), 2.25 (1H, m), 1.07 (6H, m): MS [M+Na]® 770 . (3S)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino } -4-keto-pentanoic acid (compound 23, diastereomeric) 'H NMR (500 MHz, DMSO-ds) § 8.72-8.55 (2H, m), 8.38 (IH, s), 8.04-7.85 (4H, m), 7.62 (2H, m), 7.25-7.12 (7H, m), 6.91-6.70 (3H, m),
~ 96 - 479-451 (4H, m), 3.40-3.05 (4H, m), 2.73-2.23 (2H, m), 2.01 (1H, m), 0.94-0.70 (6H, m): MS [M+Na]" 658 + (38)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino } -4-keto-5-(2,6-dichlorobenzoylo xy)-pentanoic acid (compound 28)
From less polar t-butyl ester: 'H NMR (500 MHz, DMSO-ds) § 8.68 (1H, d, J = 8.8 Hz), 8.59 (1H, d, J = 8.3 Hz), 8.40 (lH, s), 8.05-7.87 (4H, m), 7.63-7.54 (SH, m), 7.21-7.13 (5H, m), 5.98 (2H, ABq, J = 17.1
Hz), 4.74 (1H, m), 4.64 (1H, m), 3.25-3.10 (4H, m), 2.62 (1H, 4d, J = 17.1, 63 Hz), 2.37 (1H, dd, J = 16.6, 54 Hz), 2.06 (1H, m), 093 (3H, d, J] = 6.8 Hz), 0.83 (3H, d, J = 6.2 Hz): MS [M+Na]" 754
From more polar t-butyl ester: 'H NMR (500 MHz, DMSO-ds) § 8.72 (1H, d, J = 8.3 Hz), 8.59 91H, d, J = 8.8 Hz), 8.41 (1H, s), 8.01-7.87 (4H, m), 7.62-7.53 (SH, m), 7.29-7.21 (5H, m), 4.70-4.55 (4H, m), 3.44-3.10 (4H, m), 2.72-2.67 (1H, dd, J = 16.6, 7.3 Hz), 2.38-2.34 (1H, dd, J = 16.6, 7.3 Hz), 2.05 (1H, m), 0.97 (3H, d, J = 6.3 Hz), 0.79 (3H, d, J] = 6.3 Hz); MS [M+Na]' 754. . (35)-3-{3-[(1S)-1-(quinoline-2-yl-carbonylamino)-2-methyl-propyl]-5-phenox ymethyl-4,5-dihydro-isoxazole-5-carbonylamino } -4-keto-pentanoic acid (compound 22, diastereomeric mixture) 'H NMR (500 MHz, DMSO-ds) § 9.06 (1H, m), 8.82 91H, br), 8.57 (1H, m), 8.16-7.74 95H, m), 7.26-7.12 (4H, m), 6.89-6.69 (6H, m), 5.10-4.70 (4H, m), 4.48-4.20 (2H, m), 2.87-2.53 (2H, m), 2.32 (1H, m), 0.98-0.85 (6H, m): MS [M+Na]’ 675, [M+H]" 653. - (35)-3-{3-[(1S5)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenox ymethyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2-naphthyloxy)-pent anoic acid (compound 25)
From less polar t-butyl ester: 'H NMR (500 MHz, DMSO-ds) § 8.96 (1H, d, J = 7.8 Hz), 8.77 (1H, d, J = 8.3 Hz), 847 (1H, s), 8.03-7.57 (9H, m), 7.44 (1H, t, J = 6.8 Hz), 7.34 (1H, t, J = 7.8 Hz), 7.17-7.13 (4H, m), 6.88-6.82 (3H, m), 5.09 (2H, ABq), 4.84 (1H, m), 4.72 (1H, m), 438 (1H, d, J = 10.2 Hz), 423 (1H, d, J] = 10.7 Hz), 2.94 (1H, dd, J = 17.1, 6.8 Hz), 2.65 (1H, dd, J = 16.6, 5.9 Hz), 2.12 (1H, m), 0.97 (3H, d, J = 63 Hz), 0.85 (3H, d, J] = 6.3 Hz): MS [M+Na]" 724
From more polar t-butyl ester: 'H NMR (50°C, 300 MHz, DMSO-ds) § 8.72 (1H, d), 8.63 (1H, d), 8.41 (1H, s), 7.94-6.72 (19H, m), 5.03 (2H,
ABq), 4.88 (1H, m), 4.74 (1H, m), 4.42 91H, d), 4.19 (1H, m), 3.38 (2H,
ABq), 2.88 (1H, dd), 2.65 (1H, dd), 2.19 (1H, m), 1.02 (6H, two d):MS [M+Na]® 724
BC NMR (50°C, 300 MHz, DMSO-ds) § 202.1, 171.6, 170.7, 166.6, 159.3, 158.0, 155.6, 134.1, 133.9, 132.0, 131.6, 129.3, 129.1, 128.7, 127.7, 127.5, 127.3, 126.5, 126.2, 124.2, 123.6, 121.1, 118.1, 114.5, 107.4, 87.5, 70.2, 52.9, 34.4, 29.6, 194, 18.9.
More polar diastereomer's methyl ester: 'H NMR (500 MHz, CDCh) § 8.29 (1H, s), 8.02-6.68 (20H, m), 5.09-4.95 (2H, ABq, J = 16.6 Hz), 5.10 (1H, m), 5.01(1H, m), 434 (2H, ABq, J = 103 Hz), 3.70 (3H, s), 3.50-3.33 (2H, ABq, J = 17.6 Hz), 3.13 (1H, dd, J = 17.1, 4.9 Hz), 2.90 (1H, dd, J = 17.1, 5.9 Hz), 2.23 (1H, m), 1.08 and 1.02 (6H, two d, J = 6.8 Hz). . (3S)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenox ymethyl-4,5-dihydro-isoxazole-5-carbonylamino } -4-keto-5-(1-naphthyloxy)-pent anoic acid (compound 24, diasteromeric mixture) 'H NMR (500 MHz, DMSO-de) § 9.02-8.18(3H, m), 8.05-6.80 (18H, m), 5.15-4.15 (6H, m), 2.90-2.55 (2H, m), 2.14 (1H, m), 1.05-0.82 (6H, m).
- 08 - + (3S)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-4,5-dihyd ro-isoxazole-5-carbonylamino }-4-keto-5-(2-naphthyloxy)-pentanoic acid (compound 29, diasteromeric mixture) 'H NMR (500 MHz, DMSO-ds) § 8.95-8.46 (3H, m), 8.09-7.07 (13H, m), 521-475 (5H, m), 2.952.64 (2H, m), 2.19 (IH, m): MS [M+H]" 596 . (38)-3-{3-[2-methyl-(1S)-1-(2-naphthalenecarbonylamino)-propyl]-4,5-dihydr o-isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid (compound 30, diasteromeric mixture) 'H-NMR (500 MHz, DMSO-ds) § 8.76-8.69 (m, 2H), 8.45 (m, 1H), 8.04-7.90 (m, 5H), 7.61 (m, 2H), 7.31-7.19 (m, 2H), 6.97-6.81 (m, 3H), 5.09-4.68 (m, 5H), ~3.3 (m, 2H), 2.82 (m, 1H), 2.64 (m, 1H), 2.15 ((m, 1H), 1.00-0.84 (m, 6H): MS [M+Na] = 568 - (35)-3-{3-[2-methyl-(15)-1-(phenylethylcarbonylamino)-propyl]-5-phenylmet hyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)- pentanoic acid (compound 32, diastereomeric mixture) 'H-NMR (500 MHz, DMSO-ds) § 8.48 (br s, 1H), 8.00 (m, 1H), 7.61-7.54 (m, 3H), 7.30-7.15 (m, 11H), 4.93-432 (m, 4H), 3.34-2.90 (m, 4H), 2.78 (m, 1H), 1.78 (m, 1H), 0.90-0.60 (m, 6H): MS [M+Na] = 732 . (3S)-3-{3-[2-methyl-(15)-1-(1-naphthalenecarbonylamino)-propyl]-5-phenylm ethyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy )-pentanoic acid(compound 33)
From more polar t-butyl ester: "H-NMR (500 MHz, DMSO-ds) § 8.80 (d, J = 83 Hz, 1H), 8.63 (d, J = 7.8 Hz, 1H), 8.02 (m, 3H), 7.64-7.20 (m, 12H), 4.81-455 (m, 4H), 3.39 (m, 2H), 3.12 (m, 2H), 2.73 (m, 1H),
2.43 (m, 1H), 1.98 (m, 1H), 0.99 (d, J = 4.6 Hz, 3H), 0.79 (d, J = 45
Hz, 3H): MS [M+Na] = 754
From less polar t-butyl ester: ‘H-NMR (500 MHz, DMSO-ds) § 8.77 (d,
J = 87 Hz, 1H), 8.62 (d, J = 8.3 Hz, 1H), 8.08-7.97 (m, 4H), 7.61-7.21 (m, 12H), 5.00 (m, 2H), 4.77-4.67 (m, 2H), 3.39-3.27 (m, 2H), 3.15-3.11 (m, 2H), 2.64 (m, 1H), 2.40 (m, 1H), 1.99 (m, 1H), 0.96 (d, J] = 6.4 Hz, 3H), 0.85 (d, J = 6.9 Hz, 3H). . (3S)-3-{3-[2-methyl-(1S)-1-(cinnamoylamino)-propyl]-5-phenylmethyl-4,5-di hydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid (compound 38)
Fom more polar t-butyl ester: "H-NMR (500 MHz, DMSO-d¢) § 8.55 (d,
J = 87 Hz, 1H), 828 (d, J = 8.7 Hz, 1H), 7.60-7.19 (m, 14H), 6.70 (d, : © J = 156 Hz, 1H), 471-449 (m, 4H), ~3.3 (m, 2H), 3.08 (m, 2H), 2.71 (m, 1H), 2.40 (m, 1H), 1.90 (m, 1H), 0.86 (d, J = 6.4 Hz, 3H), 0.74 (d,
J = 6.4 Hz, 3H): MS [M+H] = 708
From less polar t-butyl ester: 'H-NMR (500 MHz, DMSO-ds) § 8.53 (d,
J = 83 Hz, 1H), 828 (d, J = 8.7 Hz, 1H), 7.61-7.16 (m, 14H), 6.69 (d,
J = 16.9 Hz, 1H), 499-492 (ABq, J = 17.4 Hz, 2H), 4.72 (m, 1H), 4.53 (m, 1H), 3.36 (d, J] = 17.9 Hz, 1H), 3.23 d J = 13.8 Hz, 1H), 3.10-3.04 (m, 2H), 2.61 (dd, J = 17.0, 6.4 Hz, 1H), 2.37 (dd, J = 17.0, 6.0 Hz, 1H), 1.90 (m, 1H), 0.79 (m, 6H). . (35)-3-{3-[2-methyl-(1S)-1-(phenylmethylsulfonylamino)-propyl]-5-phenylme thyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy) -pentanoic acid (compound 39, diastereomeric) 'H.NMR (500 MHz, DMSO-d) § 7.75 and 7.69 (m, 1H), 7.61-7.13 (m, 13H), 5.00 and 4.70 (m, 1H), 4.64 (m, 2H), 4.22-3.78 (m, 4H), 1.79 (m, 1H), 0.90 (m, 6H):MS [M+H] = 732.
- (38)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-4,5-dihyd ro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid (compound 40)
From more polar isomer: "H-NMR (500 MHz, DMSO-ds) § 894 (4,1 = 97 Hz, 1H), 875 (d, J = 7.8 Hz, 1H), 855 (d, J = 8.8 Hz, 1H), 8.18-8.05 (m, 3H), 7.85 (m, 1H), 7.55 (m, 3H), 522-506 (m, 3H), 4.83-4.70 (m, 2H), 3.35 (m, 2H), 2.80 (m, 1H), 2.61 (m, 1H), 2.31 (m, 1H), 0.95 (m, 6H):MS [M+H] = 643
From less polar isomer: "H-NMR (500 MHz, DMSO-ds) § 907 (d,7J = 92 Hz, 1H). 8.76 (d. J = 83 Hz 1H). 8.56 (d. J = 87 Hz 1H), 8.20-8.07 (m, 3H), 7.87 (m, 1H), 7.72 (m, 1H), 7.62-7.54 (m, 3H), 5.21-5.06 (m, 3H), 4.84-4.70 (m, 2H), 3.44-3.27 (m, 2H), 2.85 (dd, J = 17.0, 6.0, 1H), 2.66 (dd, J = 17.0, 6.9 Hz, 1H), 2.29 (m, 1H), 0.98 (d, J : = 6.9 Hz, 3H), 0.90 (d, J = 6.4 Hz, 6H) (3S)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-4,5-dihydro- 1soxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid (compound 41)
From more polar isomer: 'H-NMR (500 MHz, DMSO-ds) § 8.95 (d, 1H), 8.72 (d, 1H), 8.55 (d, 1H), 8.20-8.05 (m, 3H), 7.86 (m, 1H), 7.72 (m, 1H), 7.24-6.74 (m, SH), 5.11-4.70 (m, 5H), 3.34 (m, 2H), 2.80 (m, 1H), 2.62 (m, 1H), 2.30 (m, 1H), 0.95 (m, 6H):MS [M+H] = 547
From less polar isomer: 'H-NMR (500 MHz, DMSO-d) § 9.03 (d, 1H), 8.74 (d, 1H), 8.56 (d, 1H), 8.20-8.07 (m, 3H), 7.87 (m, 1H), 7.73 (m, 1H), 7.23 (m, 2H), 6.88 (m, 3H), 5.09-4.71 (m, 5H), 3.34 (m, 2H), 2.85 (m, 1H), 2.65 (m, 1H), 2.27 (m, 1H), 0.96-0.87 (m, 6H). - (3S)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoylo xy)-pentanoic acid (compound 42)
From more polar isomer: 'H-NMR (500 MHz, DMSO-ds) § 891 (d, J = 92 Hz, 1H), 8.59-8.52 (m, 2H), 8.17-8.06 (m, 3H), 7.87 (m, 1H), 7.72 (m, 1H), 7.58-7.53 (m, SH), 4.69-4.51 (m, 4H), 3.40 (m, 2H), 3.16 (m, 1H), 2.69 (m, 1H), 2.37 (m, 1H), 2.19 (m, 1H), 0.91-0.80 (m, 6H): MS [M+H] = 733
From less polar isomer: 'H-NMR (500 MHz, DMSO-d¢) § 892 (d, J = 9.2 Hz, 1H), 8.56(m, 2H), 8.19-8.07 (m, 3H), 7.87 (m, 1H), 7.73 (m, 1H), 7.60-7.54 (m, 3H), 7.22-7.07 (m, 5H), 5.01-4.93 (ABq, J = 16.5 Hz, 2H), 475-462 (m, 2H), 3.46 (d, J = 18.4 Hz 1H), 3.23-3.07 (m, 3H), 2.62 @d, J = 17.0, 6.9 Hz, 1H), 2.37 (dd, J = 17.0, 6.0 Hz, 1H), 2.21 (m, 1H), 0.86-0.83 (m, 6H). : . (38)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino } -4-keto-5-phenoxy-pentanoic acid (compound 43)
From more polar isomer: "H-NMR (500 MHz, DMSO-ds) 5 891 (d, J = 9.2 Hz, 1H), 8.62 (d, J = 8.3 Hz, 1H), 8.52 (d, J = 8.7 Hz, 1H), 8.15 (d,
J = 83 Hz, 1H), 8.07 (m, 2H), 7.86 (m, 1H), 7.72 (m, 1H), 7.26-7.09 (m, 7H), 6.86 (m, 1H), 6.69 (d, J = 83 Hz, 2H), 4.71-4.63 (m, 2H), 454-446 (ABq, J = 17.9 Hz, 2H), 3.42 (d, J = 17.9 Hz, 1H), 3.29 (d, J = 13.8 Hz, 1H), 3.15 (d, J = 18.4 Hz, 1H), 3.09 (d, J = 143 Hz 1H), 2.72 (dd, J = 17.0, 6.9 Hz, 1H), 2.36 (dd, J] = 17.0, 6.0 Hz, 1H), 2.15 (m, 1H), 0.88 (d, J = 6.9 Hz, 3H), 0.75 (d, J = 6.9 Hz, 3H): MS [M+H] = 637
From less polar isomer: 'H-NMR (500 MHz, DMSO-ds) § 888 (d, J = 96 Hz, 1H), 8.54 (m, 2H), 8.18-8.06 (m, 3H), 7.87 (m, 1H), 7.72 (m, 1H), 7.28-6.78 (m, 10H), 4.78-4.63 (m, 4H), 3.45 (d, J = 18.3 Hz, 1H), 3.26-3.06 (m, 3H), 2.66-2.62 (dd, J = 17.0, 6.9 Hz, 1H), 2.44-2.39 (dd, J
= 17.0, 5.5 Hz, 1H), 2.17 (m, 1H), 0.80 (m, 6H).
. (3S)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]}-5-(1-imid azolylmethyl)-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-phenoxy-penta noic acid (compound 44, diastereomeric mixture)
"H-NMR (500 MHz, DMSO-ds) § 9.09-6.60 (m, 16H), 4.92-4.62 (m, 6H), . 3.50 (m, 2H), 2.85-2.20 (m, 3H), 0.93 (m, 6H): MS [M+H] = 627
. (35)-3-{3-[2-methyl-(1S)-1-(2-naphthalenecarbonylamino)-propyl]-4,5-dihy dr o-isoxazole-5-carbonylamino }-4-keto-pentanoic acid (compound 45,
diastereomeric mixture)
'H-NMR (500 MHz, DMSO-d) § 8.77 (m.1H), 8.45 (m, 2H), 8.07-7.89
(m, 4H), 7.61 (m, 2H), 5.06 (m, 1H), 4.72 (m, 1H), 4.46 & 4.38 (two m,
1H), ~3.3 (m, isoxazoline CHp), 2.62 (m, 1H), ~2.49 (m, 1H), 2.13 (m, :
1H), 2.09 & 2.05 (two s, 3H), 1.01-0.84 (m, 6H).
. (38)-3-{3-[(1S)-1-(succinoylamino)-3-carboxy-propyl]-5-methyl-4,5-dihydro-i soxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid (compound 46,
diastereomeric mixture)
'H.NMR (500 MHz, DMSO-ds) § 8.56-8.52 (m, 1H), 8.15 (m, 1H), 7.27
(m, 2H), 6.97-6.82 (m, 3H), 4.96-4.83 (m, 2H), 4.77 (m, 1H), 4.58 (m,
1H), 3.58-2.22 (m, 10H), 2.0-1.74 (m, 2H), 147 & 1.45 (two s, 3H):MS
[M+Na] = 558.
. (38)-3-{3-[2-methyl-(18)- 1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro-is oxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid (compound 47,
diastereomeric mixture)
"H-NMR (500 MHz, DMSO-d¢) § 8.62-8.52 (m, 1H), 8.06 (m, 1H), 7.27
(m, 2H), 6.96-6.81 (m, 3H), 4.94-472 (m, 3H), 4.43-432 (m, 1H),
3.38-3.22 (m, 1H), 2.94-2.78 (m, 2H), 2.70-2.22 (m, 5H), 1.95-1.77 (m, 1H), 1.48 & 1.46 (two s, 3H), 0.86-0.70 (m, 6H): MS [M+Na] = 528. . (38)-3-{3-[2-methyl-(1S)-1-(1-naphtalenylcarbonylamino)-propyl}-5-phenylm ethyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(1-piperidinyl)- pentanoic acid (compound 48, diastereomeric) "H-NMR (500 MHz, DMSO-d¢) § 8.75 (m, 1H), 8.47 and 8.29 (m, 1H), 8.03-7.23 (m, 12H), 4.65 (m, 2H), 3.11-2.99 (m, 2H), 2.26-2.18 (m, 4H), 1.97 (m, 1H), 1.64-0.79 (m, 12H):MS [M+H] = 627. . (3S)-3-{3-[2-methyl-(1S)-1-(isoquinoline-1-carbonylamino)-propyl]-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoylo xy)-pentanoic acid (Compound 49LP) 'H-.NMR (500 MHz, DMSO-ds) § 9.03 (d, J = 92 Hz, 1H), 874 (d, J] = 83 Hz, 1H), 8.60-8.56 (m, 2H), 8.07-8.03 (m, 2H), 7.83 (m, 1H), 7.73 (m, 1H), 7.61-7.53 (m, 3H), 7.22-7.17 (m, 5H), 5.01-4.93 (ABg, J = 17.0
Hz, 2H), 4.74-4.63 (m, 2H), 341 (d, J = 17.9 Hz, 1H), 3.23 (d, J = 14.2 :
Hz, 1H), 3.13 (d, J = 179 Hz, 1H), 3.09 (d, J = 14.2 Hz, 1H), 2.60 (m, 1H), 2.36 (m, 1H), 2.10 (m, 1H), 091 (d, J = 6.9 Hz, 3H), 0.84 (d, J] = 6.4 Hz, 3H). . (35)-3-{3-[2-methyl-(1S)-1-(isoquinoline- 1-carbonylamino)-propyl]-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoylo xy)-pentanoic acid (Compound 50LP: stereoisomer of 49LP) "H-NMR (500 MHz, DMSO-ds) § 9.04 (d, J = 9.2 Hz, 1H), 8.65-8.60 (m, 2H), 8.53 (d, J = 6.0 Hz, 1H), 8.05-8.00 (m, 2H), 7.82 (m, 1H), 7.72 (m, 1H), 7.60-7.53 (m, 3H), 7.30-7.17 (m, 5H), 4.75-4.53 (m, 4H), 3.5-3.3 (m, 2H, buried under solvent peaks), 3.13 (m, 2H), 2.68 (m, 1H), 2.41 (m, 1H), 2.04 (m, 1H), 095 d, J = 6.4 Hz, 3H), 0.78 (d, J = 6.4 Hz, 3H).
~ 104 - . (3S)-3-{3-[2-methyl-(1S)-1-(isoquinoline-3-carbonylamino)-propyl]-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoylo xy)-pentanoic acid (Compound S1LP) "H-NMR (500 MHz, DMSO-ds) § 9.40 (s, 1H), 8.99 (d, J = 9.2 Hz, 1H), 8.56 (m, 2H), 826 (d, J = 7.8 Hz, 1H), 8.17 (d, J] = 7.8 Hz, 1H), 7.90-7.81 (m, 2H), 7.60-7.53 (m, 3H), 7.20-7.07 (m, 5H), 5.01-4.92 (ABq,
J = 17.0 Hz, 2H), 4.73-4.66 (m, 2H), ~3.4 (m, 1H, buried under solvent peaks), 3.23-3.05 (m, 3H), 2.60 (m, 1H), 234 (m, 1H), 2.19 (m, 1H), 0.82 (m, 6H). . (3S)-3-{3-[2-methyl-(1S)-1-(isoquinoline-3-carbonylamino)-propyl]-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoylo xy)-pentanoic acid(Compound 52MP: stereoisomer of Compound 51) : 'H-NMR (500 MHz, DMSO-ds) § 9.39 (s, 1H), 897 (d, J = 9.6 Hz, 1H), 8.58 (d, J = 8.7 Hz, 1H), 8.53 (s, 1H), 8.24 (d, J = 8.3 Hz, 1H), 8.13 : (d, JT = 7.8 Hz, 1H), 7.88-7.81 (m, 2H), 7.58-7.53 (m, 3H), 7.27-7.18 (m, 5H), 4.72-449 (m, 4H), 3.6-3.3 (m, 2H, buried under solvent peaks), 3.19-3.08 (m, 2H), 2.67 (m, 1H), 2.34 (m, 1H), 2.18 (m, 1H), 0.87 (d, J = 6.9 Hz, 3H), 0.78 (d, J = 6.9 Hz, 3H). . (3S)-3-{3-[2-methyl-(1S)-1-(isoquinoline-4-carbonylamino)-propyl}-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoylo xy)-pentanoic acid (Compound 53 LP) 'H-NMR (500 MHz, DMSO-ds) § 9.02 (m, 2H), 8.63 (d, J] = 8.7 Hz, 1H), 8.10 (d, J = 8.3 Hz, 1H), 8.01 (d, J = 7.8 Hz, 1H), 7.83 (m, 1H), 7.69 (m, 1H), 7.61-7.53 (m, 3H), 7.44 (d, J = 4.2 Hz, 1H), 7.31-7.20 (m, 6H), 4.98 (m, 2H), 4.76-4.65 (m, 2H), 3.37 (d, J = 17.9 Hz, 1H), 3.29 (d,
J = 142 Hz, 1H), 3.15-3.11 (m, 2H), 2.63 (m, 1H), 2.39 (m, 1H), 1.99
(m, 1H), 0.93 (d, J] = 6.9 Hz, 3H), 0.85 (d, ] = 6.9 Hz, 3H). . (35)-3-{3-[2-methyl-(1S)-1-(isoquinoline-4-carbonylamino)-propyl]-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoylo xy)-pentanoic acid (Compound 54 MP: stereoisomer of Compound 53 LP) 'H-NMR (500 MHz, DMSO-ds) § 9.05 (d, J = 8.7 Hz, 1H), 896 (d, J = 4.1 Hz, 1H), 8.64 (d, J = 8.7 Hz, 1H), 8.08 (d, J] = 83 Hz, 1H), 7.99 (d,
J = 7.8 Hz, 1H), 7.82 (m, 1H), 7.69-7.48 (m, 5H), 7.31-7.20 (m, SH), 4.80-4.55 (m, 4H), 3.6-3.3 (m, 2H, buried under solvent peaks), 3.14-3.09 (m, 2H), 2.72 (m, 1H), 2.41 (m, 1H), 1.95 (m, 1H), 0.96 (d, J = 6.9 Hz, 3H), 0.78 (d, J = 6.9 Hz, 3H). . (38)-3-{3-[2-methyl-(1S)-1-(benzofuran-2-carbonylamino)-propyl]-5-phenylm ’ ethyl-4,5-dihydro-isoxazole-5-carbonylamino} -4-keto-5-(2,6-dichlorobenzoyloxy )-pentanoic acid (Compound 55LP) 'H-NMR (500 MHz, DMSO-d¢) § 8.83 (d, J] = 9.2 Hz, 1H), 856 (d, J = 83 Hz, 1H), 7.79 (d, J] = 7.8 Hz, 1H), 7.68 (d, J] = 83 Hz, 1H), 761-733 (m, 6H), 7.20-7.04 (m, 5H), 5.00-4.92 (m, 2H), 4.73 (m, 1H), 4.56 (m, 1H), ~3.37 (m, 1H), 3.23-3.05 (m, 3H), 2.61 (m, 1H), 2.36 (m, 1H), 2.08 (m, 1H), 0.88-0.78 (m, 6H). . (35)-3-{3-[2-methyl-(1S)-1-(benzofuran-2-carbonylamino)-propyl]-5-phenylm ethyl-4,5-dihydro-isoxazole-5-carbonylamino} -4-keto-5-(2,6-dichlorobenzoyloxy )-pentanoic acid (Compound 56: stereoisomer of Compound 55LP) 'H-.NMR (500 MHz, DMSO-d) § 8.83 (d, J = 9.2 Hz, 1H), 855 (d, J = 8.7 Hz, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.64 (d, J = 82 Hz, 1H), 7.58-7.43 (m, 5H), 7.33-7.18 (m, 6H), 4.69-4.55 (m, 4H), 3.43-3.30 (m, 2H), 3.12-3.07 (m, 2H), 2.69 (m, 1H), 2.37 (m, 1H), 2.06 (m, 1H), 0.90 (d, J = 6.4 Hz, 3H), 0.74 (d, J] = 6.4 Hz, 3H).
. (35)-3-{3-[2-methyl-(1S)-1-(naphthalene- 1-carbonylamino)-propyl]-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-difluorobenzoylo xy)-pentanoic acid (Compound 57LP) ‘H-NMR (500 MHz, DMSO-d) § 8.77 (d, J = 9.7 Hz, 1H), 8.64 (d, J = 83 Hz, 1H), 8.06795 (m, 3H), 7.69-7.44 (m, 5H), 7.26 (m, 7H), 5.02-4.90 (ABq, J = 17.0 Hz, 2H), 4.71 (m, 2H), 3.30-3.10 (m, 4H), 2.65 (m, 1H), 2.39 (m, 1H), 1.99 (m, 1H), 0.94 (d, J = 6.0 Hz, 3H), 0.84 (d,
J = 6.0 Hz, 3H). . (38)-3-{3-[2-methyl-(1S)-1-(naphthalene- 1-carbonylamino)-propyl]-5-phenyl methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dimethylbenzoylo xy)-pentanoic acid(Compound 61: diastereomeric mixture) 'H.NMR (500 MHz, DMSO-ds) § 8.82-8.76 (m, 1H), 8.65 (m, 1H), : 8.08-7.95 (m, 3H), 7.59-7.46 (m, 4H), 7.33-7.06 (m, 8H), 4.98-4.49 (m, 4H), 3.42-3.09 (m, 4H), 2.76-2.39 (m, 2H), 2.28 & 2.25 (two s, 6H), 1.98 (m, 1H), 0.99-0.76 (m, 6H). . (35)-3-{3-[2-methy!-(1S)-1-(quinoline-8-carbonylamino)-propyl]-5-phenylmet hyl-4,5-dihydro-isoxazole-5-carbonylamino} -4-keto-5-(2,6-dichlorobenzoyloxy)- pentanoic acid (Compound 62: diastereomeric mixture) 'H-NMR (500 MHz, DMSO-d¢) § 11.19-11.08 (m, 1H), 9.04 (m, 1H), 8.65-8.50 (m, 3H), 822 (m, 1H), 7.80-7.51 (m, 5H), 7.30-7.06 (m, SH), 5.00-4.47 (m, 4H), 3.46-3.02 (m, 4H), 2.73-2.34 (m, 2H), 2.11 (m, 1H), 1.00-0.80 (m, 6H). . (38)-3-{3-[2-methyl-(18)-1-(indole-2-carbonylamino)-propyl]-5-phenylmethyl -4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)-pe ntanoic acid(Compound 63LP)
'H-NMR (500 MHz, DMSO-ds) § 11.58 (s, 1H), 8.56 (d, J = 8.7 Hz, 1H), 849 (d, J = 8.7 Hz, 1H), 7.64-7.53 (m, 4H), 7.43 (d, J] = 8.3 Hz, 1H), 7.24-7.03 (m, 8H), 5.00-4.92 (ABq, J = 17.0 Hz, 2H), 4.74-4.56 (m, 2H), ~3.5 (m, 1H, buried under solvent peaks), 3.23 (d, J] = 13.8 Hz, 1H), 3.15-3.06 (m, 2H), 2.60 (m, 1H), 2.35 (m, 1H), 2.02 (m, 1H), 0.90 (d, J = 6.4 Hz, 3H), 0.81 (d, ] = 6.9 Hz, 3H). - (3S)-3-{3-[2-methyl-(1S)-1-(indole-2-carbonylamino)-propyl}-5-phenylmethyl -4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pe ntanoic acid (Compound 64MP: stereoisomer of Compound 63LP) 'H-NMR (500 MHz, DMSO-ds) § 11.56 (s, 1H), 8.54 (m, 2H), 7.60-7.02 (m, 13H) 4.71-4.51 (m, 4H), , 3.41-3.31 (m, 2H), 3.15-3.07 (m, 2H), 2.67 (m, 1H), 2.38 (m, 1H), 2.05 (m, 1H), 092 (d, J = 6.9 Hz, 3H), 0.77 (d,
J = 6.9 Hz, 3H). . (35)-3-{3-[2-methyl-(1S)-1-(indole-3-carbonylamino)-propyl]-5-phenylmethyl -4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pe ntanoic acid (Compound 65LP) "H-NMR (500 MHz, DMSO-ds) § 11.61 (s, 1H), 8.56 (d, J = 8.3 Hz 1H), 8.08 (m, 2H), 7.91 (d, J = 9.2 Hz, 1H), 7.62-7.54 (m, 3H), 7.43 (d,
J = 83 Hz, 1H), 7.22-7.00 (m, 7H), 4.95 (m, 2H), 4.72-4.61 (m, 2H), ~3.4 (m, 1H, buried under solvent peaks), 3.23 (d, J = 13.8 Hz 1H), 3.13-3.06 (m, 2H), 2.61 (m, 2H), 2.34 (m, 1H), 1.99 (m, 1H), 0.91 (d, J = 6.4 Hz, 3H), 0.81 (d, J = 6.4 Hz, 3H). . (35)-3-{3-[2-methyl-(1S)-1-(indole-3-carbonylamino)-propyl]-5-phenylmethyl -4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pe ntanoic acid (Compound 66MP: stereoisomer of Compound 65LP) 'H-NMR (500 MHz, DMSO-ds) § 11.60 (s, 1H), 8.54 (d, J = 8.7 Hz,
1H), 8.11-8.06 (m, 2H), 7.91 (d, J = 92 Hz, 1H), 7.60-7.05 (m, 11H), 471-447 (m, 4H), 3.33 (m, 2H), 3.09 (m, 2H), 2.68 (m, 2H), 2.39 (m, 1H), 2.00 (m, 1H), 0.93 (d, J = 6.4 Hz, 3H), 0.78 (d, J = 6.9 Hz, 3H). - (38)-3-{3-[2-methyl-(15)-1-(naphthalene- 1-carbonylamino)-propyl]-5-methyl- 4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pen tanoic acid (Compound 67LP) "H-NMR (500 MHz, DMSO-d¢) § 8.86 (d, J = 9.2 Hz, 1H), 8.73 d, J = 8.3 Hz, 1H), 8.11-7.98 (m, 3H), 7.64-7.54 (m, 7H), 5.17-5.08 (ABq, J = 17.0 Hz, 2H), 4.81-4.70 (m, 2H), ~3.4 (m, 1H, buried under solvent peaks), 3.05 (d, J = 17.9 Hz. 1H), 2.87 (m, 1H), 2.65 (m, 1H), 2.02 (m, 1H), 1.55 (s, 3H), 1.00 (d, J = 6.4 Hz, 3H), 0.87 (d, J = 6.4 Hz, 3H). . (38)-3-{3-[2-methyl-(18)-1-(naphthalene- 1-carbonylamino)-propyl]-5-methyl- : 4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pen tanoic acid (Compound 68MP: stereoisomer of Compound 67LP) 'H-NMR (500 MHz, DMSO-ds) § 8.84 (d, J = 8.7 Hz, 1H), 8.69 (d, J = 8.3 Hz, 1H), 8.06-7.96 (m, 3H), 7.62-7.52 (m, 7H), 5.23-5.11 (ABq, J = 17.0 Hz, 2H), 4.82-4.67 (m, 2H), 3.6-3.4 (m, 1H, buried under solvent peaks), 3.00 (d, J = 17.9 Hz, 1H), 2.82 (m, 1H), 2.58 (m, 1H), 2.05 (m, 1H), 1.56 (s, 3H), 1.01-0.93 (m, 6H). - (35)-3-{3-[2-methyl-(1S)-1-(benzofuran-2-carbonylamino)-propyl}-5-methyl-4 ,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)- pentanoic acid (Compound 69LP) 'H-NMR (500 MHz, DMSO-ds) § 8.91 (d, J = 8.7 Hz, 1H), 8.70 (d, J = 82 Hz, 1H), 778 (d, J = 7.8 Hz, 1H), 768 (d, J = 83 Hz, 1H), 7.62-7.54 (m, 4H), 7.48 (m, 1H), 7.34 (m, 1H), 5.16-5.07 (ABq, J = 17.0
Hz, 2H), 4.79 (m, 1H), 4.61 (m, 1H), 3.44 (d, J = 17.9 Hz, 1H), 3.02 (d,
I = 179 Hz, 1H), 2.87 (dd, J = 17.0, 6.0 Hz, 1H), 2.65 (dd, J = 17.0, 7.4 Hz, 1H), 2.11 (m, 1H), 1.50 (s, 3H), 0.94 (d, J] = 6.9 Hz, 3H), 0.83 d, J = 6.4 Hz, 3H). . (3S)-3-{3-[2-methyl-(1S)-1-(benzofuran-2-carbonylamino)-propyl]-5-methyl- 4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)- pentanoic acid (Compound 70MP: stereoisomer of Compound 69LP) 'H-NMR (500 MHz, DMSO-d¢) § 8.86 (d, J = 8.7 Hz, 1H), 8.62 (d, J = 78 Hz, 1H), 7.73 (d, J] = 7.8 Hz, 1H), 7.65 (d, J = 83 Hz, 1H), 7.60-7.52 (m, 4H), 7.45 (m, 1H), 7.31 (m, 1H), 5.14-5.07 (ABq, J = 17.0
Hz, 2H), 4.71 (m, 1H), 4.62 (m, 1H), 3.44 (d, J = 17.9 Hz, 1H), 3.00 (d,
J = 179 Hz, 1H), 2.79 (dd, J = 17.0, 6.4 Hz, 1H), 2.56 (dd, J = 17.0, 6.0 Hz, 1H), 2.16 (m, 1H), 1.53 (s, 3H), 0.95-091 (m, 6H). . (3S)-3-{3-[3-carboxy-(1S)-1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid(Compound 71LP) "H-NMR (500 MHz, DMSO-ds) § 8.60 (d, J = 8.3 Hz, 1H), 8.15 (d, J = 8.3 Hz, 1H), 7.61-7.54 (m, 3H), 5.16-5.08 (ABq, J = 17.0 Hz, 2H), 4.78 (m, 1H), 4.62 (m, 1H), 3.31 (d, J = 17.9 Hz, 1H), 2.90 (d, J = 17.9 Hz, 1H), 2.85 (dd, J = 17.0, 6.0 Hz, 1H), 2.64 (dd, J] = 17.0, 6.9 Hz, 1H), 2.44 (m, 2H), 2.33 (m, 2H), 2.24 (m, 2H), 1.90-1.76 (m, 2H), 1.46 (s, 3H). . (3S)-3-{3-[3-carboxy-(1S)-1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid(Compound 72MP: stereoisomer of Compound 71LP) 'H-NMR (500 MHz, DMSO-d¢) § 8.55 (d, J = 83 Hz, 1H), 8.16 (d, J = 8.3 Hz, 1H), 7.62-7.55 (m, 3H), 5.21-5.09 (ABq, J = 17.0 Hz, 2H), 4.76
(m, 1H), 4.58 (m, 1H), 3.23 (d, J = 17.9 Hz, 1H), 2.95 (d, J = 17.9 Hz, 1H), 2.83 (dd, J = 17.0, 6.5 Hz, 1H), 2.62 (dd, J = 17.0, 6.4 Hz, 1H), 2.44 (m, 2H), 2.33 (m, 2H), 2.25 (m, 2H), 1.96 (m, 1H), 1.80 (m, 1H), 1.50 (s, 3H). . (3S5)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid(Compound 73LP) "H-NMR (500 MHz, DMSO-ds) § 8.66 (d, J = 8.3 Hz, 1H), 8.10 (d, J = 8.7 Hz, 1H), 7.62-7.57 (m, 3H), 5.14-5.05 (ABq, J = 17.0 Hz, 2H), 4.77 (m, 1H), 4.36 (m, 1H), 3.31 (d, J = 184 Hz 1H), 2.92 (d. J = 18.4 Hy, 1H), 2.87-2.83 (m, 1H), 2.66-2.61 (m, 1H), 2.44 (m, 1H), 2.37 (m, 1H), 1.84 (m, 1H), 1.48 (s, 3H), 087 (d, I = 64 Hz, 3H), 0.77 (d, J = 64
Hz, 3H). . (38)-3-{3-[2-methyl~(1S)-1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino } -4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid(Compound 74MP: stereoisomer of Compound 73LP) 'H.NMR (500 MHz, DMSO-ds) § 8.56 (d, J = 8.3 Hz, 1H), 8.08 (d, J = 8.7 Hz, 1H), 7.62-7.57 (m, 3H), 5.19-5.08 (ABq, J = 17.0 Hz, 2H), 4.75 (m, 1H), 4.40 (m, 1H), 3.30 (d, J = 179 Hz, 1H), 2.93 (d, J = 17.9 Hz, 1H), 2.82 (m, 1H), 2.60 (m, 1H), 2.44-2.31 (m, 4H), 1.92 (m, 1H), 1.51 (s, 3H), 0.86-0.84 (m, 6H). - (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl}-5-propyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid(Compound 75LP) 'H-NMR (500 MHz, DMSO-ds) § 8.64 (d, J = 8.3 Hz, 1H), 809 (d, J = 8.7 Hz, 1H), 7.60 (m, 3H), 5.17-5.04 (ABq, J = 17.0 Hz, 2H), 4.83 (m,
1H), 4.37 (m, 1H), 325 (d, J = 17.9 Hz, 1H), 2.95 (d, J] = 17.9 Hz, 1H), 2.85 (dd, J = 170, 5.5 Hz, 1H), 2.65 (dd, J = 16.5, 74 Hz, 1H), 2.46-2.35 (m, 4H), 1.84 (m, 2H), 1.70 (m, 1H), 1.36-1.15 (m, 2H), 0.88-0.76 (m, 9H). . (35)-3-{3-[2-methyl-(1S)- 1-(succinoylamino)-propyl]-5-propyl-4,5-dihydro- isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid(Compound 76MP: stereoisomer of Compound 75LP) 'H-NMR (500 MHz, DMSO-d¢) § 8.59 (d, J = 6.4 Hz, 1H), 8.07 (d, J = 9.2 Hz, 1H), 7.62-7.54 (m, 3H), 5.12 (m, 2H), 4.74 (m, 1H), 4.40 (m, 1H), 3.24 (d, J = 17.9 Hz, 1H), 2.95 (d, J = 17.9 Hz, 1H), 2.82 (dd, J = 17.0, 6.9 Hz, 1H), 2.59 (m, 1H), 2.44-2.30 (m, 4H), 1.92 (m, 2H), 1.71 (m, 1H), 1.38-1.20 (m, 2H), 0.85 (m, 9H). . (3S)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-butyl-4,5-dihydro- isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid(Compound 79LP) "H-NMR (500 MHz, DMSO-d¢) § 8.63 (d, J = 82 Hz, 1H), 8.09 (d, J = 9.2 Hz, 1H), 7.62-7.57 (m, 3H), 5.17-5.05 (ABq, J] = 17.0 Hz, 2H), 4.83 : (m, 1H), 4.37 (m, 1H), 325 (d, J = 17.9 Hz, 1H), 2.95 (d, J] = 17.9 Hz 1H), 2.85 (dd, J = 17.0, 55 Hz, 1H), 2.65 (dd, J = 17.0, 7.3 Hz, 1H), 245-235 (m, 4H), 1.84 (m, 2H), 1.71 (m, 1H), 1.28-1.14 (m, 4H), 0.88-0.76 (m, SH). . (3S)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-butyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid(Compound 80MP: stereomeric isomer of Compound 79LP) 'H-NMR (500 MHz, DMSO-ds) § 8.58 (d, J = 8.3 Hz, 1H), 807 (d, J = 8.7 Hz, 1H), 7.61-7.54 (m, 3H), 5.18-5.08 (ABq, J = 17.0 Hz, 2H), 4.76
(m, 1H), 440 (m, 1H), 3.24 (d, J = 17.9 Hz, 1H), 2.95 (d, J = 18.3 Hz, 1H), 2.83 (dd, J = 16.5, 6.4 Hz, 1H), 2.59 (dd, J = 17.0, 6.4 Hz, 1H), 244-230 (m, 4H), 1.92 (m, 2H), 1.73 (m, 1H), 1.36-1.16 (m, 4H), 0.87-0.83 (m, 9H). : - (35)-3-{3-[2-methyl-carboxy-(1S)-1-(succinoylamino)-propyl}-5-methyl-4,5- dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2-naphthyloxy)-pentancic ~~ acid (Compound 81LP) "H-NMR (500 MHz, DMSO-ds) § 8.67 (d, J = 8.3 Hz, 1H), 8.08 (d, J = 9.2 Hz, 1H), 7.83 (m, 2H), 7.73 (d, J = 7.8 Hz, 1H), 7.46 (m, 1H), 7.36 (m, 1TH), 718 (m, 2H), 5.01 (m. 2H), 483 (m. 1H), 434 (m. 1H), 330 (d, J = 17.4 Hz, 1H), 2.93-2.87 (m, 2H), 2.67 (dd, J = 17.0, 6.4 Hz, 1H), 2.45-2.34 (m, 4H), 1.79 (m, 1H), 1.49 (s, 3H), 0.80 (d, J = 6.5 Hz, 3H), 0.68 (d, J = 6.9 Hz, 3H). - (38)-3-{3-[2-methyl-carboxy-(1S)-1-(succinoylamino)-propyl]-5-methyi-4,5- dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2-naphthyloxy)-pentanoic acid (Compound 82MP: stereomeric isomer of Compound 81LP) "H-NMR (500 MHz, DMSO-ds) § 8.58 (d, J = 7.8 Hz, 1H), 8.08 (d, J = 9.2 Hz, 1H), 7.83 (m, 2H), 7.73 (d, J] = 7.8 Hz, 1H), 7.46 (m, 1H), 7.35 (m, 1H), 7.18 (m, 2H), 5.04 (m, 2H), 4.82 (m, 1H), 440 (m, 1H), 3.33 (d, J = 17.4 Hz, 1H), 2.95-2.82 (m, 2H), 2.65 (m, 1H), 2.44-2.27 (m, 4H), 1.91(m, 1H), 1.51 (s, 3H), 0.86-0.83 (m, 6H). . (3S)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-propyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid(Compound 83: diastereomeric mixture) 'H-.NMR (500 MHz, DMSO-ds) § 8.57 (m, 1H), 8.06 (m, 1H), 7.26 (m, 2H), 6.94 (m, 1H), 6.83 (m, 2H), 4.92-4.71 (m, 3H), 4.41-4.34 (m, 1H),
3.26-3.21 (m, 1H), 2.96-2.78 (m, 2H), 2.67-2.56 (m, 1H), 2.44-2.25 (m, 4H), 1.92-1.66 (m, 3H), 1.40-1.16 (m, 2H), 0.88-0.70 (m, 9H). . (38)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-hydroxymethyl-4,5- dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentano ic acid (Compound 84: diastereomeric mixture) 'H-NMR (500 MHz, DMSO-ds) § 8.57 (d, J = 8.3 Hz, 1H), 8.08 (d, J = 8.7 Hz, 1H), 7.59 (m, 3H), 5.24-5.09 (m, 2H), 4.80 (m, 1H), 4.40 (m, 1H), 3.78 (m, 1H), 3.56 (m, 1H), 3.16-3.03 (m, 2H), 2.79 (m, 1H), 2.60 (m, 1H), 2.44-2.33 (m, 4H), 1.90 (m, 1H), 0.86-0.76 (m, 6H). . (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-phenylmethyl-4,5- dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)- pentanoic acid (Compound 85LP) 'H-NMR (500 MHz, DMSO-ds) § 8.51 (d, J = 8.8 Hz, 1H), 8.05 (d, J = 8.7 Hz, 1H), 7.59 (m, 3H), 7.25 (m, 5H), 4.92 (ABq, J = 17.0 Hz, 2H), 470 (m, 1H), 4.34 (m, 1H), 3.34-320 (m, 2H), 3.07-3.02 (m, 2H), 2.58 (m, 1H), 2.44-2.30 (m, 5H), 1.82 (m, 1H), 0.81-0.73 (m, 6H). . (3S)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-phenylmethyl-4,5- dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)- pentanoic acid (Compound 86MP: diasterecomer of Compound 85LP) 'H-NMR (500 MHz, DMSO-ds) § 8.49 (d, J = 8.7 Hz, 1H), 8.06 (d, J = 8.7 Hz, 1H), 7.60 (m, 3H), 7.28-7.19 (m, 5H), 4.70 (m, 1H), 4.60-4.51 (ABq, J = 17.4 Hz, 2H), 4.36 (m, 1H), 3.32-3.26 (m, 2H), 3.07-3.02 (m, 2H), 2.73-2.68 (m, 1H), 2.42-2.28 (m, 5H), 1.82 (m, 1H), 0.83 (d, J = 6.9
Hz, 3H), 0.69 (d, J = 6.9 Hz, 3H). . (3S)-3-{3-[2-methyl~(1S)-1-(succinoylamino)-propyl]-5-methoxymethyl-4,5-
dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)- pentanoic acid (Compound 87: diastereomeric mixture)
‘H-NMR (500 MHz, DMSO-ds) § 8.80 & 8.65 (two m, 1H), 8.10 & 7.97 (two m, 1H), 7.60 (m, 3H), 5.24-5.03 (m, 2H), 4.84 & 4.68 (two m, 1H), 4.39 (m, 1H), 3.78-3.51 (m, 2H), ~3.35 (two s, 3H), 3.20-2.99 (m, 2H), 2.91-2.50 (m, 2H), 2.44-2.34 (m, 4H), 1.85 (m, 1H), 0.87 (m, 6H). . (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-n-pentyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic ~~ acid (Compound 89LP)
"H-NMR (500 MHz, DMSO-d) § 8.64 (d.
J = 8.3 Hz, 1H), 8.10 (d.
J = 8.7 Hz, 1H), 7.60 (m, 3H), 5.16-5.05 (ABqg, J = 16.5 Hz, 2H), 4.80 (m, 1H), 4.36 (m, 1H), 3.24 (d, J = 17.5 Hz, 1H), 2.94 (d, J = 17.9 Hz, 1H), 285 (m, 1H), 2.64 (m, 1I), 245-236 (m, 4H), 1.84 (m, 2H), 1.70 (m, 1H), 1.23 (m, 6H), 0.86-0.76 (m, 6H).
. (35)-3-{3-[2-methyl-(15)-1 -(succinoylamino)-propyl]-5-n-pentyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid(Compound 90MP: diastereomer of Compound 89LP
"H-NMR (500 MHz, DMSO-d¢) § 8.59 (d, J = 8.3 Hz, 1H), 8.07 (d, J = 8.7 Hz, 1H), 7.60 (m, 3H), 5.18-5.08 (ABq, J = 16.5 Hz, 2H), 4.76 (m, 1H), 4.40 (m, 1H), 3.24 (d, J = 183 Hz, 1H), 2.95 (d, J = 18.3 Hz, 1H), 282 (m, 1H), 2.58 (m, 1H), 2.44-230 (m, 4H), 1.92 (m, 2H), 1.72 (m, 1H), 1.23 (m, 6H), 0.85 (m, 6H).
. (3S)-3-{3-[2-methyl-(1S)- 1-(succinoylamino)-propyl]-5-ethyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid (Compound 91LP)
'H-NMR (500 MHz, DMSO-d) § 8.66 (d, J = 8.3 Hz, 1H), 8.10 (d, J =
8.7 Hz, 1H), 7.62-7.56 (m, 3H), 5.17-5.05 (ABq, J] = 16.5 Hz, 2H), 4.84
(m, 1H), 4.36 (m, 1H), 3.25 (d, J = 17.9 Hz, 1H), 2.95 (d, J] = 17.9 Hz,
1H), 2.85 (m, 1H), 2.65 (m, 1H), 2.45-2.35 (m, 4H), 1.91-1.71 (m, 3H),
0.88-0.74 (m, SH).
. (35)-3-{3-[2-methy]-(1S)-1-(succinoylamino)-propyl]-5-ethyl-4,5-dihydro-
isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid
(Compound 92MP: diastereomer of Compound 91LP)
'H-NMR (500 MHz, DMSO-ds) § 859 (d, J = 7.8 Hz, 1H), 8.08 (d, J =
9.2 Hz, 1H), 7.62-7.54 (m, 3H), 5.17-5.09 (ABq, J = 17.0 Hz, 2H), 475
(m, 1H), 4.40 (m, 1H), 323 (d, J = 18.3 Hz, 1H), 2.95 (d, J = 17.8 Hz
1H), 2.83 (m, 1H), 2.61 (m, 1H), 2.46-2.28 (m, 4H), 1.93 (m, 2H), 1.77
(m, 1H), 0.88-0.80 (m, SH).
. (35)-3-{3-[2-methy]-(1S)-1-(glutaroylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid
(Compound 93LP)
: "H-NMR (500 MHz, DMSO-ds) 5 8.66 (d, J = 8.7 Hz, 1H), 8.07 (d, J = 87 Hz, 1H), 7.61-7.54 (m, 3H), 5.14-5.05 (ABq, J = 16.5 Hz, 2H), 4.79 (m, 1H), 4.40 (m, 1H), 3.32 (d, J = 17.5 Hz, 1H), 2.90-2.83 (m, 2H), 2.63 (m, 1H), 2.18 (m, 4H), 1.85 (m, 1H), 1.72 (m, 2H), 1.48 (s, 3H), 0.86 (d, J = 6.9 Hz, 3H), 0.77 (d, J = 6.9 Hz, 3H).
. (39)-3-{3-[2-methyl-(1S)-1-(glutaroylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid(Compound 94MP: diastereomer of Compound 93LP)
'H.NMR (500 MHz, DMSO-ds) § 8.58 (d, J = 7.8 Hz, 1H), 8.05 (d, J = 9.2 Hz, 1H), 7.62-7.54 (m, 3H), 5.18-5.08 (ABq, J = 17.0 Hz, 2H), 4.76 (m, 1H), 4.41 (m, 1H), 331 (d, J = 17.4 Hz, 1H), 292 (d, J = 17.9 Hz,
1H), 2.80 (m, 1H), 2.60 (m, 1H), 2.16 (m, 4H), 1.91 (m, 1H), 1.70 (m, 2H), 1.51 (s, 3H), 0.85 (m, 6H).
Pharmacological Experiments
The pharmacological efficacy of the compound according to the present invention was evaluated by the following experiments. Con A was purchased from Boehringer Mannheim GmbH (Mannheim, Germany).
Peptide-based substrates of caspases (Ac-YVAD-pNA for caspase-1,
Ac-VDVAD for caspase-2, Ac-DEVD-pNA for caspase-3, 7, 8, and 9,
Ac-LEVD-pNA for caspase-4. and Ac-VEID-pNA for caspase-6) and peptide-based caspase inhibitors (Ac-DEVD-fmk, 2z-VAD-CHO) were purchased from Alexis Co. (San Diego, CA). Ac-DEVD-CHO and . z-DEVD-cmk were purchased from Bachem; Anti Fas antibody was purchased from Oncor (Cat#A8050); WI38 cell was available from ATCC;
IFN-gamma was purchased from LG Pharmaceuticals (Korea). All cell culture-media and supplements were purchased from Gibco BRL (Tsuen
Wan, Hong Kong) unless mentioned otherwise. Recombinant human caspases(1-4, 6-10) were prepared according to the method described in
Garcia-Calvo M et al, "Purification and catalytic properties of human caspase family members", Cell Death Differ, 1999, Apr.; 6(4): 362-9).
Especially Caspase-3, -6, -7 and -8 are commercially available (Pharmingen, SanDiego, CA, USA, Caspase-3: 66281T, Caspase-6: 66291T,
Caspase-7: 66301T, Caspase-8: 66311T).
Experiment 1: Screening on caspases inhibiting activity
In the present experiment, recombinant caspases were purified from a transformed bacterium after human caspase genes were cloned into the expression vector pET, and then used in the experiment (Thornberry, N.A. et .al. Nature, 1992, 356, 768. Thornberry, N.A. Methods in Enzymology, 1994, 615.).
Enzymatic activity was measured by a known procedure (Walker N.P.C. et al., Cell 1994, 78, 343). Briefly, 10 ng of recombinant protein was mixed with 50 mM Tris(pH 7.0), lmM DTT, 0.5 mM EDTA, 10% Glycerol buffer containing 1~100 uM of enzyme substrate, Ac-YVAD-AMC or
Ac-DEVD-AMC and then the changes by isolated AMC at 37°C were recorded. The inhibitory activity for caspases was calculated from the early enzyme reaction rate by measuring the changes with fluorescence excited at 380 nM and emitted at 460 nm (Range; Ki<100nM).
Experiment 2: Screening for intracellular inhibitory efficacy for caspases
Inhibitory activity for Caspase-1 was determined by screening the effects of the compounds on the IL-1/4 production in the periphery lymphocytes stimulated with LPS. Briefly, 500,000 cells/ml of human peripheral lymphocytes were treated with the test compounds at various concentrations for 2 hours and then with 10 ng/ml of LPS. After incubating the cells for 12 hours, the supernatant samples from the media were analysed by immunoantibody analysis (Amersham) in which 100 ng/well of human IL-1 f antibody is coated (Range: CICso : 0.1 ~ 10 zM).
Meanwhile, the efficacy of the compounds on apoptosis was quantified by
MTT assay in which cell death and survival ratio depending on the concentration of compounds were analyzed in Jurkat T cell treated with
Anti-FAS antibody CH11 which induces cell death (Effective range; 1.0 ~ pM).
[Table 1]
Irreversible Inhibitors
CICso EDso compound | Kobs/[I] for | Kobs/[I] for (IL-18 FAS Induced no. caspase-1 caspase-3 production) cell death
M'sec™) M sect 130000 01-104 M 1-10 4 M 87000 | 500 | ov pw o94000 | 132 | ov | ow 408000 | 160 | ov | om 577000 | 371 | oo | ow
A4 707000 19230 " " 357000 I 63 616000 2300 | oo" ow] 30800 e000 | oo Low] 14500 a0000 | 0] " 14900 Rn I 7560 000 87 3100 27400
IE EE
Reversible Inhibitor
CICso EDso compound Ki for Kobs/[I] for (IL-18 FAS Induced no. caspase-1 caspase-3 production) cell death (nM) (uM) 22mn___ | 0.125 19.2 | 01-10uM 1-10 uM _%m | 00721 | 249 | 0» 0 om 99 | 0324 | #59 | ENNIS a0 | 191 | 448 [ 000v
Eo EE CE a8 | is | 199 [oo fw s00 | 193 | oo | ov
B00 | 455 | [00000 26900 | 117 | oo 0m ome | oo 0 000v 83 oop77 [000]
Experiment 3: Hepatocyte isolation and cultivation
Male Sprague-Dawley rats (Hanlan Sprague-Dawley) were treated and bred as described by MacMicking et al, 1995, Cell 81: 641-650), and used as a source of liver cells. Rat hepatocytes were isolated, purified, and cultured as described by Stadler et al., Arch. Biochem. Biophys. 302: 4-11). Highly purified hepatocytes (>98% purity and >98% viability by trypan blue exclusion) were suspended in Williams medium E containing 10% calf serum supplemented with 15 mM HEPES (pH 7.4), 1; M insulin, 2 mM
L-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin. The cells were plated on collagen-coated plates with a density of 2x 10° cells/well in a 12-well plate for cell viability test or 5x10° cells/ 100 ml dish for enzyme assay.
Experiment 4: In vitro assay for inhibition of caspase activity in cell free system
Caspase activity was tested by measuring proteolytic cleavage of peptide-based chromogenic substrate by each enzyme. Recombinant human caspase was preincubated with 5 mM DTT in assay buffer (100 mM HEPES, pH 7.4, containing 20% (v/v) glycerol) for 20 minutes at room temperature. Aliquots of the enzyme (2 ,¢ contaiming catalytic activity of 0.2 absorbance at 405 nm/h) were mixed with 150 4,9 of 200 nu M chromogenic substrate in the presence or absence of 100 y M compound 33 in 96-well plates. The mixture was incubated at 37°C. The ahsorhance of enzymatically released pNA was measured discontinnonsly at 405 nm in a microplate reader for 1 hr. The caspase activity was calculated from initial velocity (meant SE)(n=4, in which n represents the number of repeated experiment). As a result, the compound of the invention almost completely inhibited all tested caspase activity, only except for caspase 2 (Figure 1). This result indicates that the compound of the invention is a broad-spectrum caspase inhibitor.
Experiment 5: In vivo assay for inhibition of caspase activity in rat hepatocytes
Freshly isolated rat hepatocytes were treated with 2,000 umits/ml TNFgq plus 100 ng/ml actinomycin D to induce cellular apoptosis. The cells were harvested after 10 hrs. Cytosolic solution was obtained by lysing cells with three cycles of freezing and thawing and centrifuging at 12,000 x g for 20 min. at 4 C. Cytosol (~2 yg of protein) was mixed with 200 ; M specific chromogenic substrate in 100 mM HEPES buffer (pH 7.4) containing 20% glycerol and 5 mM DTT in presence or absence of 100 3; M compound 33 and incubated 37 <C. The caspase activity was assayed by measuring the increased absorbance at 405 nm.
Strong enzyme activities were detected with Ac-DEVD-pNA (caspase-3, 7, 8 and 9), Ac-LEVD pNA (caspase-4), and Ac-VEm-pNA (caspase-6), and moderate enzyme activity was detected with Ac-VDVAD (caspase-2) (Figure 2). The compound of the invention almost completely inhibited these amplified caspase activities, and the activity was comparable with peptide-based caspase inhibitors Ac-DEVD-fmk and z-VAD-CHO (Figure 2). For Ac-YVAD-pNA (caspase-1), detected enzyme activity was relatively weak. However, the compound of the invention inhibited 74.1% of caspase-1-like activity.
Experiment 6: In vitro assay for enhancement of cell viability in isolated rat hepatocytes
The cells were treated with 2,000 units/ml TNF, plus 100 ng/ml actinomycin D with or without 100 ; M caspase inhibitor(compound 33) for 12 hrs. Then cell viability was measured by crystal violet staining method (n=4).
As a result, the compound of the invention prevented the death of rat hepatocytes (meant SE)(Figure3). The result of this experiment indicates that the compound of the invention protected hepatocytes from apoptotic death induced by TNFy plus actinomycin D.
Experiment 7: Effect on Con A-induced acute hapatitis mice
Step 1: Preparation of blood sample
Female 6-week-old Balb/c mice (Charles River Laboratory, Osaka, Japan) were kept at 22 °C and 55% relative humidity in a 12-h day/night rhythm with free access to food and water. Con A was dissolved in pyrogen-free saline to a concentration of 2.5 mg/ml and was injected via the tail vein in an amount of 20pg/kg based on Con A. The animals were ip. injected twice with compound 33 dissolved into a vehicle which consists of olive oil and 10% DMSO, or a vehicle alone, at 1 hr before and 4h after Con A injection. Animals were sacrificed by cervical dislocation at 24 hrs after Con A injection to obtain liver and blood samples.
Sten 2: Assav for nlasma aminotransferase activity
Blood samples obtained at step 1 were collected at 24h after Con A injection. Plasma AST and ALT activity were measured using Autokit : (Youngdong Pharmaceutical Co., Seoul, Korea) following manufacturer's instruction.
Two independent experiments were performed to confirm the result. In the two experiments, ConA induced dramatic elevation of serum AST and
ALT activity, and compound 33 suppressed the elevated enzyme activities in a dose-dependent manner (Figure 4A, B). In the second experiment (Figure 4B), the differences between Con A/vehicle group and Con
A/4mg/kg compound 33 group did not reached at statistically significant level (AST : p=0.2972, ALT : p=0.1378) since enzyme activities of each mouse showed some variation. However, in 20 mg/kg of compound 33 group, AST and ALT activities were definitely reduced compared with
ConA/vehicle group (AST: p=0.0174, ALT: p=0.0011). In the first experiment (Figure 4A), compound 33 slightly increased AST activity by itself but this increase did not reach at statistically significant level
(p=0.1033). These results indicate that the compound of formula (I) suppressed the elevated AST and ALT activities induced by Con A in vivo, but did not provoke significant liver toxicity by itself.
Step 3: Cytokine assay
Although a large part of the pathogenesis of hepatic disease remains vague, several lines of evidence suggest that cytokines may be involved in the hepatic injury directly or by activating the immune system, and cytokine including TNFq , IL-2, IL-4, and IFNy by sandwich ELISA were reported to increase in patients with liver disease (See: Chisari, F.
V., 1992, Mol Genet. Med. 2: 67-104; Fukuda, R. et al, Clin. Exp.
Immunolol. 100: 446-451; Yoshioka, K. et al, Hepatology 10: 769-773).
Therefore, the present inventors assessed the effect of the present compound to serum cytokine concentrations elevated by Con A.
Blood samples were collected at 6 hrs after Con A injection at step I.
Murine IL-1g (Endogen Inc. Bostone, MA), IL-2, IL-4, IFNy (Pharmingen,
San Diego, CA) amounts in plasma were measured by ELISA kits. The assays were performed exactly as described by the manufacturer. Each sample was determined twice.
The results showed that the compound of the invention suppressed the Con
A-induced elevation of IL-13 in a dose-dependent manner (see Figure 5).
Meantime, the compound of the invention moderately reduced IL-4 concentration showing a dose-dependent tendency, but the differences between treat groups did not reach at statistically significant level. On the other hand, the compound of the invention did not significantly affect IL-2 and IFNy concentrations. The compound of the invention itself slightly reduced all four cytokines compared with vehicle alone, but those differences did not reach at statistically significant level (0.05<p<0.95 for all 4 cytokines).
Experiment 8: Histologic examination and detection of apoptosis
The present inventors estimated the prevalence of apoptotic cells in the mouse liver to certify the apoptosis-blocking effect of the compound of the present invention specifically in hepatocytes. Mice were treated ConA in the presence or absence of various dosages of compound 33 [A and G:
ConA and vehicle freatment, B and H: ConA and compound 33 4po/ke treatment, C and I: ConA and compound 33 20pg/kg treatment, D and J:
ConA and compound 33 100pg/kg treatment] to prepare frozen liver sections. Also, mice were treated with PBS and vehicle (E and K), or
PBS and compound 33 100pg/kg (F and L) to prepare frozen liver sections. Freshly excised mouse liver was immediately immersed in 25 % sucrose solution at 4 °C for overnight, then frozen in liquid nitrogen, and cryosectioned into 4 np.
For histological examination, liver sections were fixed in 1% buffered paraformaldehyde and stained with hematoxilin & eosin (Fig. 6A to F).
To detect apoptotic cells in liver, frozen liver was stained using an
ApopTag in situ apoptosis peroxidase detection kit (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling: TUNEL assay) (Oncor, Gaithersburg, MD) and DAKO liquid DAB (DAKO,
Carpinteria, CA)(Fig. 6G to L). Staining was conducted according to manufacturer's instruction. After completion of staining, the samples were observed under an optical microscope. Each photograph represents typical results obtained from 10 mice per group. Histological examinations revealed that Con A induced severe morphological and histological changes to hepatocytes (Figure 6 A) and the apoptotic lesions were clearly detectable through the affected liver (Figure 6 G). However, in the liver of mice treated with the compound of the invention(Compound 33), the apoptotic lesions were reduced dose-dependently (Figure 6B-D), and cellular histology were gradually recovered with increasing dose of compound 33 (Figure 6 H-J). These results indicated that the compound of the invention protected hepatocytes from the fatal apoptogenic effect of
ConA.
Experiment 9: Western blotting
In this experiment, the cleavage of PARP was identified by the appearance on Western blot analysis of an 85 kDa-cleavage product in hepatic cell lysate obtained from mice treated with Con A and various doses of the compound of formula (I).
Freshly harvested livers treated with Con A or PBS together with various doses of compound 33 were rinsed in cold PBS and homogenized into three volumes per weight of cold PBS containing 1% Nonidet P-40, 0.1 %
SDS, 1 mM PMSF, and protease inhibitor cocktail tablet Complete” (Boehnger Mannheim, used according to manufacturer's instruction). The homogenates were incubated on ice for 30 min. Samples were then centrifuged at 16,000 x g for 30 min at 4°. Supernatants were transferred to fresh tubes and centrifuged for additional 30 min. Harvested lysates were precleared by incubating with protein G-sepharose (Pharmacia,
Uppsala, Sweden) at 4 °C for ovemight, gently shaking. Supernatants were harvested by centrifugation at 1000 x g for 30 sec. at 4 C and separated on 7 % SDS-polyacrylamide ‘gel and transferred to nitrocellulose membrane. Blots were blocked for | hr at room temperature in PBS containing 5% skimmed milk and 0.1% Tween 20 under gentle shaking.
E Membranes were then incubated overnight with 1:1000 diluted monoclonal anti-PARP antibody (Pharmingen) under gentle shaking. After washing three times with PBS-Tween, the blots were hybridized with goat anti-mouse IgG-horse radish peroxidase (1:1000 dilution). After washing three times PBS-tween, signals were developed with ECL Western blotting kit (Amersham-Pharmacia Biotech, San Francisco, CA) and visualized by autoradiography.
In accordance with histological examination, the compound of the invention inhibited PARP cleavage caused by Con A-induced apoptotic death of hepatic cells (Figure 7). The apoptosis-blocking effect of the compound appeared in a dose-dependent manner.
Experiment 10: Effect of the caspase inhibitor on the protection of apoptosis
In order to determine the efficacy of the compound according to the present invention on the protection of apoptosis, the following experiments were conducted.
WI38 cells (human embryonal lung fibroblast) were grown in a medium containing DMEM-10% FBS within 10¢; diameter dishes until reaching at confluency. The cells were seeded into a 24-well plate at day 1 and incubated overnight while the volume of medium was maintained to 400.
Cells were treated with 200 units/p¢ of IFNy at day 2 and incubated over 12 hrs or more. At day 3, each 100 ,¢ of test compound was added to the cells after diluting the 10mM stock compound in DMSO to final
= 127 - concentrations of 50, 10, 2, and 04 ; M, respectively. The cells were incubated for 2 hrs in order for allowing the compound to enter into the cells and then treated with 40ng/well of anti-Fas antibody(apoptosis was induced 2 hrs after antibody was treated and the incubation was continued overnight). The control was not treated with Fas antibody. At day 4, after cells were observed with a microscope, 300,¢ of medium per well and then 150,¢ of XTT working solution were added to the medium and cultivation was continued for 2 hrs. After coloring, 100-200,9 of the supernatant was transferred to a 96-well plate and the absorbance at 490 nm was read with ELISA plate reader. For the blank, XTT solution was added to the well containing the medium only. Plotting was determined by comparing with the control group (100% when Fas antibody was not treated). The results thereof are shown in Table 2 below. [Table 2) :
CE 0 0 HF
ZN EE TR A
[ee [fen ea ee ee ow eee a 1 Lew wn ew [we [wa
As can be seen from the above table 2, only 15% of cells were survived when treated with the both IFNy and the anti-Fas antibody together while the existing caspase inhibitors, Ac-DEVD-CHO(reversible inhibitor) or z-DEVD-cmk(irreversible inhibitor) treatment (50; M) resulted in viability ratio of 35.1% and 47.3%, respectively. However, when treated with compound 22, compound 28, and compound 33 according to the invention - at the same concentration, viability ratio was increased to 78%, 90%, 100%, respectively. Therefore, it is noted that the caspase inhibitors according to the invention prevented apoptosis much stronger than the existing drugs (See Fig. 8).
Experiment 11: Effect of the caspase inhibitor on anti-Fas antibody-induced liver apoptosis 3-4 Weeks-old C57BL/6 female mice(18-20 g) were injected ip. with compound 33MP dissolved in vehicle which consists of olive oil and 10%
DMSO, or vehicle alone, at 1 hr before iv. injection with 10 pug of
Anti-Fas antibody (Jo2). Following 4 hrs of iv. injection with Jo2 antibody, animals were placed under inhaled isoflurane anesthesia for blood collection and liver isolation. Mice were also i.p. injected with 0.2 1g/20 g of TNF and 12 mg/20 g of D-galactosamine(TNFy /GalN) and compound 33MP or its salt form (Compound 33MP-Na). 8 hrs later, blood and liver tissues were isolated from anesthetized animals. The liver tissues were snap-frozen and stored at -80° C until use. Plasma was isolated from blood by centrifugation at 12,000 x g for 10 min at 4° C and stored at -80° C. In some experiments for animal mortality, mice were ip. injected with TNFq /GalN and caspase inhibitor was injected 1 hr before, simultaneously, 2 hrs, or 4 hrs after TNFq /GalN injection.
Step B: DNA fragmentation
Whole tissues (0.5 g) were homogenated in ice-cold lysis buffer (5 mM
Tris, 20 mM EDTA, 0.5% Triton-X 100, pH8.0). The lysate was centrifuged at 12,000 x g for 20 min at 4° C. The supernatant was obtained and extracted twice with a mixture of phenol and chloroform.
One-tenth volume of 3 M sodium acetate was added to the solution, and
DNA was precipitated by adding an equal volume of isopropanol. After storing at -20° C overnight, a DNA pellet was obtained by centrifugation at 12,000 x g for 15 min. at 4 ° C and washed twice with 75% ethanol.
The pellet was dried and resuspended in 100 yl of 20 mM Tris-HCI, pH 8.0. After digesting RNA with DNase-free RNase (0.1 mg/ml) at 37 ° C for 1 hr, samples (15 ml) were electrophoresed through a 1.2% agarose gel in 450 mM Tris borate + EDTA (TBE), pH 8.0 buffer. DNA was photographed under visualized with UV light.
Step c: Enzyme assay
Liver tissues were homogenated in 10 mM HEPES buffer containing protease inhibitors (5 pg/ml aprotinin, 5 pg/ml pepstatin A, 10 ug/ml leupeptin, and 0.5 mM PMSF) and lysed by three freeze/thaw cycles. The cytosolic fraction was obtained by centrifugation at 12,000 x g for 20 min. at 4° C. Protein concentration was determined with BCA protein assay reagent (pierce, Rockford, IL). Cytosol containing 200 pg protein was combined in 96-well plate with 200 mM of synthetic substrate
Ac-DEVD-pNA in 150 yl of 100 mM HEPES, pH 7.4, containing the protease inhibitors, and the reaction was conducted for 1 hr at 37° C.
Cytosolic caspase-3-like activity was assayed by measuring the increased absorbance at 405 nm. Plasma level of aspartate aminotransferase (AST) was analyzed by spectrophotometry using each enzyme assay kit (Sigma).
Step D: Hepatocyte culture and treatment
Primary rat hepatocytes were isolated and purified from male
Sprague-Dawley rats using a collagenase digestion method. The hepatocytes were purified over 30% Percoll gradient by centrifugation at 1,000 x g for 10 min. at 4° C. Highly purified hepatocytes (>98% purity and >95% viability by trypan blue exclusion) were suspended in Williams medium E supplemented with 10% calf serum, 1 yM insulin, 2 mM
L-glutamine, 15 mM HEPES (pH 7.4), 100 units/ml penicillin, and 100 ug/ml streptomycin. The cells were plated on collagen-coated tissue enlture plates at a density of 2 x 10° cells/well in 12-well plates for cell viability analysis or 5 x 10° cells/100 mm dish for enzyme assays. After 18 hrs preculture, the cells were treated with 2,000 units/ml TNF, and 0.2 pg/ml Actinomycin (ActD). Caspase activity and cell viability was determined by colorimetry using a caspase substrate Ac-DEVD-pNA and crystal violet staining method at 8 hrs and 12 hrs, respectively.
As can be seen from the result of Fig. 9A, liver apoptosis from the mice injected with 0.4 mg/20 g, 1 mg/20 g of compound 33MP, or vehicle alone (olive oil and 10% DMSO) 1 hr before the antibody injection, as determined by DNA fragmentation, was significantly increased in anti-Fas antibody-injected animals after 4 hrs of the antibody injection. Treatment with compound 33MP was suppressed the liver apoptosis in a dose-dependent manner. The suppression was higher than that of well-known peptide caspase inhibitor Z-VAD-fmk. Similarly, the release of liver enzyme, AST was increased in animal treated with anti-Fas antibody (Fig. 9B). The enzyme release was also significantly suppressed by the injection with compound 33MP. This suppressive effect was higher than that of Z-VAD-fmk. These results indicate that compound 33MP can protect liver from anti-Fas antibody-induced liver damage. As the activation of caspase-3-like proteases is required for execution phase of apoptosis, caspase-3-like activity was assessed after anti-Fas antibody injection by measuring hydrolytic product of the caspase-3-like substrate Ac-DEVD-pNA at 405 nm. Caspase activity was increased by about 25-folds in liver tissues treated with the antibody (Fig. 10). The increased activity was abrogated by compound 33MP treatment. Furthermore, most of anti-Fas antibody-treated animals (85%) died within 24 hrs, whereas treatment with compound 33MP reduced mortality by about 30% (Fig. 11). This inhibition was more effective than that of Z-VAD-fink. This result suggests that inhibition of caspase activity and/or activation by compound 33MP is sufficient to protect mice from anti-Fas antibody-induced apoptotic mortality.
Liver dysfunction and failure are common problems during endotoxemia and sepsis. It is generally accepted that proinflammatory cytokines, especially TNFq , are critical for the liver damage and mortality. We examined the effect of compound 33MP on TNF -mediated liver toxicity.
Treatment with TNFy /ActD induced DNA fragmentation in liver tissues and this toxicity was significantly reduced by administration of compound 33MP (Fig. 12A). The release of AST following TNFq /ActD treatment was also suppressed by treatment with compound 33MP (Fig. 12B). The protective effect of compound 33MP was higher than that of Z-VAD-fmk.
TNFq /ActD-mediated liver toxicity was accompanied by increase in caspase-3-like activity (Fig. 13). The increased caspase activity was suppressed by compound 33MP, which showed higher inhibitory effect than
Z-VAD-fmk. These data indicate that the suppression of proapoptotic caspase activity by compound 33MP is correlated with the suppression of liver damage with apoptotic DNA fragmentation. Since fulminant liver damage and destruction are associated with animal mortality, we examined the effect of the compound of the invention on TNFg /ActD-mediated mouse mortality. When injected with TNFg /ActD and vehicle (olive oil and 10% DMSO), most of mice (~80%, 1 of 6) died within 24 hrs, whereas 80% of compound 33 MP-treated animals survived (Fig. 14).
Similar results were obtained by injection with Z-VAD-fmk. Thus, our results suggest that new non-peptide caspase inhibitor according to the invention may have therapeutic applications in the treatment of fulminant liver damage.
The inventors prepared the sodium salt form of compound 33 MP to increase its solubility and examined the effect of this compound (Compound 33MP-Na) on caspase activity and cell wiability in TNFg /ActD-treated primary rat hepatocytes. Caspase-3-like activity was increased in cultured hepatocytes following treatment with TNF /ActD for 8 hrs (Fig. 15A). This increase was suppressed by adding 100 yM compound 33MP-Na and this inhibition was not different from those of compound 33MP, Ac-DEVD-cho, or Z-VAD-fmk. Treatment with TNFq /ActD decreased cultured hepatocyte viability to about 30%, whereas all caspase inhibitors showed the similar protective effects on TNFq /ActD-induced hepatocyte apoptosis (Fig. 15B). These results indicate that cytoprotective effect of compound 33 MP-Na is not different from that of its non-salt form.
Therapeutic drugs are administrated after diagnosis of disease symptoms.
We examined the protective effect of the compound of the invention on preinduced hepatocyte toxicity. Hepatocytes were treated first with TNFq /ActD and then 100 yM of compound 33MP-Na was added at different time points. After 12 hrs of TNFg /ActD treatment, cell viability was determined by crystal violet staining. When added compound 33MP-Na between 0 and 6 hrs after TNFq /ActD treatment, cell viability was not decreased (Fig. 16). Addition of compound 33MP-Na after 6 hrs of TNFq /ActD treatment decreased cell viability in a time-dependent manner. No different results were obtained between compound 33MP-Na and
Z-VAD-fmk. Treatment of mice with TNF /ActD induced high mortality (95%). This mortality was significantly reduced (~80%) when injected with compound 33MP-Na at 1 hr before, 0 h, or 2 hrs after TNFy /ActD injection (Fig. 17). When administered 4 hrs after lethal challenge compound 33MP-Na still conferred a partial protection (50%). Moreover, death that occurs within 10-14 hrs in TNF a /ActD-injected animals was significantly delayed up to 24 hrs for the non-surviving compound 33MP-Na (data not shown).
The above results with inhibition of both anti-Fas antibody and TNF « -mediated hepatocyte apoptosis provide the strong evidence that a simple galenic formulation of caspase-inhibiting drugs constitutes a new promising therapeutic strategy for acute liver disease involving uncontrolled apoptosis.
Both the compound of the invention and its salt form can also be used for promising therapeutic drugs for fulminant liver damage and mortality.
Claims (16)
1. An isoxazoline derivative of the formula (I) ONT TF Rr ~N ST > ® R "R3 RZ o R' “Rl in which, R and R' each independently represents hydrogen, simple alkyl chain (-SAC), simple cycloalkyl (-SCAC), aromatic (-Ar), or simple alkyl chain substituted with aromatic (-SAC-Ar); rR! represents -SAC, -SCAC, -Ar, or -SAC-Ar, or represents side chain of amino acids, or -(CH2):COOZ (in which n is 1 or 2, and Z is hydrogen, -SAC, -Ar or -SCAQ); rR? represents -SAC, -SCAC, -Ar, -SAC-Ar, or side chain of amino acids; R® represents -H, -SAC, -SCAC, -Ar, or -SAC-Ar, or represents side chain of amino acids, or represents -(CH2)o(O)wR’ (in which R’ = -SAC, -SCAC, -Ar, -SAC-Ar; n=0, 1 or 2; and m=0 or 1), or -(CH2),OC(=O)R’ (in which R® = -SAC, -SCAC, -Ar, or -SAC-Ar; and n=1 or 2); R’ represents a) amino acid residue in which () the carboxyl group attached to the chiral carbon of amino acid is bound to the amine group to form an amide bond, @ the chiral carbon of amino acid has either R or S configuration, (9 the amino group attached to the chiral carbon of amino acid is protected by formyl, acetyl, propyl, cyclopropylcarbonyl, butyl,
methanesulfonyl, ethanesulfonyl, propanesulfonyl, butanesulfonyl, methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, butyloxycarbonyl, methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl, butylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, dipropylcarbamoyl, dibutylcarbamoyl or cyclopropylaminocarbonyl, or the amino group may be replaced with a hydrogen atom, and @ the carboxyl group in the side chain may form an ester group with -SAC or -SCAC,
b) -C(=O)R’ (in which R’ = -SAC, -SCAC, -Ar, -SAC-Ar), -CO:R? (in which R® = hydrogen or R’), -C(=0)NR'R®, -SOR’, -SO.R’, or -C(=0)CH=CH-Ar,
c) (C=0)-L-CO:R®, in which L represents a divalent (=capable of double substitution) linker selected from a group consisting of Cis alkyl, Css cycloalkyl, furan, thiophene, diazole (1,2 or 1,3), triazole (1,2,3 or 1,3,4), tetrazole, oxazole, isoxazole, thiazole, isothiazole, diazine (1,2 or 1,3 or 1,4), triazine, -Ph(-R%)- (in which R® = H, F, Cl, Br, I, CHO, OH,
OCH, CFs, OCF;, CN, C(=0)Me), tetrahydrofuran, tetrahydrothiophene, 1,4-dioxane, -CH=C(R'- (in which RH, methyl, ethyl), -CH=CHCH(R'%- , -CH(OR')CH;-, -CH;C(=0)CH;-, -C(=0)CH2CHa-
In cases where R' and the adjacent R', and/or R’ and the adjacent R are connected to each other to form a cyclic compound, R'R' or RR together represents -(CHz2)n-, -(CH2)a-O-(CH2)m-, Or ~(CH2)a-NR"*-(CH2)m- (in which n+m<9, R"”=SAC, -SCAC, -Ar, -SAC-Ar, -C(=0)-SAC, -C(=0)-SCAC, -C(=0)-Ar, or -C(=0)-SAC-Ar),
X represents -CN, -CHO, -C(=O)R" (in which R'" = -SAC, -SCAC, -Ar, -SAC-Ar, or -CHN;), -C(=0)OR"’ (in which R” = -SAC, -SCAC, -Ar, or -SAC-Ar), -CONR'R" (in which R'® and R' each represents -H, -SAC, -0-SAC, -SCAC, -Ar, or -SAC-Ar), -C(=0O)CH20(C=0O)Ar" (in which Ar"
- 136 ~ = 2,6-disubstituted phenyl with F, Cl, Br, I, or CHs), -C(=O)CH,OR" (in which R'® represents -SAC, -SCAC, -Ar, or -SAC-Ar), or -C(=0)CH,0C(=0)R" (in which R"” = -SAC, -SCAC, -Ar, or -SAC-Ar), or X represents -COCH2-W, wherein W represents -Na, -F, -CI, -Br, -I, -NR®R® or -SR* (in which wherein R®, R* and R® each independently represents -SAC, -SCAC, -Ar, or -SAC-Ar or R® and R* are connected to form a cyclic compound); or W represents 0] R Ng R 0 \ YY \ vr _, 0 o / x It o) [ N | ot K Log Se’ ; R R R R in which Y represents -OH, OR® (in which R* = -SAC, or -SCAC), .C(=0)R* (in which R* = -H, -SAC, or -SCAC), -F, -Cl, -Br, -I, -CN, NC, Nj, -CO;H, -CF5 -COR® (in which R*® = -SAC, or -SCAC), _C(=O)NHR® (in which R® = -SAC, or -SCAC), and -C(=O)NR”R* (in which RY, R® = -SAC, or -SCAC) and can be mono- or poly-substituted at its maximum regardless of the order and the kinds, the pharmaceutically acceptable salts, the esters and the stereochemically isomeric forms thereof.
2. The compound of formula (I) according to Claim 1, in which R* represents -C(=O)(CH2),COOZ (in which p is 1 to 4, and Z is hydrogen, -SAC, -Ar or -SCAQ).
3. The compound of formula (I) according to Claim 1, in which R! represents -(CH2),COOZ (in which n is 1 or 2, and Z is hydrogen, -SAC, -Ar or -SCAC).
4. The compound of formula (I) according to Claim 1, in which a) R and R' represent hydrogen, b) R' represents -CH,COOH, -CH,COOCHs3, or CH;COOCH2CHs, c) R? represents -(CH2)(O)sR’ (in which R’ = -SAC, -SCAC, -Ar, -SAC-Ar; n=0, 1 or 2; and m=0 or 1), SAC, Ar, or Hydrogen, d) R® represents -CH(CHs),, -CH,COOH, -(CH2):CO:H, -CH.C(O)NH: or -(CH.)2C(O)NHz, e) R* represents -C(=0)(0).R* (in which n=0, 1; R®= -Ar or -SAC-Ar), -SO,R® (in which R¥= -Ar or -SAC-Ar), or -C(=O)NHR* (in which R* = -Ar, or -SAC-Ar), or f) X represents -C(=0)CHN, -C(=0)CH:Br, -C(=0)CH:Cl, -C(=0)CH20Ph or -C(=O)CH,OC(=0)Ar" (in which Ar"=2,6-dichlorophenyl, 2,6-difluoro- phenyl or 2,6-dimethylphenyl).
5. The compound of formula (I) according to Claim 1, which is selected from the group consisting of the following: (3S)-3-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-4,5-di- hydro-isoxazole-5-carbonylamino}-4-keto-pentanoic acid; (35)-3-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-5-phenoxy methyl-4,5-dihydro-isoxazole-5-carbonyl-amino }-4-keto-pentanoic acid; (2S)-2-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-5-phenoxy methyl-4,5-dihydro-isoxazole-5-carbonyl-amino}-succinic acid 1-(N-methyl- N-methoxy)-amide; (35)-3-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-4,5-dihydro -isoxazole-5-carbonylamino}-4-keto-5-diazo-pentanoic acid, (3S)-3-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-4,5-dihydro -isoxazole-5-carbonylamino}-4-keto-5-bromo-pentanoic acid; (3S)-3-{3-[(1S)-1-phenylmethyloxycarbonylamino-2-methyl-propyl]-4,5-dihydro
WO U1/21600 PCT/KR00/01047 ~- 138 -
-isoxazole-5-carbonylamino } -4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; (35)-3-{3-[(1S)-1-(naphthalene-1-carbonylamino)-2-methyl-propyl]-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid; (38)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl}-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-phenoxy-pentanoic acid; (35)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid; (35)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-bromo-pentanoic acid; (38)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid,
: (3S)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenyl-
~ methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-diazo-pentanoic acid(LP and MP), (35)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-bromo-pentanoic acid(LP and MP); (38)-3-{3-[(1S)-1~(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid(LP and MP); (38)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-3-carboxy-propyl]-5-methyl-4, 5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid; (39)-3-{3-[(1S)-1-(quinoline-2-yl-carbonylamino)-2-methyl-propyl}-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-pentanoic acid, (35)-3-{3-[(1S)-1-(naphthalene-2-sulfonylamino)-2-methyl-propyl]-5-phenoxy-
methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid; (35)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino } -4-keto-5-(2-naphthyloxy)- pentanoic acid, (35)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl]-5-phenoxy- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(1-naphthyloxy)- pentanoic acid, (3S)-3-{3-[(1S)-1-(2S)-2-acetylamino-succinoylamino)-3-carboxy-propyl]-5- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-phenoxy-pentanoic acid; (3S)-3-{3-[(1S)-1-(naphthalene-2-carbonylamino)-2-methyl-propyl}-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2-naphthyloxy)-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(2-naphthalenecarbonylamino)-propyl]-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid (diasteromeric mixture);
(3S)-3-{3-[2-methyl-(1S)- 1-(phenylmethyloxycarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-diazo-pentanoic acid; (35)-3-{3-[2-methyl-(1S)- 1-(phenylmethyloxycarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-bromo-pentanoic acid,
(3S)-3-{3-[2-methyl-(1S)- 1-(phenylmethyloxycarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid; (38)-3-{3-[2-methyl-(1S)-1-(phenylethylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid, (3S)-3-{3-[2-methyl-(1S)-1-(phenylethylcarbonylamino)-propyl}-5-phenylmethyl -4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-bromo-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(phenylethylcarbonylamino)-propyl]-5-phenyl-
~ 140 - methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl-
oxy)-pentanoic acid; (3S)-3-{3-[2-methyl~(1S)-1-(1-naphthalenecarbonylamino)-propyl]-5-pheny!- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(1-naphthalenecarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-bromo-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(1-naphthalenecarbonylamino)-propyl|-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobénzoylo xy)-pentanoic acid, (3S)-3-{3-[2-methyl-(1S)-1-(1-naphtalenesulfonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-diazo-pentanoic acid (diastereomeric mixture); (35)-3-{3-[2-methyl-(1S)-1-(1-naphtalenesulfonylamino)-propyl}-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-bromo-pentanoic acid (diastereomeric mixture); (35)-3-{3-[2-methyl-(1S)-1-(1-naphtalenesulfonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid (diastereomeric mixture); (35)-3-{3-[2-methyl-(1S)-1-((3-indolyl)ethylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-diazo-pentanoic acid, (35)-3-{3-[2-methyl-(1S)-1-((3-indolyl)ethylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-bromo-pentanoic acid; (38)-3-{3-[2-methyl-(18)-1-((3-indolyl)ethylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino } -4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-((3-indolyl)methylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid,
- 141 ~- (38)-3-{3-[2-methyl-(1S)-1-((3-indolyl)methylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-bromo-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-((3-indolyl)methylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(cinnamoylamino)-propyl]-5-phenylmethyl-4,5- dihydro-isoxazole-5-carbonylamino}-4-keto-5-diazo-pentanoic acid, (3S)-3-{3-[2-methyl-(1S)-1-(cinnamoylamino)-propyl]-5-phenylmethyl-4,5- dihydro-isoxazole-5-carbonylamino}-4-keto-5-bromo-pentanoic acid, (3S)-3-{3-[2-methyl-(1S)-1-(cinnamoylamino)-propyl]-5-phenylmethyl-4,5- dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)- pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(phenylmethylsulfonylamino)-propyl}-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-diazo-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(phenylmethylsulfonylamino)-propyl]-5-pheny!- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-bromo- pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(phenylmethylsulfonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid; (38)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-bromo-pentanoic acid; (38)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid,
WG 61/21600 PCT/KR00/01047 ~- 142 -
(3S)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-diazo-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)- 1-(quinoline-2-yl-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino} -4-keto-5-bromo-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl}-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(quinoline-2-yl-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid; (38)-3-{3-[2-methyl-(18)-1-(quinoline-2-yl-carbonylamino)-propyl]-5-(1- imidazolyl-methyl)-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-phenoxy- pentanoic acid; (38)-3-{3-[2-methyl-(1S)-1-(2-naphthalenecarbonylamino)-propyl}-4,5-dihydro- isoxazole-5-carbonylamino}-4-keto-pentanoic acid; (38)-3-{3-[(15)-1-(succinoylamino)-3-carboxy-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid, (38)-3-{3-[2-methy!-(1S)-1-(1-naphthalenylcarbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(1-piperidinyl)- pentanoic acid; (38)-3-{3-[2-methyl-(1S)-1-(isoquinoline-1-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(isoquinoline-3-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid,
(3S)-3-{3-[2-methyl-(1S)-1-(quinoline-4-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyl- oxy)-pentanoic acid; (3S)-3-{3-[2-methyl-(18)-1-(benzofuran-2-carbonylamino)-propyl}-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoylo xy)-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(naphthalene- 1-carbonylamino)-propyl}-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-difluorobenzoylo xy)-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(quinoline-3-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoylo Xy)- pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(naphthalene-1-carbonylamino)-propyl]-5-phenyl- methyl-4,5-dihydro-isoxazole-S-carbonylamino} -4-keto-5-(2,6-dimethylbenzoylo xy)-pentanoic acid[diastereomeric mixture]; (3S)-3-{3-[2-methyl-(1S)-1-(quinoline-8-carbonylamino)-propyl}-5-phenylmethy 1-4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)- pentanoic acid [diastereomeric mixture]; (3S)-3-{3-[2-methyl-(1S)-1-(indole-2-carbonylamino)-propyl]-5-phenylmethyl-4, 5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)- - pentanoic acid, (3S)-3-{3-[2-methyl-(1S)-1-(indole-3-carbonylamino)-propyl]-5-phenylmethyl-4, 5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)- pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(naphthalene-1-carbonylamino)-propyl]-5-methyl-4, 5-dihydro-isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)- pentanoic acid, (3S)-3-{3-[2-methyl-(1S)-1-(benzofuran-2-carbonylamino)-propyl]-5-methyl- 4,5-dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pen tanoic acid; (35)-3-{3-[3-carboxy-(1S)-1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino } -4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-S-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-propyl-4,5-dihydro- isoxazole-S-carbonylamino} -4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(N-piperidine)-pentanoic acid[diastereomeric mixture]; (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl}-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(N-pyrrolidine)-pentanoic acid [diastereomeric mixture]; (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-butyl-4,5-dihydro- 1soxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid, (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-methyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2-naphthyloxy)-pentanoic acid; (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-propyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-phenoxy-pentanoic acid [diastereomeric mixture]; (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-hydroxymethyl-4,5-dihy dro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid [diastereomeric mixture]; (39)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-phenylmethyl-4,5- dihydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentano ic acid, (35)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-methoxymethyl-4,5-di- hydro-isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid [diastereomeric mixture];
- 145 ~ (39)-3-{3-[2-methyl-(1S)-1-(succinoylamino)-propyl]-5-n-pentyl-4,5-dihydro- isoxazole-5-carbonylamino}-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; (35)-3-{3-[2-methyl-(18)-1-(succinoylamino)-propyl]-5-ethyl-4,5-dihydro- isoxazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; (3S)-3-{3-[2-methyl-(1S)-1-(glutaroylamino)-propyl]-5-methyl-4,5-dihydro- iso-xazole-5-carbonylamino }-4-keto-5-(2,6-dichlorobenzoyloxy)-pentanoic acid; and (3S)-3-{3-[2-methyl-(1S)-1-(phenylmethyloxycarbonylamino)-propyl]-4,5- dihydro-isoxazole-5-carbonylamino}-4-keto-pentanoic acid methyl ester.
6. A caspase inhibitor which comprises an isoxazoline derivative of the formula (I), the pharmaceutically acceptable salts, esters or stereochemically isomeric forms thereof as claimed in any one of Claims 1 to 5.
7. A pharmaceutical composition for treating disease caused by inflammation or apoptosis which comprises as an active ingredient a therapeutically effective amount of an isoxazoline derivative of the formula (I), the pharmaceutically acceptable salts, esters or stereochemically isomeric forms thereof as claimed in any of Claims 1 to 5 and pharmaceutically acceptable carrier.
8. The composition according to Claim 7, wherein the disease is selected from the group consisting of the diseases in which cells are abnormally died, dementia, cerebral stroke, brain impairment due to AIDS, diabetes, ‘gastric ulcer, cerebral injure by hepatitis, fulminant hepatic failure (FHF), sepsis, organ transplantation rejection reaction, rheumatic arthritis, cardiac cell apoptosis due to ischemic cardiac diseases and anti-inflammation.
9. The composition according to Claim 7, wherein the disease is fulminant hepatic failure in human,
10. The composition according to Claim 7, in the form for administration orally, percutaneously, or by parenteral injection.
11. Use of an isoxazoline derivative of the formula (I), the pharmaceutically acceptable salts, the esters or stereochemically isomeric forms thereof, according to any one of Claims 1 to 5 or the pharmaceutical composition according to any one of Claims 7 to 10, for treating patients suffering from the : diseases caused by caspases activation, by local or systemic administration.
12. A process for preparing the pharmaceutical composition as claimed in any of Claims 7 to 10, characterized in that a pharmaceutically acceptable : carrier is intimately mixed with a therapeutically effective amount of a compound of formula (I) as claimed in any of Claims 1 to 5.
13. A process for preparing a derivative of the formula (I), the pharmaceutically acceptable salts, esters or stereochemically isomeric forms thereof, characterized in that hydroxamoyl chloride (VD) is reacted with acrylate derivative (VII) to give isoxazoline derivative (VII), and isoxazoline derivative (VII) is then deprotected and R* is introduced therein to give a compound of formula (IX) which is then reacted with a compound of formula (X) and, if necessary, the isoxazoline derivative (VIH) is directly reacted with the compound (X) to give a compound of formula (I), and if necessary, the compound of formula (I) having the _ protecting group P is converted into other compound having substituent R* AMENDED SHEET
. © WO 01/21600 PCT/KR00/01047 : y#OH N id sa H N—O H N—0O RR i R ) R? \'2! p” SA AKeo, RY COo,P; + ER yp FR x R? H NX Aco, Py OX — RY i vil X Bow FR Riri ! in which the sustituents are the same as defined in Claim 1. .
14. An isoxazoline derivative of the formula (I) as claimed in any one of Claims 1 to 5, substantially as herein described and exemplified and/or described with reference to the accompanying figures.
15. A composition according to any one of Claims 7 to 10, substantially as herein described and exemplified and/or described with reference to the accompanying figures. :
16. Use as claimed in Claim 11, substantially as herein described and exemplified and/or described with reference to the accompanying figures. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR1999/000561 WO2001021599A1 (en) | 1999-09-17 | 1999-09-17 | Caspase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200202148B true ZA200202148B (en) | 2003-05-28 |
Family
ID=19571062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200202148A ZA200202148B (en) | 1999-09-17 | 2002-03-15 | Caspase inhibitor. |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5762899A (en) |
WO (1) | WO2001021599A1 (en) |
ZA (1) | ZA200202148B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE273705T1 (en) * | 1999-09-17 | 2004-09-15 | Lg Chem Investment Ltd | CASPASE INHIBITORS |
KR100399361B1 (en) * | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | Therapeutic composition comprising caspase inhibitor |
US6878743B2 (en) | 2001-09-18 | 2005-04-12 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
KR100594544B1 (en) * | 2003-08-27 | 2006-06-30 | 주식회사 엘지생명과학 | Caspase inhibitors containing isoxazoline ring |
KR100774999B1 (en) * | 2005-02-26 | 2007-11-09 | 주식회사 엘지생명과학 | Isoxazoline derivatives and novel process for its preparation |
CN105853408B (en) * | 2016-04-15 | 2018-12-04 | 浙江大学 | Benzoyl amine derivative is preparing the application in Caspase-1 inhibitor |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ334906A (en) * | 1996-10-11 | 2000-09-29 | Basf Ag | A sulphonamido pentanoic acid derivative useful as an interleukin-1-beta converting enzyme inhibitor |
US6004933A (en) * | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
EP1062210B1 (en) * | 1998-03-09 | 2005-06-01 | Vertex Pharmaceuticals Incorporated | 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors |
-
1999
- 1999-09-17 AU AU57628/99A patent/AU5762899A/en not_active Abandoned
- 1999-09-17 WO PCT/KR1999/000561 patent/WO2001021599A1/en active Application Filing
-
2002
- 2002-03-15 ZA ZA200202148A patent/ZA200202148B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001021599A1 (en) | 2001-03-29 |
AU5762899A (en) | 2001-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2943483B1 (en) | Benzylamine derivatives | |
AU2011331296B2 (en) | Method of treating contrast-induced nephropathy | |
JPH10507205A (en) | Novel carbonamide with antifungal activity | |
AU2012296662A1 (en) | Lysophosphatidic acid receptor antagonists | |
WO1991015487A1 (en) | Novel 4h-3,1-benzoxazin-4-one derivative | |
MXPA97002380A (en) | New carboxamides with antifung activity | |
HU222277B1 (en) | Substituted biphenyl isoxazole sulfonamides and pharmaceutical compositions containing them | |
CA2125021A1 (en) | Alpha-heteroaryloxymethyl ketones as interleukin-1 beta converting enzyme inhibitors | |
KR19980086847A (en) | Sulfonylaminocarboxylic acid | |
JP2000515165A (en) | Phosphatase inhibitors and methods of use | |
KR20220004978A (en) | Androgen receptor modulators and methods for use as proteolytic target chimeric ligands | |
AU3871100A (en) | Inhibitors of protein tyrosine phosphatase | |
US20090111860A1 (en) | Sulfonamide compounds useful as adg receptor modulators | |
EP1212309B1 (en) | Caspase inhibitor | |
US6747050B1 (en) | Isoxazoline derivative and a process for the preparation thereof | |
US8119673B2 (en) | Compounds 148 | |
AU6143200A (en) | Pyrazinones, compositions containing such compounds | |
ZA200202148B (en) | Caspase inhibitor. | |
CZ20011506A3 (en) | Omega-amides of N-arylsulfonylamino acids, process of their preparation and medicament containing thereof | |
JPH06135968A (en) | Hydantoin derivative, its salt and maillard reaction inhibitor containing the compound as active component | |
US6852744B2 (en) | Pyrrolidine derivatives and their use as chymase inhibitor | |
CA2965873C (en) | Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-n-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes | |
JP2005537216A (en) | Propyl carbamate derivatives as inhibitors of serine and cysteine proteases | |
US20240123072A1 (en) | Protected hdac (histone deacetylase) inhibitors | |
JP2004137185A (en) | Antimicrobial agent containing thiophene skeleton |